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Abstract 
Introduction: PBAD is a common cause of watery diarrhoea. It is diagnosed by the SeHCAT 
test and is characterized biochemically by elevated bile acid biosynthesis and low fasting 
FGF19. FGF19 is a gut hormone produced in the terminal ileum which negatively feeds back 
on hepatic BA synthesis. 
Aims: To assess the role of FGF19 in the pathogenesis of PBAD through characterization of 
fasting and postprandial FGF19 levels and through identification of associations with other 
biochemical and genetic factors. To show an increase in the fasting level of FGF19 in PBAD 
patients through the use of an FXR agonist. 
Methods: Subjects with PBAD and idiopathic diarrhoea were recruited and their data added 
to a previously recruited cohort. Fasting FGF19, BA, lipids, B12, vitamins A and D were 
measured. A subgroup was characterized using post-prandial levels of these factors. SNP 
genotyping was performed in candidate genes. A subgroup had BA species characterized by 
UPLC-MS. 10 PBAD subjects entered a study investigating changes in FGF19 following 
administration of the FXR agonist obeticholic acid. 
Results: Low fasting and post-prandial levels of FGF19 have been demonstrated in PBAD 
with lowest levels in those with low SeHCAT retention. Fasting and postprandial FGF19 
correlates with total BAs.  No strong associations have been found between diagnosis or 
FGF19 with vitamins A and D or with genetic variants. Approximately 30% of PBAD subjects 
have been found with elevated triglycerides and normal or high FGF19. Significant 
improvement in FGF19 and symptoms has been shown in PBAD subjects with the use of 
OCA. 
Conclusion: Abnormalities in FGF19 levels have been explored with biochemical phenotypes 
described. A subset of PBAD subjects with elevated triglycerides has been identified. A 
central role for total BAs in the aetiology has also been shown. Potential therapeutic benefit 
of OCA has been found warranting further investigation. 
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1. Introduction 
 
1.1 Background 
It has been known for over four decades that bile acids can cause diarrhoea. Alan Hofmann 
first described the condition as cholerheic enteropathy in 1967(1) and much work has been 
done in the intervening years to further understand bile acid absorption, malabsorption, 
and to unravel the underlying causes(2)(3).  In recent years advances have been made to 
determine the pathophysiology of the so-called idiopathic type of primary bile acid 
malabsorption(4)(5). Furthermore the potential for future therapeutics is being explored to 
augment today’s existing modalities. Frustratingly however, it remains under recognized in 
the medical community, including within the specialty of gastroenterology(6)(7). 
In health over 95% of bile acids are reabsorbed at the terminal ileum. In patients with 
terminal ileal resection or with impaired terminal ileal function secondary to disease such as 
Crohn’s, bile acids are absorbed to a lesser extent, spilling over into the colon where they 
cause chloride and water secretion resulting in symptoms. This has been termed secondary, 
or type 1 bile acid malabsorption (BAM)(8). A similar picture of bile acid malabsorption 
occurs in patients with a histologically normal terminal ileum(9)(10), and has been called 
type 2 or idiopathic bile acid malabsorption (IBAM) or primary bile acid diarrhoea (PBAD).  
The nature of this disorder will be discussed further in the light of recent findings.  BAD is 
also well described in patients with a variety of other gastrointestinal disorders, such as 
following gastric surgery, post cholecystectomy or in coeliac disease; this is termed type 3 
BAD(8). 
Although bile acid malabsorption is not life threatening, it can lead to copious watery 
diarrhoea, the passage of mucus, urgency and to faecal incontinence significantly impairing 
quality of life. Symptoms of diarrhoea are usually continuous and may last years and often 
decades. Other symptoms include bloating and abdominal pain, mean this is often 
diagnosed as diarrhoea-predominant irritable bowel syndrome (D-IBS). 
 
1.2 The Enterohepatic Circulation of Bile Acids 
Historical perspective: It was noted in 1883 that following the administration to fistula dogs 
of beef bile coloured green due to biliverdin, the dog bile changed from brown to green 
suggesting a possible circulation of bile pigments from the gut to the biliary system(11). The 
first clear evidence that the enterohepatic circulation may exist was provided by Broun in 
his 1923 paper examining the output or yield of biliary fistulae in dogs(12). Sheep’s bile was 
instilled into the stomachs of the dogs by tube. Bile from the dog underwent chloroform 
extraction and spectroscopy. The bile composition was noted to include cholohaematin 
which was previously not noted but was rich in sheep bile. Over the coming days the 
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spectroscopic line representing cholohaematin disappeared thus providing the first 
objective evidence that bile pigments are reabsorbed from the gut.  
In 1927 the Nobel committee awarded the Chemistry prize to Henry Wieland and in 1928 to 
Adolf Windaus for their work on elucidating the chemical structure of bile acids. Their use of 
basic chemistry techniques had advanced understanding but arrived at the wrong 
conclusion regarding the steroid structure(13). Desmond Bernal developed techniques in 
the use of x-ray diffraction to study organic compounds and these were applied by Wieland 
and Dane in Munich and Rosenheim and King in London to bile acids. The steroid nuclear 
structure was thus discovered and published in 1934 (14).  
In Sweden Jan Sjorvall developed mass spectrometry for the measurement of bile acids 
leading to advancement of the understanding of BA metabolism(15). His research group at 
the Karolinska Institute identified primary and secondary BAs as well as intermediates in the 
biosynthesis of BAs. Volunteers were intubated to identify sites of absorption in the gut and 
it was found that the BA pool circulates twice per meal, work published in 1957(16). The 
early 1960s saw advances made in the understanding of conjugated BA absorption in animal 
models and it was shown in 1961 that BAs are transported by active transport against a 
concentration gradient in the distal quarter of ileum in guinea pigs. This was achieved using 
the everted gut sack technique, in which the gut is effectively turned inside out (17). It was 
shown that the distal ileum was also likely the site of conjugated BA absorption in man (18). 
Ileal absorption of conjugated bile acids was thought to be active for a number of reasons. 
Firstly, absorption occurred against a concentration gradient, secondly individual BAs inhibit 
absorption of other BAs, thirdly the absorption kinetics demonstrated saturation features 
and finally absorption was dependent on sodium ions in the lumen(19)(20)(21). 
Biochemistry: Cholesterol is converted into bile acids in hepatocytes via pathways which 
involve 17 different enzymes. Bile acids consist of a steroid ring which is hydroxylated at 
different positions to give it different biochemical properties and a side chain which maybe 
conjugated with the amino acids glycine and taurine. The principal steps involved in the 
synthesis of BAs are the 7α-hydroxylation of sterol precursors, modification of the ring 
structure, oxidation and shortening of the side chain and finally conjugation(22). 
90 to 95% of human BAs are synthesized via the classical route, initiated by the enzyme 
cholesterol 7α-hydroxylase (CYP7A1). This has been found to be the rate limiting enzyme in 
the production of BAs. The final step in BA synthesis is the conjugation of taurine or glycine 
to carbon 24 of the side chain.  
BA are secreted into the biliary tract and stored in the gall bladder. When food enters the 
duodenum, bile is secreted into the small bowel under the effect of cholecystokinin. When 
the bile reaches the terminal ileum over 90% of the BA are absorbed(23). Daily production 
of BA is approximately 600mg per day, with the entire BA pool cycling 6 – 10 times per 
day(24). The bile acid pool size is approximately 2 – 4g. 
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The terminal ileum 
The ileum is the section of small intestine between the jejunum and the ileocaecal valve.  
Anatomically the ileum is attached to the posterior abdominal wall by its mesentery. 
Opposite the mesentery are Peyer’s patches which are aggregated lymphatic nodules, 
numbering about 30 in adulthood. Peyer’s patches are most prominent in the distal ileum.  
The ileum differs from the jejunum in that it has a smaller diameter and muscular circular 
folds are reduced or absent in the terminal portion(25).  
The clinical implications of the terminal ileum functioning as the site of bile acid 
reabsorption were realised when Alan Hofmann and Johann Poley published work 
examining the effect of different resection lengths on individuals symptoms and response to 
cholestyramine(26). Patients with diarrhoea with ileal resections of different lengths were 
examined. Stool weight, volume and fat content were measured. Of 12 patients with some 
remaining ascending colon and with terminal ileal resection lengths of less than 100 cm it 
was found that 10 responded to cholestyramine. Of 8 patients with resections of more than 
100cm none responded to bile acid sequestrant therapy. It was also found that faecal fat 
content was predictive of response to cholestyramine. All 8 subjects with less than 20g fat 
responded versus none of five subjects with greater steatorrhoea. This work confirmed the 
clinical importance of the role of the terminal ileum and importantly established the degree 
of resection that could be tolerated without a reduction in the bile acid pool size sufficient 
to cause fat malabsorption.  
Genetic influence of GI differentiation has been explored in recent years using animal 
models. The functional diversity of the GI tract depends on the on-going production of stem 
cells at the base of intestinal crypts. These differentiate into the main intestinal cell type: 
enterocytes, goblet cells, enteroendocrine cells and Paneth cells. Gene expression at 
different regions reflect the physiology of the site; genes encoding proteins for digestion 
and absorption of macronutrients are mainly jejunal whereas specific transporters for B12 
and BAs are expressed in the distal ileum(27). Wnt, Hedgehog and Notch signalling have 
been found to be important regulatory pathways for differentiation through the use of gene 
knockout and over expression models(28). Gata4 is a zinc finger transcription factor that is 
necessary for a range of developmental pathways. It is expressed highly in duodenum and 
jejunum of adult mice, but not of ileum. In Humans it is highly expressed in jejunum but not 
in ileum. In experiments using a transcriptionally inactive Gata4, mutant mice were found to 
have greatly reduced expression of enterocyte genes in jejunum but not in ileum. 
Furthermore, in the mutant mice there was expression of ASBT in jejunum at a similar level 
to ileal expression on control mice. These findings show that Gata4 is central to the 
differentiation of jejunal and ileal tissue(29). 
1.3 Bile acid transporters in liver and intestine 
Bile acids are secreted into the bile by the bile salt export protein (BSEP) at the canalicular 
membrane. It is highly expressed in hepatocytes and efficiently pumps conjugated bile acids. 
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Mutations of its gene ABCB11 have been shown in patients with progressive familial 
intrahepatic cholestasis type 2, supporting its role in BA export(30).  At the basolateral 
membrane of hepatocytes, BAs are transported from the portal circulation by the sodium 
taurocholate co-transporting protein (NTCP), gene SLC10A1. 
In the intestine, BAs are absorbed actively and passively. Passive absorption occurs down 
the length of the small intestine(31). Within the ileum the absorption of BA involves the 
uptake into the enterocyte across the apical surface by active transport. This is performed 
by the apical sodium linked bile acid transporter (ASBT) which is encoded by the gene 
SLC10A2. It transports all the major BAs, with very limited uptake of other solutes. Studies 
have shown expression within the intestine limited to the terminal ileum. Interestingly, 
ASBT-null mice demonstrate features of BAD and certain cases of idiopathic or PBAD have 
been shown to have a loss of function mutation of this transporter(30)(32).  This mutation 
appears not to be the cause in most patients(33). 
BAs are then bound by ileal bile acid binding protein (IBABP, gene FABP6) within the 
cytoplasm and transported across the cell. At the basolateral membrane, they are then 
transported out of the cell by the heterodimer organic solute transporter α and β (OSTα, 
OSTβ). There has been significant experimental support for the role of OST in BA efflux from 
ileal enterocytes(30)(34). The expression of these transporters broadly follows that of ASBT 
with highest concentration in the terminal ileum. They are also found at other sites of bile 
acid efflux including hepatocytes, and are up regulated on exposure to higher 
concentrations of BA. 
1.4 Regulation of Bile Acid synthesis 
The bile acid pool size is maintained within limits by the precise control of BA synthesis 
through positive and negative feedback mechanisms. When BA concentration increases, the 
expression of cholesterol 7α-hydroxylase and sterol 12α-hydroxylase is decreased. In 
circumstances of cholesterol accumulation, cholesterol 7α-hydroxylase expression is 
increased.  
Central to the control of BA synthesis is the Farnesoid X Receptor (FXR). This nuclear 
receptor binds BAs and activates expression of genes involved in BA metabolism (35). Genes 
controlled by FXR include those encoding short heterodimer partner (SHP), IBABP, OSTα & 
β, ASBT and FGF15/19. BAs vary in their potency as FXR agonists, with studies showing that 
some such as chenodeoxycholic acid act as powerful ligands with other BAs such as cholic 
acid are less potent (36). 
There are two mechanisms responsible for the repression of CYP7A1. Within the liver, SHP 
transcription is activated by the action of FXR. SHP represses BA synthesis by binding to and 
inhibiting Liver Receptor Homologue 1 (LRH-1) which is required for the expression of 
CYP7A1 and sterol 12α-hydroxylase (a cytochrome P450 required for production of cholic 
acid). It was found that a second pathway of negative feedback must exist as removing 
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elements of the SHP pathway did not abolish the ability of BAs to self-regulate themselves 
(22).  
It had been suspected for some time that the intestine plays a role in the negative feedback 
regulation of BA, following studies showing that bile duct ligation in mice led to an up 
regulation of CYP7A1.  This is now know to be a function of fibroblast growth factor 19 
(FGF19) and its orthologue in mice FGF15 (37).  FGF15 and FGF19 are atypical members of 
the fibroblast growth factor family which consists of 22 known members. It has been 
demonstrated that FGF15 is expressed in terminal ileum following activation of FXR in 
response to BAs.  FGF15 is then carried in the portal circulation to the liver where it 
interacts with fibroblast growth factor receptor 4 (FGFR4) leading to the inhibition of 
CYP7A1. β klotho is a protein which modulates FGFR4 function. Recent work has shown that 
β klotho is an endoplasmic reticulum (ER) resident protein that interacts with FGFR4. It is 
thought that the activity of FGFR4 depends upon its form of glycosylation, and it is through 
modulating this glycosylation that β klotho exerts its effect (38). 
It is now thought of the two pathways that regulate BA synthesis, the FGF19 – FGFR4 axis 
physiologically predominates. Tissue-specific FXR-null mouse models were treated with the 
FXR agonist GW4064. In mice lacking liver FXR, CYP7A1 was significantly repressed, but this 
did not occur in intestinal FXR-null mice, indicating the predominance of the FGF19 
regulatory mechanism (39). In man, FGF19 displays a diurnal variation related to peaks in 
serum BAs. The peaks in FGF19 occurred 90 – 120 minutes after the post-prandial rise in 
BAs. It was also found that FGF19 levels reduced when patients were given a BA sequestrant 
and rose following feeding with chenodeoxycholic acid (40). 
Work by Schmidt et al has revealed an unexpected regulator of BA metabolism. Experiments 
on mice have shown that vitamins A and D induce FGF15 expression, leading to reduced BA 
synthesis. Induction of FGF15 by vitamin D occurs via its receptor, whereas induction by 
vitamin A occurs through FXR and its heterodimer, Retinoid X Receptor (RXR). This effect on 
FXR/RXR is independent of BAs suggesting a function as a Vitamin A receptor (41). 
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 Figure 1  The BA – FXR - FGF15 – cyp7a1 axis(37) 
1.5 Bile acids and the microbiome 
The microbiome: There are 500 – 1000 separate subspecies of bacteria in the GI tract, with 
anaerobic species predominating. Composition varies between individuals; even identical 
twins have been shown to have less than 50% of phylotypes in common. There is huge 
genetic diversity contained in the microbiome with many genes playing metabolic roles 
including uptake of lipids, vitamin synthesis, metabolism of carbohydrate and modulation of 
the intestine’s absorptive function.  The microbiota also plays a role maintaining health 
through protective functions such as production of antimicrobial peptides and inhibiting 
attachment sites. Immunomodulation occurs by induction of T cells and through the 
activation of dendritic cells resulting in IgA production from plasma cells(42).  
BA transformation: BAs which pass into the colon undergo transformation by bacteria 
through deconjugation, epimerisation, oxidation, hydroxylation and dehydroxylation (43). 
The result of this biotransformation is the production of secondary BAs including lithocholic 
acid and deoxycholic acid. Bile salt hydrolases (BSH) which catalyse the breakdown of the 
C24 N-acyl amide bond in conjugated BAs are thought to be a crucial gateway enzyme to 
allow further metabolism of BAs by the microbiota. Metagenomic analyses have identified 
functional BSH in all major bacterial phyla in the gut.  Free BA are then made available to 
other pathways of BA modification generating secondary and tertiary forms(44).  
BA signalling: BAs and their metabolites function as signalling molecules not only through 
the nuclear BA receptor FXR but also through the cell surface receptor TGR5. TGR5 is 
agonised mainly by secondary BAs.  It is widely expressed on endocrine tissue, adipocytes, 
muscle cells, immune organs, spinal cord and the enteric nervous system. The activation of 
TGR5 plays a role in energy expenditure and basal metabolism. Its activation may also lead 
to lower levels of proinflammatory cytokines(45). FXR activation in addition to its direct role 
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in BA homeostasis plays a role in protecting terminal ileum from bacterial invasion through 
its induction of enteroprotective genes(46). The degree of activation of these receptors 
depends on not only the BA quantity but also on the BA profile which is dependent on the 
microbiome. Diet has also been shown to affect BA composition. Mice fed a high fat diet 
were found to have a proportional decrease in UDCA versus DCA. Physiologic concentrations 
of DCA have been shown to increase intestinal permeability(47). 
Antimicrobial properties of BAs: BAs are directly toxic to cell membranes; this was shown 
first in experiments with erythrocytes. BAs may dissolve membrane lipids at high 
concentrations and damage integral membrane proteins. The effect on membranes is 
determined by the type of BA. Conjugated BAs which are ionised in water exist mainly in the 
outer part of the phospholipid bilayer whereas unconjugated BAs will diffuse through 
passively. BAs also affect other bacterial components inducing structural changes in RNA 
and leading to direct DNA damage through toxic effects to DNA repair proteins. Detergent 
effect can also lead to denaturation of bacterial proteins. Other effects include oxidative 
stress, osmotic effects and direct effects from low pH(48). 
Microbiome and IBS: It is known that in Irritable Bowel Syndrome there is a different 
proportional composition of bacterial phyla compared with healthy controls with increased 
Firmicutes and reduced level of Bacteroidetes. There is in general a lower diversity of gut 
microbiota in IBS (49)(50)(51). In a study of 47 IBS patients mucosal associated microbiota 
was examined using rectal biopsies. Comparison was made between IBS-C and IBS-D. 
Bifidobacteria were lower in the diarrhoea group than in the constipation group. 
Importantly, no attempt was made to diagnose PBAD as no SeHCAT or other test of BA 
turnover was conducted(52). No work has yet been carried out looking at the microbiome in 
bile acid diarrhoea. 
1.6 Diagnosing Diarrhoea due to Bile Acid Malabsorption 
BAD causes symptoms related to diarrhoea due to excess levels of unabsorbed BAs in the 
colon. This has a number of effects. BAs induce secretion in the colon by activating 
intracellular secretory mechanisms, increasing mucosal permeability, inhibiting Cl-/OH- 
exchange and by detergent effects causing mucus secretion. Colonic water secretion 
depends on the type of bile acid, with micellar concentrations of 3-10mmol leading to 
secretion (53).  Increased colonic permeability can also result in increased motility 
worsening urgency and diarrhoea (54).   
Measurement of total and specific BA in the stool is the absolute standard for defining this 
disorder. This is not available outside of research settings and is unpopular with patients 
and laboratory staff.  Alternative tests were developed, including C14-labeled glycocholate 
or taurocholate excretion, but these again relied on stool measurements (55)(56).  The 
development of the gamma emitter, selenium-75-homocholic acid taurine (SeHCAT), was a 
major advance (57). 
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SeHCAT remains the mainstay diagnostic tool in diagnosing BAD. A SeHCAT capsule is 
administered orally, and measured by whole body counting using a standard gamma camera 
at 3 hours and at 7 days. The usual way to express the result is as percentage retention at 7 
days although half-life can also be calculated (58). The labelled BA is absorbed and excreted 
at the same rate as cholic acid and is resistant to deconjugation and dehydroxylation. It has 
been shown to have good clinical applicability and predicts reliably a response to BA 
sequestrants (10)(59)(60). A 7d-retention under 15% is abnormal, with values less than 10% 
highly predictive of a response to therapy (10).  Studies have shown it to have a sensitivity 
of 100% and specificity of 94% (61). It has been shown that SeHCAT values in the same 
patient remain remarkably stable over time (62).  
There has been discrepancy between North America and Europe in the recognition of 
primary BA diarrhoea patients. A study using the 14C-taurocholate test demonstrated that 
although most patients with chronic idiopathic diarrhoea have some degree of bile acid 
malabsorption, treatment with cholestyramine made no significant difference to stool 
weight. This paper concluded that BAD was most likely secondary to increased transit rather 
than being the primary cause of diarrhoea (56). However, other studies have failed to show 
a correlation between transit and the SeHCAT result, and SeHCAT has also been shown to 
discriminate accurately between different causes of diarrhoea, providing evidence that BAD 
is not an inevitable result of diarrhoea (10)(63). 
BAD is now thought to be much more common than previously appreciated. For instance, a 
study at Rotherham General Hospital UK reviewed 304 patients with chronic diarrhoea and 
divided them into 4 categories: Crohn’s disease with resection, Crohn’s in remission with no 
resection, post vagotomy/ pyloroplasty, and diarrhoea predominant IBS (64). It found 
positive SeHCAT results in 97%, 58%, 54% and 33% respectively. Although the proportion of 
D-IBS patients was the lowest, due to the high numbers of patients with D-IBS this 
represents the largest group of patients. 
A systematic review of 18 studies reporting SeHCAT tests for BAD in chronic diarrhoea found 
that 32% of patients had SeHCAT retention values of less than 10% (60). It is calculated that 
the adult population prevalence is 1%; many millions in the world could benefit from having 
a firm diagnosis established. 
An alternative to the SeHCAT test is measurement of serum 7α-hydroxy-4-cholesten-3-one 
(C4, also known as 7αHCO or 7αC4), the precursor in BA synthesis. This compound has been 
shown to be a reliable measure of CYP7A1 activity and as such parallels bile acid 
malabsorption. In comparison with SeHCAT it has a sensitivity of 87-90% and specificity of 
79-86% (65)(66). The disadvantage of this test is that C4 is relatively unstable, and 
specialized laboratory expertise is required in its measurement using high performance 
liquid chromatography (HPLC) (65).  With the addition of tandem mass spectrophotometry, 
C4 has been used in recent studies of BA and bowel function (67)(68)(69)(70). 
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It has recently been suggested that measurement of FGF19 maybe prove to be a useful 
marker in the diagnosis of BAD. FGF19 has an inverse relationship with C4 and reduced 
levels have been found in patients with PBAD (4)(71). Initial data suggest a specificity of 89% 
and sensitivity of over 75%, although work on greater numbers is required. In a paper by 
Lenicek et al examining BAD in inflammatory bowel disease the inverse relationship 
between C4 and FGF19 was again demonstrated and FGF19 was found to be a useful marker 
of BAD (72). FGF19 has the advantage of being a simple ELISA. 
In many centres, a trial of therapy with a BA sequestrant remains the most common 
approach (6). This has the advantage of not requiring specialist investigations; however, as 
treatment can be unpalatable and response variable, requiring titration and alteration (73), 
this method is far from straight forward for the patient and is likely to lead to a false 
negative diagnosis. Furthermore a diagnosis likely to require lifelong treatment is best made 
definitively to ensure patient compliance and for reassurance. 
A recent study has shown potential wider application of the SeHCAT scan. 141 IBS patients 
of all 3 sub-types underwent SeHCAT testing and it was found that retention less than 10% 
correlated with faster colonic transit time. Stool form, colonic transit and SeHCAT retention 
was similar between IBS alternating type and IBS diarrhoea type indicating a role for BAs in 
both these conditions (74). 
 
 
1.6 Treatment 
Treatment of bile acid malabsorption has been with anion exchange resins since the 1960s 
(26). Cholestyramine (RIN colestyramine) binds BAs and prevents them from exerting their 
effect in the colon. Unfortunately cholestyramine and colestipol are provided as a powdered 
resin and are unpalatable, leading to reduced patient compliance. The dose required can be 
variable between individuals and dose should be increased gradually to avoid side effects. 
Commonly, they can lead to constipation and cramping discomfort which again limits their 
tolerability.  
A newer agent, colesevelam, has more recently become available which comes in tablet 
form. This has been shown to be better tolerated by patients (73). It is important to 
remember that these anion exchange resins are capable of binding other compounds and 
therefore can impair absorption of other drugs and lipid-soluble vitamins. Therefore, bile 
acid sequestrants should be taken at a different time from other medications. 
In patients with type 1 BAD secondary to Crohn’s disease, it has been shown that the 
transporter ASBT is upregulated by glucocorticoids (75). Treatment with prednisolone can 
improve symptoms of BAD possibly acting by this mechanism in Crohn's disease.  In 
microscopic colitis, where a considerable proportion of patients have abnormal SeHCAT 
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tests indicating BAD (76)(77), treatment with budesonide has been shown to be effective in 
96% of patients (78), probably through a stimulation of BA absorption (79).  Other potential 
future treatments to increase BA absorption or reduce BA production may become relevant. 
1.7 Pathogenesis of primary bile acid diarrhoea 
The cause of primary BA diarrhoea has been debated since the characterization of the 
condition in the 1970s. It seemed reasonable to look for malabsorption as in the patients 
with secondary causes. Research has focused on three main possible pathogenic 
mechanisms; mutations in BA transporters in the terminal ileum, reduced length of ileum 
expressing transporters and increased small bowel transit, with reduced time spent in the 
ileum. Recently a novel explanation for the pathophysiology of the condition has been 
postulated in which there is disordered negative feedback of BA production, resulting in 
over production of BAs which overwhelm the ability of the ileum to absorb them. 
There is some evidence that a transporter defect is responsible for a small fraction of cases 
of PBAD. In one study, a family with congenital PBAD was identified and 4 polymorphisms 
were identified in SCL10A2, the gene encoding ASBT. In transfected cells, it was shown that 
although transporter protein expression and trafficking to the membrane were not affected, 
transport of BAs was abolished (32). A further study looked at 13 patients with PBAD, 
screening for these polymorphisms. ASBT polymorphisms were found in 5 patients; however 
these polymorphisms were also found in control subjects and did not appear to affect ASBT 
function (33). Polymorphisms have also been sought in FABP6 encoding IBABP, but 
frequencies were found to be similar between patients and controls (80). In the same study 
transcript expression was analysed for ASBT, IBABP, OSTα and OSTβ in terminal ileal tissue 
in patients and controls, with no significant difference demonstrated.  
Interestingly no impairment of BA transport has been demonstrated in studies of terminal 
ileal tissue. In fact, active bile acid transport was found to be increased in patients 
compared to controls in an in vitro study of brush-border membrane vesicles from terminal 
ileal biopsies in 10 patients (58). In another study, taurocholate uptake into terminal ileal 
biopsies was also found to be increased in patients (81). 
It has also been suggested that fast small bowel transit maybe responsible for reduced BA 
malabsorption, however the evidence is conflicting. Sciarretta et al failed to demonstrate 
any significant correlation between SeHCAT result and small bowel transit time, measured 
by hydrogen breath test after lactulose or by Tc99m-HIDA cholescintigraphy (61). Another 
study showed significant differences in small bowel transit between controls and those with 
PBAD in women, although in men the difference was less pronounced (82).  Furthermore, 
the migrating motor complex phase III induced jejunal secretion may be upregulated in BAD 
patients which may overload reabsorption capacity in the colon (83). 
1.8  FGF19 in BA diarrhoea 
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With research failing to demonstrate clear abnormalities in BA transport and with 
conflicting evidence with regard to the role of transit, other possible causes of primary BA 
diarrhoea were considered. 
Van Tilburg et al published data in 1992 where, as expected, the BA content of stools was 
significantly raised in patients with primary bile acid malabsorption. Counterintuitively, their 
data also showed that the BA pool size was in fact increased (7.0mmol in patients versus 
3.7mmol in controls) (84). It has been known for many years that BA synthesis, as measured 
by C4, is increased in PBAD. This previously had been explained as a compensatory 
mechanism for increased BA loss. 
When these data are interpreted together with evidence of normal or increased BA mucosal 
transport and lack of transporter defect in the majority of patients with primary bile acid 
diarrhoea, it becomes apparent that there may be no true malabsorption of BAs. It has been 
suggested that the disorder may best be explained by a mechanism in which there is 
uncontrolled BA synthesis due to a lack of negative feedback control, thereby overwhelming 
the ability to absorb BA (4). 
As discussed above, the FGF19 – FGFR4 axis has been shown to be the primary means of 
negative feedback controlling BA synthesis (37)(39). Our group has postulated that primary 
BA diarrhoea results from impaired negative feedback secondary to disordered signalling by 
FGF19.  Work on FGF15-knockout mice has shown that they develop diarrhoea similar to the 
patients. In a drug safety study looking at the use of anti-FGF19 antibody in cynomolgus 
monkeys it was found that they developed severe diarrhoea in addition to weight loss and 
liver toxicity (85). In research published in 2009, 17 patients with chronic watery diarrhoea, 
13 of whom had a SeHCAT test all with retention of less than 8% at one week, were 
compared with controls. Fasting FGF19 and C4 were measured. Median C4 was significantly 
higher in the patient group, (51 versus 18 ng/l). There was a negative correlation between 
C4 and FGF19, and median FGF19 was found to be significantly lower in patients compared 
with controls, (120 versus 231pg/l) (4). A much larger prospectively recruited study has 
confirmed these data and importantly has shown a significant difference in FGF19 between 
patients with primary BA diarrhoea (diagnosed by abnormal SeHCAT tests) and those with 
chronic diarrhoea but with a normal SeHCAT result.  This indicates that the reduced FGF19 is 
not just a function of diarrhoea per se (86)(87). 
Recent work has demonstrated the importance of genetic variation in the control of BA 
levels and in turn on bowel transit time. Rao et al have recently looked at the use of 
chenodeoxycholate in females with IBS-C (69). They found that colonic transit and ascending 
colon emptying was significantly increased compared with placebo. Stool frequency was 
increased and stools were looser. There was a significant association between fasting C4 
level and bowel transit, however no association with FGF19 was found. It was found that a 
SNP in the FGFR4 gene was associated with increased transit with the 2 different doses of 
CDCA administered. The authors suggest that patients with this genotype may be more 
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susceptible to the effects of endogenous BAs. An association was identified with a SNP in 
KLB (encoding klotho β), with a different effect of the two doses on the participant 
subtypes. Another paper has shown that a functional variant of KLB mediating protein 
stability is associated with colonic transit in IBS-D (70). This work reveals a possible role of 
genetic variation in individual’s response to endogenous BAs. Such genetic variation may be 
involved in IBS-D and BAD in determining patient’s clinical response to perturbation of 
intraluminal BAs and warrants further investigation. 
A further connection between low FGF15/19 levels and diarrhoea has recently been 
uncovered.  In a 2010 study mice were given ampicillin or a vehicle. Treated mice were 
found to have significantly lower FGF15 mRNA and increased levels of primary bile acids in 
stool (88). These results may shed some light on the causes of antibiotic associated 
diarrhoea and raise the possibility of some bacterial involvement in primary BA diarrhoea. 
Following the discovery of the central role played by FGF19 in the pathogenesis of primary 
BA diarrhoea, interesting possibilities regarding possible novel therapeutic options have 
arisen. As mentioned previously, vitamins A and D have been found to self-regulate their 
absorption in mice through induction of FGF15 and hence repression of BA synthesis. There 
may be a therapeutic benefit in PBAD in taking exogenous vitamins A or D. In a similar vein, 
FXR activation through the use of synthetic agonists may have a beneficial effect. 
Obeticholic acid (OCA) is a semisynthetic FXR agonist developed for use in liver disorders. 
OCA, (also known as 6a-ethyl-CDCA and INT–747) is about 100-fold more potent an FXR 
agonist than CDCA. Clinical trials of OCA in primary biliary cirrhosis (PBC) and non-alcoholic 
steatohepatitis (NASH) have been published or are in progress, with treated patients 
showing apparent dose-dependent increases in FGF19 (89)(90)(91). 
1. 9 Conclusions 
Great advances have been made in recent years in exploring the regulation and metabolism 
of bile acids and this in turn has led to a greater understanding of bile acid malabsorption. 
The body of research contained in this thesis will focus on the FGF19 - FGFR4 axis in primary 
BA diarrhoea. As our understanding increases, so will therapeutic options.  It has become 
apparent that there is a large population of patients with this disorder and the means to 
diagnose them needs to be more available.   
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2. Hypothesis and Aims 
2.1 Hypothesis 
The hypothesis is that abnormal signalling by FGF19 is the key abnormality underlying the 
condition of Primary Bile Acid Diarrhoea.  It is hypothesised that differences in fasting, post 
prandial and/ or stimulated serum levels of FGF19 will be detected between individuals with 
PBAD and those with idiopathic chronic diarrhoea. It is further hypothesised that levels of 
fat soluble vitamins will differ between subjects and controls and that there are genotypic 
differences between subjects and controls. Finally it is hypothesised that the low FGF19 
levels seen in PBAD will be increased through the administration of the FXR agonist 
obeticholic acid to patients. 
2.2 Aims 
Study 1 
1.  To recruit subjects with unexplained chronic diarrhoea. 
2. To characterise subjects as primary bile acid diarrhoea, secondary bile acid diarrhoea 
or idiopathic diarrhoea on the basis of SeHCAT result and other investigations. 
3. To measure serum FGF19, bile acids, lipids, vitamin B12, vitamin A and vitamin D in 
this group and to describe associations between these factors and other parameters 
including SeHCAT retention. 
Study 2 
4. To extract DNA from blood and explore genetic polymorphisms in candidate genes 
involved in BA homoeostasis in the subject subgroups. 
Study 3 
5. To characterise BA species in a smaller groups of age and sex matched subjects with 
PBAD and ID 
Study 4 
6. To recruit subjects with PBAD and ID into a further study measuring changes in 
FGF19 and BA over the course of 6 hours in response to meals. 
7. To describe different patterns of FGF19 and BA fluctuation in response to meals in 
patients with PBAD. 
Study 5 
8. To measure fasting FGF19 in a previously recruited cohort of healthy individuals of 
different ages and to describe any relationships between age and FGF19. 
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Study 6 
9. To set up a drug study exploring the use of the FXR agonist obeticholic acid (OCA) in 
subjects with BAD and ID: ‘Obeticholic acid treatment in patients with bile acid 
diarrhoea: an open-label, pilot study of mechanisms, safety and symptom response’  
10. To recruit subjects to the study and investigate changes in fasting FGF19 before and 
after OCA treatment. 
11. To explore changes in meal stimulated response of FGF19 and BAs after OCA 
treatment. 
12. To investigate effect of OCA on symptoms in the subgroups. 
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3. Materials and methods 
3.1 Study 1 
3.1.1 Recruitment 
Ethical approval for the study was obtained from the Hammersmith and Queen Charlotte's 
& Chelsea Research Ethics Committee ref 2000/5795. 
Patients were recruited prospectively at Imperial College Healthcare NHS Trust, Charing 
Cross Hospital and Hammersmith Hospital sites. Patients were approached at routine 
gastroenterology outpatient clinics and when attending for SeHCAT scanning at the Nuclear 
Medicine Department. 
Verbal information and a patient information sheet was provided to patients and 
opportunity provided to ask any questions. Written consent was obtained. 
3.1.2 Patient characterisation 
Patients with a history of 3 or more month’s diarrhoea were recruited. Diarrhoea was 
defined as 3 or more stools per day of Bristol Stool Form type 6 or 7. Patient information 
was recorded on a proforma (Appendix 1). Demographics were noted including ethnicity. 
Height and weight were recorded and the body mass index (BMI) calculated. Symptoms 
including stool type, frequency, duration and presence of nocturnal symptoms were noted. 
Other symptoms including the presence of abdominal pain, weight loss, rectal bleeding, 
steatorrhoea, urgency and incontinence were also recorded. Past medical History and drug 
history were taken down. Further clinical information was accessed by interrogating Trust 
clinical IT systems and accessing medical notes where necessary.  
Investigation results were recorded including:  
• Full blood count, routine biochemistry, C reactive protein, thyroid function tests and 
tissue transglutaminase. 
•  Stool MC&S, Ova, cyst and parasite examination and faecal elastase. 
• Colonoscopy, Flexible sigmoidoscopy and colonic +/- ileal biopsy 
• Cross sectional imaging if available 
 When SeHCAT retention was calculated subjects were classified as: 
1. Type 1 bile acid diarrhoea  
2. Type 2 bile acid diarrhoea or Primary Bile Acid Diarrhoea (PBAD) 
3. Type 3 bile acid diarrhoea 
4. Idiopathic diarrhoea (ID) 
5. Other cause of diarrhoea 
6. No diarrhoea 
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A cut off value of 15% SeHCAT retention at 7 days was used to define normal bile acid 
retention. 
A fasting blood sample was taken in a 4ml serum separator vacutainer and immediately 
centrifuged at 3100rpm for 10 minutes. 0.5ml was then pipetted into 4 x 2ml vials and 
stored at -80c. 10ml of blood was also taken in an EDTA vacutainer and was stored at -20c 
for later DNA preparation. 
The recorded information was then pseudanonymised and transferred to a database in 
accordance with the Data Protection Act.  
3.1.3 Serum Analyses 
FGF19 
Reagent preparation 
1. Wash buffer: 20 mL of Wash Buffer Concentrate diluted into deionized water to 
prepare 500 mL of Wash Buffer. 
2. Substrate Solution: 10ml Color Reagent A and 10ml reagent  mixed together in equal 
volumes . 200μL of mixture is used per well. 
3. Calibrator Diluent RD5P (1X): 10 mL of Calibrator Diluent RD5P diluted into into 20 
mL of deionized water to prepare 30 mL of Calibrator Diluent RD5P (1X). 
4. FGF-19 Standard:  FGF-19 Standard reconstituted with 1.0 mL of deionized water. 
Resulting in stock solution at concentration 10,000 pg/mL. Standard and gently 
agitated for 15 mins. 900 µL of Calibrator Diluent RD5P (1X) pipetted into the 1000 
pg/mL tube. 500 µL Calibrator Diluent RD5P (1X) pipetted into the remaining tubes. 
Stock solution used to produce dilution series (Figure 2). Each tube was mixed 
thoroughly before the next transfer.  
 
Figure 2 Use of stock solution to make dilution series. Image taken from R&D systems Quantikine FGF19  manual(92) 
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Assay procedure 
1. 100 μL assay diluent added to each well. 
2. 100 μL of  standard, control, or sample added to each well and covered with 
adhesive strip. Samples were done in duplicate. 
3. Samples incubated for 2 hours at room temperature 
4. Each well washed 4 times using the Wash Buffer using a squirt washer. Aspirated 
after each wash. Blotted clean on paper towels. 
5. 200 μL FGF19 conjugate added to each well and covered using adhesive strip. 
6. Incubated 2 hours at room temperature 
7. Washed and aspirated 4 times a s before 
8. 200 μL substrate solution added to each well. 
9. Incubated 30 mins. 
10. 50 μL stop solution added to each well 
11. Optical density of each well measured using microplate reader 
  
 
Figure 3 Assay procedure. Taken from R&D systems Quantikine FGF-19 manual(92) 
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Results calculation 
1. Sample readings were averaged and the average zero standard optical density 
subtracted. 
2. Standard curve generated using optical density from standards using Elisa 
analysis software. 
3. FGF19 concentration determined by finding the absorbance value on the Y axis 
and extending to the curve. Then extended down to the X axis. 
Total Bile Acids 
Total bile acids were measured by an enzymatic colorimetric method using 3-α-
hydroxysteroid dehydrogenase, (Ref. no. 6K9001, Sentinel Diagnostics, Milan, Italy). This 
assay was performed by the Clinical Chemistry Department, Hammersmith Hospital. 
Vitamin D 
25 OH vitamin D was measured using a semi-automated method by liquid/liquid 
chromatography-Tandem mass spectrometry which has been previously described(93). This 
assay was performed by the Clinical Chemistry Department, Hammersmith Hospital. 
Vitamin A 
Vitamin A was calculated by reverse phase high performance liquid chromatography 
following extraction into iso-hexane and re-constitution into ethanol. Detected by UV 
absorption at 325nm (94). This was performed at Rotherham General Hospital. 
Analysis 
Data has been combined with a previously recruited prospective cohort of patients and 
analysed. Subject recruitment, characterisation, recording and assays have been conducted 
in an identical fashion using the same standards in the current cohort and the previously 
recruited cohort. It will be made clear in the results section whether the current study 
cohort or the combined cohort is being described.  
Statistical analyses and Power Calculations 
GraphPad Prism was used for all data analysis in each of the sub studies. Statistical 
differences in FGF19, Total BA, vitamins A and D was achieved using non-parametric Mann-
Whitney or Wilcoxon paired tests with significance defined as p < 0.05. 2 tailed statistical 
testing was performed in calculations. 
 
Spearman Rank coefficient was used to seek significant relationships between variables.  
 
  
29 
 
3.2 Study 2: Genetic Polymorphisms in PBAD and ID 
3.2.1 DNA Extraction 
Genomic DNA was extracted from whole blood using a commercial DNA extraction kit 
(QiAMP DNA mini kit, Applied biosystems, Foster City, CA). Leukocytes in the whole blood 
were lysed during the freeze thaw cycle involved with storage of the samples. The minikit 
works on the principle of DNA binding to a silica membrane, which then undergoes 4 
washing steps using mini spin columns and a microcentrifuge, before the DNA is eluted 
using elution buffer (95). 
Procedure 
The following DNA extraction was carried on 10 samples at a time. 
1. 20 μl QIAGEN Protease pipetted into the bottom of  1.5 ml microcentrifuge tube. 
2. 200 μl blood sample added to the microcentrifuge tube.  
3. 200 μl Buffer AL added to the sample. Pulse-vortexed for 15 s until mixed to a 
homogeneous solution. 
4. Incubated at 56°C for 10 min. 
5.  1.5 ml microcentrifuge tube centrifuged 2s to remove drops from the inside of the lid. 
6. 200 μl ethanol (96–100%) added to the sample, and mixed again by pulse-vortexing for 
15s. After mixing, the 1.5 ml microcentrifuge tube was centrifuged for 2s to remove drops 
from the inside of the lid. 
7. Mixture pipetted to the QIAamp Mini spin column in a 2 ml collection tube without 
wetting the rim. Cap closed, and centrifuged at 6000 x g (8000 rpm) for 1 min.  QIAamp Mini 
spin column placed in a clean 2 ml collection tube, filtrate tube discarded. Each spin column 
closed. Centrifuged at 6000 x g (8000 rpm). 
8. Mini spin column opened and 500 μl Buffer AW1 added without. Cap closed and 
centrifuge at 6000 x g (8000 rpm) for 1 min. Spin column placed in a clean 2 ml collection 
tube collection tube containing the filtrate discarded. 
9. Spin column opened and 500 μl Buffer AW2 added without wetting the rim. Cap closed 
and centrifuged at full speed (20,000 x g;14,000 rpm) for 3 min. 
10. Spin column placed in a new 2 ml collection tube, old collection tube with the filtrate 
discarded. Centrifuged at full speed for 1 min. 
11. Spin column placed in a clean 1.5 ml microcentrifuge tube. Collection tube containing 
the filtrate discarded. Spin column opened and add 200 μl Buffer AE added. Incubated at 
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room temperature (15–25°C) for 1 min, and then centrifuged at 6000 x g (8000 rpm) for 1 
min. 
Determination of DNA purity 
12. 1μl of purified DNA pipetted to optical surface of NanoDrop ND-100 spectrophotometer.  
13. ‘Measure’ function selected 
This instrument utilises fibreoptics and surface tension to directly measure absorption at 2 
wavelengths, 260nm and 280nm. Samples with values outside the ratio 1.7 to 1.9 were 
extracted again and retested. Samples were diluted with buffer to achieve concentrations of 
3 – 25 ng/μl. 
3.2.2 Genotyping 
SNP genotyping was performed on the samples using TaqMan assays (Applied Biosystems, 
Foster City, CA). This technique utilises commercially produced primers specific to a DNA 
region to amplify the allele. Chromophore labelled probes specific to the SNP hybridise to 
the polymorphism allowing allele discrimination. The probe chromophore is at the 5’ end 
and a quencher is at the 3’ end. If the probe hybridises perfectly with the polymorphism the 
5’ nuclease cleaves the 5’ end releasing the chromophore from the quencher, which creates 
a signal detectable by the StepOnePlus thermal cycler (Applied Biosystems). 
 
Figure 4 Showing genotyping work flow(96) 
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Procedure 
A genotyping mix was made containing 7.5μl TaqMan genotyping master mix, 0.375μl SNP 
assay, 6.125μl DNase free water per assay to be performed. 96 well plates were used, 2 
wells had no DNA for control purposes.  
Genotyping mix procedure 
1. TaqMan Universal PCR Master gently swirled 
2. 20✕ SNP Genotyping Assay vortexed and centrifuged briefly. 
3. 750μl TaqMan master mix, 37.5μl SNP assay and 612.5μl DNase free water pipetted into 
sterile microcentrifuge tube. 
4. Tube capped and inverted several times to mix. 
5. Tube centrifuged briefly 
6. 2 wells of a 96 well reaction plate had 1μl water pipetted as controls.  
7. 1μl DNA was pipetted into each of up to 94 wells. Careful note was made of sample 
idetifiers and reaction well allocation. 
8. Reaction plate centrifuged 10s 
9. 14μl of the prepared reaction mix pipetted into each of the wells 
10. Adherent optical cover sealed onto plate. 
11. Plate vortexed 2s then briefly centrifuged 
Thermal cycling 
StepOne software was programmed to cycle according to either Standard Protocol or 
Alternate Protocol depending on the SNP assay.  
Standard protocol:  10minutes at 95°c followed by  
40 cycles of:  denature period - 15secs at 92°c  
anneal/extend period - 60secs at 60°c. 
Alternate Protocol: 10minutes at 95°c followed by  
50 cycles of:  denature period - 15secs at 92°c  
Anneal/extend period - 90secs at 60°c. 
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Data was plotted automatically by the StepOne software, with calls assigned to each sample 
depending on the chromophore signal detected. 
3.2.3 Statistical analysis and power calculations 
Minor allele frequency (MAF) was calculated for subjects with PBAD and for subjects with 
ID. Fisher’s exact test was used to compare MAFs using GraphPad Quickcalc software 
(GraphPad Software Inc., La Jolla CA). A p value of <0.05 was deemed significant. A genetic 
dominance effect was sought by comparing number of homozygote wild types with 
combined heterozygous and homozygous mutants, again using Fisher’s exact test. The data 
was reanalysed comparing MAFs of disease and controls within ethnic groups. SeHCAT and 
FGF19 values were compared between subjects with wild type and mutant alleles to detect 
differences using Mann-Whitney rank sum test. Power and sample size calculations were 
performed using an online calculator (http://osse.bii.a-star.edu.sg/calculation1.php). 
Power calculations were performed for the polymorphisms. Quoted MAFs varied widely 
between SNPs from 0.16% to 48%. In this study a 2 fold difference was sought between 
disease subjects and controls with a power of 80%. 6 of the 9 SNPs had a MAF of 18% or 
more. For these SNPs a sample size of 94 was calculated to be necessary. One SNP had a 
MAF of 9.4%, one of 4.4% and one of < 1 %. For these polymorphisms using the criteria 
above the samples would be underpowered however it is important to emphasise the 
hypothesis generating nature of this study and the SNPs with lower MAFs are investigated 
for the possibility of a much stronger association with the disease phenotype. 
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3.3 Study 3: Bile Acid Species Characterisation 
If abnormalities in FGF19 signalling are the underlying abnormality responsible for the 
clinical condition of PBAD then it would be expected that there would be an effect on BA 
concentration and composition. In this sub-study we have in collaboration with colleagues 
at the Department of Biomolecular Medicine, South Kensington Campus sought to describe 
serum BA species composition through the use of Ultra Performance Liquid 
Chromatography – Mass Spectrometry. From the previously recruited cohort described in 
3.1, fasting serum samples from 20 patients, 10 with PBAD and 10 with ID were analysed. All 
the following experimental methodology was performed by colleagues of the Department of 
Biomolecular Medicine. 
3.3.1 Subjects 
Subject characteristics are shown in the table. PBAD subjects with SeHCAT of < 10% and ID 
subjects with SeHCAT > 20% were selected. No formal randomisation or matching process 
was used however attempts were made to make the 2 groups comparable in terms of 
clinical characteristics. 
Table 1 Subject characteristics. 
Subject Diagnosis Age Sex BMI Movements/24hrs Stool 
type 
Duration 
yrs 
FGF 
19 
SeHCAT 
BD06 PBAD 38 F 32 7.0 7.0 3.0 56.0 5.4 
BD118 PBAD 38 M 27 6.5 7.0 25.0 30.0 4.0 
BD29 PBAD 32 F 22 7.5 6.5 5.0 59.0 3.0 
BD37 PBAD 29 F 28 13.0 6.5 0.7 68.0 5.0 
BD40 PBAD 70 F 27 11.0 6.0 2.0 172.0 5.0 
BD43 PBAD 37 M 24 4.0 6.0 8.0 97.0 0.5 
BD70 PBAD 59 F 32 5.0 7.0 10.0 94.0 6.2 
BD81 PBAD 26 F 33 12.0 6.5 2.0 125.0 4.8 
BD83 PBAD 27 M 27 10.5 7.0 3.0 145.0 6.7 
BD93 PBAD 47 M 26 7.0 7.0 2.0 146.0 2.0 
MEDIAN  37.5  27 7.3 6.8 3.0 95.5 4.9 
BD117 ID 69 F 25 5.0 6.0 0.5 498.0 31.0 
BD12 ID 18 F 20 4.0 5.0 1.5 195.0 48.6 
BD14 ID 60 M 20 4.0 6.0 5.0 479.0 57.0 
BD21 ID 51 F 22 5.0 6.0 1.0 178.0 39.0 
BD22 ID 75 F 23 8.5 6.0 40.0 215.0 34.0 
BD47 ID 60 M 36 4.0 5.0 1.0 547.0 48.0 
BD49 ID 90 F 18 5.0 7.0 0.5 276.0 74.5 
BD62 ID 31 M 23 4.0 7.0 14.0 213.0 35.0 
BD74 ID 58 M 30 3.0 7.0 0.5 272.0 48.0 
BD98 ID 29 M 21 15.0 7.0 5.0 396.0 73.5 
MEDIAN  59  22.5 4.5 6.0 1.3 274.0 48.0 
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3.3.2 Sample preparation protocol 
Samples have been prepared and analysed according to the method validated by Want et al 
and described elsewhere (97). Serum samples were prepared for UPLC-MS analysis by 
methanol protein precipitation. Cold methanol (150 μL) was added to 50 μL of serum, 
vortexed for 30 s, incubated at -20 °C for 20 min, centrifuged at 16089g for 20 min, and the 
supernatant transferred to a clean tube. This supernatant was dried down in an Eppendorf 
vacuum evaporator, reconstituted in 100 μL of water/methanol 1/1 mixture, and 
transferred into 350 μL volume 96-well plates. The reconstitution solvent has been modified 
compared to Want et al. to improve solubilisation of bile acids by addition of methanol. 
Quality control (QC) samples were prepared by pooling 15 uL of each extract and were used 
for column conditioning and system stability assessment. 
3.3.3 UPLC-MS Analysis 
Metabolite extracts (5 μL) were injected onto a 2.1 X 100 mm (1.7 μm) HSS T3 Acquity 
column (Waters Corp., Milford, MA) and eluted using a 25 min gradient of 100% A to 100% B 
(A: water, 0.1% formic acid; B: acetonitrile, 0.1% formic acid), with the last 4 min as column 
re-equilibration. Samples were analyzed using a UPLC system (UPLC Acquity, Waters Ltd., 
Elstree, U.K.) coupled online to a Q-TOF Premier mass spectrometer (Waters MS 
Technologies, Ltd., Manchester, U.K.) in negative electrospray mode with a scan range of 
50-1000 m/z. MSE mode has been used to distinguish glycine (m/z 74) and taurine 
conjugates (80, 106 and 124) by their fragmentation pattern. Low energy acquisition has 
been performed with collision energy of 5 eV while it was set up at 50 eV for the high 
energy acquisition. Leucine enkephalin was used as the Lockmass. 
 
3.3.4 Data processing and analysis 
Chromatograms were processed in both a targeted and untargeted way using QuanLynx and 
XCMS respectively. 
Targeted analysis 
BA were annotated based m/z ratio and retention time reported by Want et al. and updated 
from data collected from the analysis of a mixture of 18 authentic BA standards. Extracted 
ions chromatograms were created with a mass window of 100 mDa and retention time were 
specified with a 2 second tolerance. A 1 X 2 smoothing was applied before peak integration.  
Peak areas were determined by Apex3D algorithm and systematically reviewed manually. 
Areas of BA chromatographic peaks were compared by a two-tailed unpaired t-test after 
variance has been assessed in the control and PBAD groups (Origin Pro 8.6). A p-value of less 
than 0.05 was taken to be significant. 
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Untargeted analysis 
Peak picking was performed by the centWave algorithm optimised for high mass accuracy 
UPLC-MS data. Detected features were grouped and chromatograms aligned. Features not 
detected in one or more sample were kept and background integrated to avoid missing 
values in the dataset which is then exported. 
Multivariate statistical analysis (MVA) was performed with SIMCA P+ v12 (Umetrics, Umeå, 
Sweden). Principal Component Analysis (PCA) was used to identify outliers and trends in the 
dataset.  A supervised MVA was then performed by introducing sample group knowledge in 
the model. Partial Least Squares – Discriminant Analysis (PLS-DA) was used to relate 
experimental data to sample classification.  To improve classification of samples and make 
interpretation easier, orthogonal PLS-DA model (OPLS-DA) was created to separate the 
(orthogonal components).  
3.4 Study 4: Meal Response 
See Appendix 2 for full schedule of events. 
Subjects were recruited and characterised as described in 3.1.1. Bile acid sequestrants were 
omitted in the week leading up to the testing day. Subjects were asked to fast from 9pm the 
night before and the following morning attended the research ward, The Sir John 
McMichael Centre at 08.30. Consent was confirmed. A peripheral cannula was then inserted 
and 4ml blood drawn for processing. Blood was centrifuged and decanted as described 
above. At 9.00am breakfast consisting of cornflakes, 2 slices of toast with butter and jam, a 
banana and tea/coffee was provided.  Total weight 395g, total energy 2153KJ, protein: 
carbohydrate: fat energy ratio 9%:71%:20%. Peripheral venous blood was collected every 
90mins at 10.30am, 12.00pm, 1.30pm and 3.00pm. Lunch was given immediately after the 
12.00pm sample collection and consisted of a cheese and lettuce sandwich, crisps, yoghurt 
and a drink. Total weight 690g, total energy 2860KJ, protein: carbohydrate: fat energy ratio 
11%: 58%: 31%. Serum samples were labelled and stored at -80°c immediately for later 
processing. Serum FGF19 and total bile acids were measured as described at a later date. 
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3.5 Study 5: Ageing study 
In collaboration with Prof Gary Frost’s team of the Nutrition and Dietetics Research Group at 
Imperial College we have explored fasting serum FGF19 levels in individuals of different 
ages.  Subjects were recruited by the Nutrition and Dietetics Group as part of their research 
project ‘Comparison of gut appetite hormones in healthy older and young adults’. Ethical 
approval was provided by the Riverside Research Ethics Committee (REC No 08/H0706/128). 
Serum samples and data were made available to our group for analysis. 
The subjects were all healthy with no acute or chronic disease, and having undergone no 
surgery or taking any medication known to interfere with gut peptide secretion. They were 
matched to sex and BMI (within ±3Kg/M²). 
Subjects with the following were excluded: 
• History of alcoholism or substance abuse within the last 5 years. 
• History of major haematological, renal, gastrointestinal, hepatic, respiratory, 
cardiovascular or psychiatric disease or any other illness or use of any medications 
including over the counter (OTC) products, which, in the opinion of the investigators, 
would either interfere with the study or potentially cause harm to the volunteer. 
• Medical or psychological condition or social circumstances which could interfere 
with ability to participate reliably in the trail. 
• Women who are pregnant, breastfeeding or unable to maintain adequate 
contraception for the duration of the study and for one month afterwards. 
• Treatment with an investigational drug within the preceding 2 months. 
• Volunteers who have donated, or intend to donate blood within 3 months before or 
following study completion. 
•  Smokers. 
Those on statins, antihypertensives and analgesics were not excluded.  
Full study details are described elsewhere but briefly, subjects were admitted for 4 hours to 
the research ward at 8.30am after an overnight fast from 9pm(98). A peripheral cannula was 
sited and blood drawn. This was centrifuged and pipetted into vials and frozen at -20°c. 
These samples were made available to our group, thawed and assayed for FGF19. Further 
samples were taken and a test meal provided – these samples were not used as part of our 
study. 
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 Table 2 Subject characteristics 
Subject Age Gender BMI Subject Age Gender BMI Subject Age Gender BMI 
F        27 M 21 R        57 F 23.4 O        65 M 26.6 
N        34 F 22.9 V        55 F 22.6 AE       60 M 25.3 
L        23 F 22.2 AC       54 F 24.3 AF       60 M 24.7 
Q        29 M 24.2 AJ       53 M 26.1 AA       67 M 25.9 
S        33 F 20.5 AI       40 M 25 AD       70 M 26 
T        22 F 22.1 AP       53 M 24.5 AG       75 F 22.5 
W        26 M 24.6 AR       58 F 20.5 AM       72 M 20.4 
X        21 M 22.5 AU       40 F 23.8 AQ       64 F 24.4 
Y        31 F 20.6 AT       44 M 24.5 BE       61 M 22.6 
AH       24 M 25.9 AV       48 M 24.9 BF       67 F 25.1 
AN       30 M 22.4 AW       56 F 21.2 BL       61 F 24.9 
AO       23 M 21.5 AX       59 M 20.5 BO       63 F 20.5 
AL       29 F 24 AY       48 M 25.3 M        81 F 26.8 
AZ       23 F 22.8 BG       42 F 25.6 BB       80 F 26.3 
BC       21 F 23.8 BD       56 F 25 BJ       89 F 24.2 
BA       21 M 24.4 BI       46 M 23.2 BK       86 F 20.5 
BH       29 F 20.5 A        70 F 23.1 BM       82 F 21.3 
AS       23 M 21.6 D        72 M 26.8 BN       92 F 21.7 
C        54 M 24.2 H        65 F 23.1     
I        43 F 22.2 P        79 M 24.1     
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3.6 Study 6: Obeticholic acid treatment in patients with bile acid diarrhoea: 
an open-label, pilot study of mechanisms, safety and symptom response 
(Obadiah 1) 
 
3.6.1 Introduction 
Bile acid diarrhoea is the condition in which excess bile acids reach the colon where they 
exert their toxic effect on colonic mucosa and the enteric nervous system leading to water 
and chloride secretion and motility changed, resulting in symptoms of diarrhoea and 
urgency for patients. We have shown lower fasting levels of serum FGF19 in patients with 
both primary BAD and secondary BAD.  Lower levels of FGF19 are associated with bile acid 
dysregulation with excess bile acid synthesis as reflected by elevated levels of C4 in those 
with BAD when compared with diarrhoea controls.  
Obeticholic acid is a potent Farnesoid X receptor agonist which has been shown in clinical 
studies to lead to elevated serum FGF19 levels in patients with other medical conditions and 
healthy volunteers. Its 100 times more powerful a FXR ligand than the natural ligand 
chenodeoxycholic acid(89)(90)(91). It is hypothesised that administration of OCA to 
individuals with primary and secondary BAD will increase their fasting FGF19 level, which 
may in turn lead to reduced bile acid synthesis with lower C4 levels. If the markers of bile 
acid biosynthesis are normalised by OCA this may lead to clinical improvement in symptoms.  
This study is designed to test this hypothesis by taking subjects with primary BAD and 
examining the effects of OCA on FGF19, bile acid biosynthesis markers, clinical symptoms 
and other safety markers. 
NB. The OBADIAH study is designed to examine the effects of OCA in 3 groups of patients, 
those with ID and SBAD in addition to PBAD. Only the PBAD cohort will be discussed in 
detail in this thesis. 
3.6.2 Study design 
The study was an open label with no placebo controlled arm. It was a pilot study 
investigating mechanisms of BAD as well as symptom and safety response to the treatment. 
The study was sponsored by Imperial College London and Imperial College Healthcare NHS 
Trust. The study was registered with the Europeans Medicine Agency through the trial 
register EudraCT (registration number 2011-003777-28). The trial was also registered 
through the US clinical trials register ClinicalTrial.gov (registration number NCT01585025). 
Ethical approval was provided by the National Research Ethics Service Committee (REC 
reference 12/LO/0123). Obeticholic Acid was provided free of charge by Intercept 
Pharmaceuticals, Inc (San Diego, CA). The use of OCA was approved by the Medicines and 
Healthcare products Regulatory Authority (MHRA, LONDON, UK).  
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All subjects had the study explained to them orally and were provided with a patient 
information sheet (PIS) for further information. Written informed consent was obtained in 
all cases.  Subjects were free to withdraw from the study at any point. The study was 
conducted in accordance with the principles of Good Clinical Practice. An independent Data 
and Safety Monitoring Committee reviewed study progress and safety criteria at regular 
intervals. 
Each participant attended for a screening visit to ensure that inclusion and exclusion criteria 
were met, for screening bloods and for consent purposes.  The study lasted 6 weeks for 
each subject. Any usual bile acid sequestrants were stopped at the start of the study and not 
permitted throughout. They continued with their other usual medication. Rescue therapy of 
up to 16mg of loperamide was allowed daily. A symptom diary was kept by the subject 
throughout the study period (Appendix 2).  Every day the time and type of stool (according 
to the Bristol Stool Form Scale) was recorded.  Hours of abdominal pain per day and pain 
severity on a scale of 0 – 10 were recorded. Additionally urgency and bloating were assessed 
also on a scale of 0 – 10. Number of loperamide per day was recorded. Patients were asked 
to record any adverse events on the diary.  
 
Figure 5 OBADIAH trial design 
 
Weeks 1 and 2 were a ‘wash out’ phase to allow the effects of any bile acid sequestrants on bile acid 
physiology to normalize. On the first day of week 3 and the first day of week 5 subjects attended the 
Sir John McMichael Centre at 8.30am having been nil by mouth from 9pm the night before. On 
arrival routine observations were performed and bloods were taken for Liver Function Tests, lipids, 
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total serum bile acids and a sample for centrifugation for later analysis of FGF19 and C4. At 9am OCA 
25mg was given immediately followed by a standard breakfast consisting of cornflakes, 2 slices of 
toast with butter and jam, a banana and tea/coffee was provided.  Total weight 395g, total energy 
2153KJ, protein: carbohydrate: fat energy ratio 9%:71%:20%.  
Subjects had a peripheral cannula inserted and venous blood was collected every 60mins at 10am, 
11am, 12pm, 1pm, 2pm and 3pm. Lunch was given immediately after the 12.00pm sample collection 
and consisted of a cheese and lettuce sandwich, crisps, yoghurt and a drink. Total weight 690g, total 
energy 2860KJ, protein: carbohydrate: fat energy ratio 11%: 58%: 31%. 
3.6.3 Subjects 
35 patients with PBAD were recruited from the Nuclear Medicine departments and 
Gastroenterology outpatient departments of Hammersmith and Charing Cross Hospitals. 
Subjects were aged 18 to 80 and all had had chronic diarrhoea prior to recruitment. Chronic 
diarrhoea was defined as 3 or more Bristol Stool type 6 or 7 stools per day for at least 3 
months. Patients had had standard investigation for chronic diarrhoea including standard 
blood tests including TTG and CRP. All had endoscopic assessment of the lower bowel with a 
flexible sigmoidoscopy or colonoscopy plus biopsy to exclude microscopic colitis. Other 
causes of diarrhoea were excluded including neoplasia, inflammatory bowel disease, enteric 
infection, coeliac disease, lactose intolerance and drug induced diarrhoea. 
All patients in the Primary BAD group had a SeHCAT scan performed and had a 7 day 
retention value of less than 10%. All subjects in the idiopathic diarrhoea group also had a 
SeHCAT performed and had retention of more than 15% at 7 days. Those in the Secondary 
BAD group all had either had terminal ileal resection or had evidence of overt terminal ileal 
disease. A SeHCAT scan was not deemed necessary for this group as it is known that >90% of 
those individuals with resected TI with chronic diarrhoea have a SeHCAT retention of less 
than 10%. There were 2 subjects in the secondary BAD group with Crohn’s disease who had 
not had resections. These 2 patients had SeHCAT tests with 7 day retention values of 8% and 
10%. The ileal resection lengths ranged from 15 to 71cm with a median of 34cm. 
 
3.6.4 Statistical analysis 
The primary endpoint was change in fasting serum FGF19 before and after 2 weeks 
administration of obeticholic acid. The serum level of FGF19 on D0 immediately before the 
first dose of OCA and the fasting FGF19 level on D14 immediately before the final dose of 
OCA. Secondary outcomes were changes in fasting serum total bile acids, C4, lipids and liver 
function tests. Further outcomes were analysis of areas under the curve of FGF19 and bile 
acids with comparison of AUC between the first and final days of OCA, D0and D14. 
Clinical symptoms were analysed. Comparison was made between clinical symptoms in 
week 2, the second run in week in which no bile acid sequestrant or OCA was taken and 
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week 4, the second week of OCA treatment. Stool frequency was calculated as total stool 
numbers/ week. Stool consistency was calculated as average BSFS for weeks 2 and 4.  
A stool index was devised as follow: 
Stool index = (Total stool number * mean BSFS) + 3 * total weekly loperamide use in mg. 
This index provides a composite score of frequency and consistency whilst allowing for 
individual’s variable use of loperamide. The score equates one 2mg tablet of loperamide to 
one type 6 stool.  
Data are usually reported as medians and interquartile ranges (IQR).  Nonparametric tests 
were used to look for treatment effects including Kruskal-Wallis comparisons between the 
three groups, Mann-Whitney U unpaired or Wilcoxon paired rank tests and Spearman rank 
correlations.  Statistical analyses were performed using Winstat for Excel (R. Fitch Software, 
Bad Krozingen, Germany).  P values <0.05 were considered significant. 
 
3.6.5 Sample analysis 
At each time point blood was drawn into 3 x 4ml  gold top serum separator tubes using the 
BD vacutainer system. 2 serum separator tubes were centrifuged at 3100rpm for 10 
minutes. 1ml of serum was pipetted into 4 x vials. These were labelled and stored at -80c 
awaiting later processing. FGF19 was measured by quantitative sandwich enzyme 
immunoassay technique using a commercially available kit as previously described 
(Quantikine catalogue 1900, R&D systems, Minneapolis).  
Serum C4 was measured at the Department of Clinical Chemistry, Western General Hospital, 
Edinburgh using High Performance Liquid Chromatography (HPLC) following solid phase 
extraction. Total bile acids were measured by an enzymatic colorimetric method using 3-α-
hydroxysteroid dehydrogenase (Ref. no. 6K9001, Sentinel Diagnostics, Milan Italy). Liver 
function tests and lipids were measured by standard techniques by Clinical Chemistry at 
Hammersmith Hospital. 
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4. Results 
4.1 Study 1 
95 patients were prospectively recruited from out-patient clinics and at Nuclear Medicine at 
Imperial College Healthcare NHS Trust. 3 subjects did not attend one or both nuclear 
medicine appointments and were thus excluded. 3 further subjects were excluded as they 
did not fit criteria for diarrhoea on closer questioning. Another 3 subjects were excluded 
because another cause of diarrhoea was found, 1 idiopathic ulcerative colitis, 1 microscopic 
colitis and 1 with radiation colitis. 86 subjects were left for analysis.  
There were 51 females and 35 males. 41 subjects had SeHCAT retention of > 15% and were 
classified as idiopathic diarrhoea. 2 subjects were classified as type 1 BAD, 1 with previous 
right hemicolectomy and 1 with evidence if of ileal inflammation on TI biopsy. 34 subjects 
were classified as type 2 or primary BAD. 8 subjects had type 3 BAD, 6 with a history of 
cholecystectomy and 2 with coeliac disease. 
Table 3 Subjects recruited 
Diagnosis  SeHCAT 
0 - 5 % 
 
5.1 – 10 % 
 
10.1 – 15 % 
Median 
Age 
M : F Total 
Idiopathic 
diarrhoea 
 - - - 50 15:26 41 
Type 1 
BAD 
right hemi 
TI inflam 
1  
1 
- 37 0:2 2 
Type 2 
BAD 
 12 13 10 48 18:17 35 
Type 3 
BAD 
cholecyst 
coeliac 
5 
1 
1 
- 
- 
1 
49 
51 
2:4 
0:2 
6 
2 
Total  19 15 11 48 35:51 86 
 
Combined data 
The data have been combined with a previously recruited prospective cohort of patients. 
The previous cohort was prospectively recruited by the same criteria, with identical 
recording and analysis methodology and the same assay standards between October 2008 
and October 2010. 
In total 197 subjects were classified as either Idiopathic diarrhoea, type 1 BAD, type 2 BAD 
or type 3 BAD.  There were 93 with ID, 60 female and 33 male, median age 48. 35 subjects 
had secondary BAD (types 1 and 3 combined). 24 female and 11 male with median age 53.  
There are 69 subjects with primary BAD, 36 female, 33 male. Median age for those with 
primary BAD is 48. 
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The focus of this research is primary bile acid diarrhoea. The results and discussion will 
reflect this with the dataset containing only those without other significant GI disease, that 
is PBAD and ID. 
General characteristics 
Age 
The median age for PBAD is 47 and 48 for ID. There is no significant age difference between 
those with PBAD and those with ID. There were also no differences when PBAD was split by 
SeHCAT into mild (10.1 – 15%), moderate (5.1 – 10%) and severe (0 – 5%) groups. The 
median ages for these groups were 48, 45 and 47, respectively. 
Sex 
More subjects with ID are female than those with PBAD. The female to male ratio for ID as a 
whole is 1.8:1. The ratio for PBAD is 1.1:1. This difference does not meet significance 
(p=0.15 Fishers). Those with SeHCAT retention of less than 5% the F:M ratio is = 0.8:1; 5.1-
10% = 1.4:1, 10.1-15% = 1.2:1. There are no significant differences between any of these 
groups. 
Ethnicity 
The ethnicity make up of each group and sub group were similar. For ID most (74.2%) were 
white, followed by Asian (12.9%) with Afro-Caribbean accounting for (4.3%). There were 8 of 
other race (8.6%). PBAD proportions were white (68.1%), Asian (13.0%) Afro-Caribbean 
(4.3%) and other (14.5%). No significant differences were found between the groups and 
subgroups. 
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  PBAD 
0 - 5 % 
 
5.1 – 10 
% 
10.1 – 
15 % 
All PBAD ID p value  
Total 
subjects 
 18 29 22 69 93   
Age 
 
 47 48 45 47 48   
Sex (F:M) 
 
 0.82 1.5 1 1.09 1.82   
Ethnicity 
(%) 
W 
 
AC 
 
Ai 
 
O 
15(75) 
 
1(5) 
 
1(5) 
 
3(15) 
20(69.0) 
 
1(3.4) 
 
4 (13.8) 
 
4 (13.8) 
12(60) 
 
1(5) 
 
4(20) 
 
3(15) 
47(68.1) 
 
3(4.3) 
 
9(13.0) 
 
10(14.5) 
69(74.2) 
 
4(4.3) 
 
12(12.9) 
 
8(8.6) 
 
  
BMI 
 
 27.00 24.04 26.00 27.001 23.951 1<0.05  
BO/24hrs 
 
 5.25 5.75 5.00 5.00 5.00   
Av.Bristol 
stool form 
 
 6.50 6.25 6.00 6.50 6.00   
Duration 
(yrs) 
 
 4.251,2,3 2.001 1.502 2.00 1.833 1&2 <0.05 
3 = 0.06 
 
Steatorrhoea 
(%) 
 551 45 25 39 261 1 = 0.02  
Pain (%) 
 
 55 55 65 57 63   
Bloating (%) 
 
 80 75 75 74 68   
Incontinence 
(%) 
 
 55 25 20 36 39   
Figure 6 Subject clinical characteristics according to subgroup defined by SeHCAT retention 
 
BMI 
The median body mass index of those with PBAD is 27.00kg/m2 and 23.95 kg/m2 in ID. This 
is significantly different p = 0.009. Between subgroups the only significant difference is 
between mild PBAD and ID (p=0.03). 
All PBAD and ID subjects were analysed together. BMI correlates with age (R=0.24 p=0.001). 
This correlation is lost in the PBAD but is present in the ID group (R = 0.37 p = 0.0002) 
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BMI also correlated with fasting serum triglyceride level in ID and PBAD combined (R = 0.35 
p = 0.0001), and in the separate diagnoses in (PBAD: R = 0.35 p = 0.006, ID: R = 0.38 p = 
0.07).  
BMI correlated negatively with SeHCAT retention (R = -0.18, p = 0.008). This correlation did 
not reach significance in the ID or PBAD groupings. FGF19 tended to be lower in those with 
higher BMI (R = -0.11, p = 0.09). There was no significant correlation between BMI and 
FGF19 in ID or PBAD groups when analysed separately. 
Symptoms 
Symptoms are similar between those with PBAD and those with ID. The median number of 
bowel motions per day is 5.0 for both PBAD and ID. Similarly the median Bristol stool form is 
not significantly different between the 2 groups, 6.5 for PBAD and 6.0 for ID. 
Those with PBAD tend to report more steatorrhoea, 39% of those with PBAD and 26% with 
ID (p=0.08). 55% of those with PBAD and a SeHCAT of < 5% report steatorrhoea which is 
significantly different compared with the whole ID group (p = 0.02). 
57% of PBAD and 63% of ID subjects experience abdominal pain. Bloating is 74% and 68% 
for PBAD and ID respectively. Faecal incontinence is experienced by 36% with PBAD and 39% 
with ID. All symptoms tend to be worse in PBAD with SeHCAT < 5% than in PBAD with higher 
SeHCAT retention or compared with Idiopathic diarrhoea.  
Those with PBAD have had symptoms for a similar length of time to those with normal 
SeHCAT retention, 2.00 versus 1.83 years. In those with SeHCAT retention of less than 5% 
however, individuals have had symptoms significantly longer than those with retention of 5 
– 10% (2.00 years) or 10 – 15% (1.5 years).   
 
FGF19 
Median fasting FGF19 levels were compared between PBAD and ID. PBAD have significantly 
lower fasting FGF19 than ID (148 pg/ml vs 235 pg/ml, p = 0.0005) (Figure 7).  
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Figure 7 Median fasting FGF19  
When PBAD subjects are analysed as subgroups by SeHCAT (mild 0 – 5%, moderate 5.1- 
10%, severe 10.1-15%) each subgroup has a significantly lower fasting FGF19 than the ID 
group. Medians: ID 236.0 pg/ml, severe PBAD 95.83 pg/ml, mod PBAD 190 pg/ml, mild PBAD 
173.2 pg/ ml (Figure 8).  
Difference in medians between the different severities of PBAD neared significance between 
severe and moderate (p = 0.06); and severe and mild (p = 0.08) 
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Figure 8 Median fasting FGF19 in PBAD subgroups and ID 
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Spearman rank non-parametric correlations have been performed, seeking associations 
between FGF19 and other variables. As has been demonstrated before (87) there is a strong 
correlation between FGF19 and SeHCAT retention (R = 0.3345, p < 0.0001; Pearson linear 
regression p = 0.0013 R = 0.06). 
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Figure 9 Correlation between SeHCAT and FGF19. Pearson linear regression shown 
There were associations between fasting serum lipids and FGF19. Strongest association was 
found between FGF19 and total cholesterol (r = 0.33, p =0.009) and LDL cholesterol (r = 
0.34, p = 0.01). There is a non-significant association between FGF19 and HDL cholesterol ( r 
= -0.14, p = 0.27).  
Triglycerides 
Serum triglycerides display some interesting associations. Higher FGF19 is associated with 
higher serum triglycerides (r = 0.20, p = 0.04) (See Figure 10). Given that FGF19 correlates 
with SeHCAT retention one may also have expected triglycerides to correlate positively with 
SeHCAT retention, that is those with PBAD and low SeHCAT retention to have a 
correspondingly low triglyceride level to go along with their low serum FGF19. However, 
there is a significant negative association between triglycerides and SeHCAT retention (R = -
0.32, p = 0.0008).  As can be seen from Figure 11 there is a clear negative correlation. In 
particular however is a subset of subjects with a serum triglyceride level of over 2.4mmol/L 
the majority of whom have PBAD (12 out of 17) and of the 5 subjects with triglycerides of 
over 2.4 mmol/L with idiopathic diarrhoea 3 out of 5 have SeHCAT retention of under 20%. 
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These subjects with elevated triglycerides and low SEHCAT retention may represent a 
separate subset of disease with different underlying aetiology.  
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Figure 10 Correlation FGF19 vs Triglycerides 
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Figure 11 Negative correlation between SeHCAT retention and fasting triglycerides. PBAD subjects with elevated 
triglycerides boxed. 
 
 
A comparison therefore has been made between FGF19 levels of those PBAD subjects with 
triglycerides of under 2.4 mmol/L against those with levels above 2.4 mmol/L. As can be 
seen from Figure 12 those with higher triglycerides have significantly higher fasting FGF19 
236.9 pg/ml vs 124.7 pg/ml.  
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Figure 12 FGF19 level of PBAD subjects, split according to serum triglyceride level 
Therefore a group of patients has been identified with low SeHCAT retention, high 
triglycerides and higher than expected FGF19. The significance of this is that these subjects 
with low SeHCAT retention would be expected to have a low FGF 19, but in fact they have a 
fasting level slightly higher than those with idiopathic diarrhoea and normal SeHCAT 
retention (236.9 vs 236.0 pg/ml). Duane et al have examined gene expression of ASBT from 
terminal ileal biopsies in subjects with hypertriglyceridaemia and controls. Significantly 
lower ASBT expression was found in hypertriglyceridaemics(99). The fact that this group has 
normal FGF19 levels implies normal FGF19 production and signalling in a group with a 
primary transporter defect.  
It may be that our subjects with higher triglycerides had higher SeHCAT retention and thus 
higher fasting FGF19 levels so the SEHCAT retention was compared between the two 
triglyceride PBAD groups and there was no significant difference  ( trigs < 2.4 SeHCAT 6.7%, 
trigs > 2.4 SeHCAT 7.0%, p = 0.94, see figure 13). 
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Figure 13 SeHCAT retention of PBAD subjects, split according to triglyceride level 
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Figure 14 Total BA ID vs PBAD 
Cholesterol 
Cholesterol was measured in 62 of 162 subjects with ID and PBAD. Fasting FGF19 correlates 
with total cholesterol, see Figure 15. There is no correlation between FGF19 and HDL 
cholesterol (r = -0.14, p = 0.27) however there is a correlation between FGF19 and LDL 
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cholesterol (r = 0.33, p = 0.01). 5 subjects had a cholesterol of 7.0 mmol/L or more, the 
highest value measured was 9.6 mmol/L. Of these 5 subjects 2 has ID and 3 had PBAD with 
SeHCAT ranging from 0 to 75%. They are all clinically unremarkable. At the other end of the 
scale, there were 6 individuals with cholesterol of under 3.5 mmol/L. 3 had PBAD and 3 ID, 
SeHCAT range 0 – 65%, FGF19  21.7 – 200.4 pg/ml. These patients are also clinically 
unremarkable. 
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Figure 15 Correlation Total cholesterol and FGF19 
Bile Acids 
Of all the factors with which FGF19 correlates, the strongest is with serum fasting total bile 
acids. All ID and PBAD was analysed together. Total BA values were available for 157 of 161 
patients. All had FGF19 values. As can be seen from Figure 16, Subjects with lowest fasting 
FGF19 had lowest BA and those with highest FGF19 had very high BA values (R = 0.32, p < 
0.0001). This correlation is maintained when analysing the PBAD group separately (r = 0.35, 
p = 0.004).  
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Figure 16 Correlation fasting FGF19 vs Total BA 
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Figure 17 PBAD subjects only, FGF19 vs Total BA 
There was no significant relationship found between BA and SeHCAT retention, however. 
Nor was there a significant difference between median fasting BA levels between ID and 
PBAD (2.25 mmol/L vs 2.1 mmol/L, p = 0.68, Figure 19). Subgroups of PBAD according to 
SeHCAT (0 – 5%, 5 – 10%, 10 – 15%) also had no difference in BA from each other or 
compared with ID. Correlation of BA with other variables does not reach significance. BA 
tend to increase with serum triglycerides (r = 0.19, p = 0.06). 
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Figure 18 SeHCAT vs Total BA. No significant association 
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Figure 19 Total BA ID vs PBAD 
Summary 
In this part of Study 1 fasting levels of FGF19, cholesterol, triglycerides and total bile acids 
have been explored in subjects with ID and PBAD. As has been shown previously, subjects 
with PBAD have lower fasting levels of FGF19, and FGF19 correlates with SeHCAT retention 
as a whole and within the two diagnoses of ID and PBAD. It has been shown that 
triglycerides correlate with FGF19 and SeHCAT retention and that there is a subset of 
patients with elevated triglycerides, low SeHCAT retention and normal FGF19 who may have 
PBAD due to reduced ASBT expression.  
55 
 
It has also been shown that fasting total BA correlates strongly with fasting FGF19 across the 
whole cohort and within the diagnoses, however BA does not correlate with SeHCAT 
retention.  
56 
 
4.1.3 Fat soluble vitamins A and D 
Serum vitamin A ranged from 0.67 – 4.8 µmol/l. Only one subject had a value below our 
laboratory’s normal range. The subject was a 56 year old female of Asian origin with 
diabetes and cirrhosis, with a SeHCAT of 1.4% and FGF19 of 260 pg/ml. Liver disease is 
known to lower serum vitamin A (100). 20 subjects had values above the normal range. The 
diagnoses were similar in proportion to those subjects within the normal range. 
The median serum vitamin A level for the diarrhoea control group was 1.95 µmol/l (IQR 1.50 
- 2.33). In the primary BAD group the median was 2.10 µmol/l (IQR 1.83 - 2.39) and in the 
secondary BAD group 1.90 µmol/l (IQR 1.60 - 2.35) (Figure 20). The differences were not 
significant between the diarrhoea controls and primary or secondary BAD (p = 0.116, 0.908) 
or between the two BAD types (p = 0.207). 
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Figure 20 Serum vitamin A in diarrhoea controls, PBAD and SBAD. IQR, 10 – 90 centiles, outliers. 
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FGF19 and vitamin A did not correlate (r  = -0.037, p > 0.06).  There was also no correlation 
when analysed within the diarrhoea control, primary or secondary BAD groups (r = -0.02, -
0.11, 0.30 p = 0.82, 0.45, 0.12) (Figure 21). Vitamin A also did not correlate with SeHCAT 
retention (r = -0.068, p = 0.39). Again, there was no correlation within groups (r = -0.14, 
0.037, 0.11; p = 0.25, 0.80, 0.56).  
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Figure 21 Vitamin A and FGF19 levels in individual subjects in the 3 groups 
Serum 25 OH vitamin D ranged from 10 – 135 nmol/l. Using a generally recognised cut-off of 
50 nmol/l, 57% of subjects had hypovitaminosis D (101).  Proportions of subjects with BAD 
above and below 50 nmol/l were similar (51%, 55% p = 0.55). 
Median serum 25 OH vitamin D level for diarrhoea control subjects was 45 nmol/l (IQR 26.0 
– 71.5). Median level for primary BAD was 38 nmol/l (IQR 24.00 – 63.45) and for secondary 
BAD 47 nmol/l (IQR 27.0 – 62.5) (Figure 22). The differences between diarrhoea controls and 
primary and secondary BAD was not significant (p > 0.3, 0.89). There was no significant 
difference between primary and secondary BAD (p = 0.611).  
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Figure 22 25 OH Vitamin D in diarrhoea controls, PBAD and SBAD IQR, 10 – 90 centiles and outliers. 
 
25 OH vitamin D did not correlate with FGF19 (r = -0.05, p > 0.55). When analysed within the 
diarrhoea control, primary and secondary BAD groups there was also no significant 
correlation groups (r = -0.14, 0.17, -0.29; p = 0.22, 0.27, 0.13) (Figure 23). There was also no 
correlation between 25 OH vitamin D and SeHCAT retention either as a whole, or within the 
groups (r = 0.02, -0.011, -0.070, -0.14; p = 0.74, 0.92, 0.62, 0.46). 
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Figure 23 25 OH vitamin D and FGF19 in individuals subjects in the 3 groups. 
Significant differences in serum vitamin A and D were also sought in those with more severe 
BAD. PBAD with SeHCAT retention of ≤ 5% were compared with diarrhoea controls however 
they were not significantly different. Vitamin A median 2.08 vs 1.95 p = 0.583, vitamin D 
median 41.8 vs 45.0, p = 0.78. 
Vitamin levels were also analysed according to ethnicity. No significant differences in serum 
vitamin A were found between ethnic groups. As would be expected subjects of Indian 
origin had significantly lower serum vitamin D levels than those of white British origin (32.5 
vs 50.7 p= 0.004). There were no other significant differences found in vitamin D between 
ethnic groups.  Among subjects of Indian origin those with type 2 BAD had lower vitamin D 
levels although this was non-significant (15.0 vs 34.4 p = 0.14). Significant differences within 
the other racial groups were not found. There were no significant differences in vitamin A 
between type 2 BAD and diarrhoea controls within racial groups. 
Neither serum vitamin A nor 25 OH vitamin D level correlated with various other factors 
including age, body mass index, number of stools per day or duration of illness.  Vitamin A 
and D levels did not correlate with each other. There was also no correlation between 
Vitamin A and D with total serum BAs (p > 0.7, 0.4). 
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4.1.4 Vitamin B12 
Vitamin B12 data was available for 101 subjects, 62 with ID and 39 with PBAD. Those 
subjects taking supplemental hydroxocobalamin were excluded from analysis. 4 individuals 
on regular parenteral hydroxocobalamin were identified. 2 were elderly women aged 79 
and 90, one with ID and the other with PBAD. They were clinically unremarkable with no 
significant co-morbidities. There was a further clinically unremarkable female aged 60 with 
ID on supplemental B12. There was a 46 year old male on supplemental B12 with no major 
illnesses but who took a proton pump inhibitor. B12 deficiency is common in the elderly and 
may relate to diet. Iatrogenic achlorhydria due to PPI may explain the need for 
supplemental B12 in the 46 year old male.  
Imperial College Clinical Chemistry laboratory quotes normal reference range for B12 as 180 
– 800 pg/ml (102). 14 subjects had levels < 180 pg/ml. 8 had ID, 6 had PBAD. 8 were female 
and 6 male. Their clinical characteristics were not significantly different to the rest of the 
study group. There were no individuals with a B12 level higher than the normal range. 
Correlations have been sought between B12 and other biochemical parameters including 
FGF19, total bile acids, vitamin A and D and triglycerides. There was a trend for higher 
FGF19 with higher B12 level (Figure 24). The other correlations did not near significance. 
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Figure 24 All ID and PBAD subjects: correlation between serum B12 and fasting FGF19 
 
Subjects with PBAD have non-significantly lower median B12 levels than ID (295 vs 375 
pg/ml p = 0.15). Subgroups of PBAD divided by SeHCAT retention (0 – 4.9%, 5.0 – 9.9%, 10 – 
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15%) have similar B12 levels (Figure 26). Comparison between ID and each of the PBAD 
subgroups does not reveal significant differences in serum B12 level. 
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Figure 25 B12 levels in ID and PBAD (medians, 10 – 90 centile + outliers) 
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Figure 26 Serum B12 in PBAD subgroups of differing severity 
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4.1.5 Reproducibility of FGF19 data 
Previous work on FGF19 stability: The short term stability of FGF19 has been investigated 
by my predecessor Dr Sanjeev Pattni. In studies on 3 healthy subjects blood was drawn and 
centrifuged. A 0 hour sample was processed for FGF19.  Serum was then kept at room 
temperature on a lab bench. Samples were processed at 3 and 6 hours. After 6 hours the 
mean percentage change was 8%. 
Longer term stability was also assessed. Whole blood from 4 healthy individuals was again 
drawn and centrifuged and a zero hour FGF19 level measured by ELISA. Samples were 
stored at room temperature for 6, 12, 24 and 48 hours and processed at these time points. 
Mean change in FGF19 was 9% at 24 hours and 6% at 48 hours(103). 
The effect of freeze – thaw cycles was also determined. Serum from 3 healthy volunteers 
was frozen and then thawed twice over a period of 5 days with no significant changes 
FGF19.  Mean change was +15%. 
Reproducibility of Fasting FGF19:  Of the 21 subjects who underwent serial sampling for 
FGF19 in the day series study (Study 4) 20 had previously provided a fasting sample for 
FGF19 analysis in Study 1. A comparison has been made of the fasting values in these 20 
subjects on the 2 testing days. The time between the samples varied widely between 
subjects between 2 weeks and 5 months. The percentage change varied from – 34 to + 
542%. The % change was made +ve for each individual and the median was calculated as 
36.5% difference between the 2 testing days. 
Subject original Day series  % change 
BD213 25.7 16.8 34.6 
BD93 146 92 37.0 
BD244 43.4 279 542.9 
BD118 30 36 20.0 
BD81 125 77 38.4 
BD40 172 143 16.9 
BD06 290 508 75.2 
BD83 145 154 6.2 
BD110 142 153 7.8 
BD25 146 752 415.1 
BD214 198.9 142.9 28.2 
BD229 286.1 349.4 22.1 
BD38 406 119 70.7 
BD212 241.4 74.5 69.1 
BD90 268 114 57.5 
BD86 142 572 302.8 
BD224 655.7 386.8 41.0 
BD222 178.9 114.6 35.9 
BD265 321.8 304.1 5.5 
BD235 150.6 140.2 6.9 
  Median +36.5 % 
Table 4 Fasting FGF19 from study 1 and at later date from study 4 
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Most (12/20) subjects had variation of less than 65 pg/ML between the two samples however 5 
showed much greater variation with differences of > 200 pg/ML. 
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Figure 27 Fasting FGF19 from study 1 and at later date from study 4 
4.1.6 Biological significance of results 
It has been confirmed in study 1 that those with PBAD have lower fasting FGF19 than those 
with ID and furthermore that FGF19 correlates with SeHCAT over the whole cohort and 
within ID and PBAD. The biological significance of this is that it shows perturbation of the 
homeostatic mechanism regulating the bile acid pool. Although it is not possible to say 
whether the lower FGF19 level is the primary abnormality, there is increased BA synthesis 
and turnover due to reduced feedback from the FXR – FGF19 axis. This increased synthesis 
has been shown previously through higher levels of C4(86).  
The finding of a subset with high triglycerides and normal FGF19 is important and its 
biological significance is that it may reflect reduced BA absorption at the enterocyte, 
possibly due to reduced ASBT expression or transport. 
The finding that self-reported steatorrhoea is more common in severe PBAD is relevant as 
this suggests fat malabsorption. The simplest explanation would be ‘true’ BA malabsorption 
leading to reduction in bile acid pool size. Other than the triglyceride findings above there 
are no biochemical results to suggest actual BA malabsorption.  
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B12 levels are non-significantly lower in PBAD than ID and B12 nears significant correlation 
with FGF19. The significance of lower B12 is that this may reflect small intestinal bacterial 
overgrowth which is known to cause B12 deficiency. The near correlation of FGF19 and B12 
may be due to reduced BA concentration in the TI. Lower BA would have less bactericidal 
properties and would lead to less FXR activation and vice versa. 
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4.2 Genetic polymorphisms 
161 subjects had blood taken for DNA extraction and later analysis. The general 
characteristics of the group are described in detail in Study 1 section of results. Successful 
DNA extraction occurred in all 161 patients. All but 4 subjects had an A260/A280 nanodrop 
purity of 1.7 – 1.9. These samples were then re-extracted and then fell within range. One 
subject yielded no results due to accidental loss of extracted DNA. In total there were 1326 
successful genotype calls from the sample set with 123 fails, a total success of 91.5%. Two 
batches of genotyping failed. The first affected SNP rs61755050 was due to expiration of 
SNP assay. Unfortunately time limitations did not permit a repeat of this experiment with 
fresh SNP assay. The second batch failure was the final batch run and this was due to 
running out of extracted DNA, due to its use in previous experiments. When these batches 
are excluded the call rate was 97%.  
 
Gene 
product 
Gene SNP  Position Number of 
subjects 
MAF P  
     ID PBAD ID PBAD   
FGF19 FGF19 rs1789170 G>A 3’-UTR 84 72 0.357 0.396 0.48  
  rs948992 A>G 3’-UTR 86 71 0.366 0.331 0.55  
FXR NR1H4 rs61755050 T>C Met173Thr 60 51 0 0.020 0.21  
  rs56163822 G>T Translation start 80 67 0.044 0.030 0.76  
FGFR4 FGFR4 rs376618 T>C Leu136Pro 86 70 0.285 0.221 0.24  
KLB KLB rs17618244 G>A Arg728Gln 86 71 0.186 0.120 0.12  
ASBT SCL10A2 rs188096 C>A Ala171Ser 86 71 0.098 0.113 0.71  
OSTα SLC51A rs939885 G>A Val86Ile 55 57 0.482 0.493 0.90  
TNFSF15 TNFSF15 rs7848647 C>T 5’-flanking 87 71 0.282 0.338 0.33  
Table 5 Summary table 
rs1789170 
This is a SNP in the FGF19 gene. There were 5 fails, 156 successful results. Minor allele 
frequency (MAF) of 37.5%, no significant difference between patient groups and no 
dominance effect found. 
Table 6 rs1789170 
Dx AA AG GG A G MAF% p 
ID 10 40 34 60 108 35.7 0.48 
PBAD 13 31 28 57 87 39.6  
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Table 7 Dominance effect 
Dx AA+AG GG p 
ID 50 34 0.87 
PBAD 44 28  
 
rs948992 
Polymorphism in FGF19. There were 3 failed samples with no significant difference in MAF% 
identified. No dominance effect was found. 
Table 8 rs948992 
Dx AA AG GG A G MAF% p 
ID 35 39 12 109 63 36.6 0.55 
PBAD 32 31 8 95 47 33.1  
 
Table 9 Dominance effect 
Dx AA+AG GG p 
ID 50 34 0.8708 
PBAD 44 28  
 
rs61755050 
FXR SNP 518T>C has previously been shown to affect FXR expression and function (104).  
Unfortunately later assays failed due to expiry of the SNP assay. Only 2 subjects out of 111 
successful genotypes had the minor allele CT. Both have severe PBAD with SeHCAT 
retention of 3% and 2% and low FGF19 levels of 59 pg/ml and 149 pg/ml respectively. Total 
BA were 0.9 mmol/L and 5.9 mmol/L. Comparison of genotype frequencies using Fishers 
exact test did not reach significance. Mann-Whitney test for comparison of SeHCAT and 
FGF19 between subjects of different genotype is not significant, possibly due to small 
sample size. For the previously recorded minor allele frequency of 0.16% the study is 
inadequately powered. For a significance of 0.05 and a power of 0.80 necessary sample size 
would have to be 494. 
Table 10 rs61755050 
Dx CC CT TT C T MAF% p 
ID 0 0 60 0 120 0 0.21 
PBAD 0 2 49 2 100 2  
 
Table 11 Dominance effect 
Dx CC+CT TT p 
ID 0 60 0.21 
PBAD 2 49  
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rs56163822 
This is a SNP in gene FXR with associations demonstrated with IBD and intrahepatic 
cholestasis of pregnancy. It leads to -1G>T change. There is a low reported MAF of 2.2%. No 
significant differences have been found between disease and control subjects; however the 
sample size is too low to detect small differences for this allele frequency. 
Table 12 rs56163822 
Dx GG GT TT G T MAF% p 
ID 74 5 1 153 7 4.38 0.76 
PBAD 63 4 0 130 4 2.99  
 
One individual was homozygous for the minor allele. She had ID with a 7 day SeHCAT 
retention of 20.9%, fasting FGF19 237.0 pg/ml. There was no GI disease but the patient has 
bipolar disorder.  
No dominance effect was detected. There were 137 successful genotype calls with 13 fails 
due to technical reasons. 
Table 13 Dominance 
Dx CC+CT TT p 
ID 0 60 0.21 
PBAD 2 49  
 
rs17618244 
This is a polymorphism in the KLB gene encoding klotho-β, a protein that modulates the 
function of FGFR4. Associations with diarrhoea predominant IBS has been shown(105). The 
G allele was more frequent in PBAD than in ID (p = 0.12). The G allele has previously been 
shown to be associated with faster gut transit time in response to oral chenodeoxycholic 
acid. 7 subjects had the genotype AA of whom 6 had ID and 1 had PBAD. The PBAD 
individual had a SeHCAT of 7.1%. The 6 individuals with ID had 7 day SeHCAT retention 
ranging from 19 – 51 % with a median of 21.5%. Performing Fisher’s exact test of AA 
genotype against AG + GG in the disease types reveals a difference in proportions p = 0.07. 
There were 4 failed genotype calls. 
Table 14 rs17618244 
Dx AA AG GG A G MAF% p 
ID 7 18 61 32 140 18.6 0.12 
PBAD 1 15 55 17 125 11.97  
 
 
68 
 
Table 15 Dominance effect 
Dx AA+AG GG p 
ID 25 61 0.37 
PBAD 16 55  
 
rs939885 
This SNP in OSTα has been investigated by others for associations with IBS-D. No significant 
associations have been found in this study. 34 individuals could not be genotyped because 
of insufficient DNA due to previous analyses. With very similar MAFs in the 2 groups and a 
high p value, slightly higher sample size would have made no material difference to 
significance. 
Table 16 rs939885 
Dx AA AG GG A G MAF% p 
ID 14 25 16 53 57 48.2 0.90 
PBAD 18 30 19 66 68 49.3  
 
Table 17 Dominance 
Dx AA+AG GG p 
ID 39 16 1.00 
PBAD 48 19  
 
rs7848647 
This polymorphism results in a C to T change in the TNFS15 gene at position 116608867.  
The TNFS15 family of proteins are involved in the aetiology of inflammatory bowel disease 
and SNPs have been associated with both post infectious IBS and diverticulitis (106)(107).  
 
Table 18 rs78448647 
Dx TT CT CC T C MAF% p 
ID 5 39 43 49 125 28.2 0.33 
PBAD 8 32 31 48 94 33.8  
 
Genotyping was successful in 158 of 161 samples. The T allele was found to be more 
prevalent in the PBAD population, not reaching significance.  There was no dominance 
effect noted. TT subjects did not differ clinically from those with other genotypes. 
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Table 19 Dominance 
Dx TT+TC CC p 
ID 44 43 0.52 
PBAD 40 31  
 
rs376618 
The FGFR4 variant rs376618 is non-synonymous (Leu136Pro) and has been linked to faster 
colonic transit in TT homozygotes.  It has been investigated previously for a possible role in 
hepatic tumorigenesis. 156 assays successfully completed. 
No significant difference in MAF was found but there was a lower proportion of CT 
heterozygotes in PBAD compared with in ID subjects (24% vs. 43%) and the frequency of TT 
versus CC + CT was significantly higher (p = 0.05).  TT subjects have a significantly lower 
SeHCAT to those in the combined CT + CC group (11 vs. 19, p = 0.037) but FGF19 levels were 
not significantly different (214 vs. 178 pg/mL, p = 0.33.  
Table 20 rs376618 
Dx CC CT TT C T MAF% p 
ID 6 37 43 49 123 28.5 0.24 
PBAD 7 17 46 31 109 22.1  
 
The minor allele was more common in PBAD, however did not reach significance.  For the 
minor allele frequencies found the sample size would have to be 817 to reach significance 
[online calculator www.stat.ubc.ca/~rollin/stats/ssize/b2.html].  
 
Table 21 Dominance 
Dx TT+CT CC p 
ID 80 6 0.57 
PBAD 63 7  
 
When a Fisher’s exact test is used to compare frequencies of TT versus CC + CT there is a 
significant difference in proportions, p = 0.05.  
rs188096 
Polymorphism in SCL10A2 gene encoding apical sodium linked bile acid transporter (ASBT) 
with a MAF of 16.0% (108). SNP leads to Ala to Ser substitution at amino acid 171. It has 
been found to be present in a family with the congenital version of PBAD(32). 
No significant difference in MAF was found although the sample size is low for the reported 
MAF. 3 individuals had the AA genotype, one with ID SeHCAT of 37% and two had PBAD 
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both severe with SeHCAT of less than 2%. All 3 individuals were clinically otherwise 
unremarkable. The ID individual had an FGF19 of 238 pg/ml which is unremarkable. The 2 
PBAD individuals with extremely low SeHCAT retention has surprisingly high FGF19 levels of 
260 and 313 pg/ml. Triglycerides for the ID individual was 0.76 ml/L, and 1.43 and 1.86 
mmol/L for those with PBAD. One of the PBAD subjects had very elevated total BA (14.2 
mmol/L) the others BA were well within the normal range. 
Analysing subgroups by SeHCAT also reveals no significantly different proportions of alleles. 
Table 22 RS188096 
Dx AA AC CC A C MAF% p 
ID 1 15 70 17 155 9.9 0.7148 
PBAD 2 12 57 16 126 11.3  
 
Table 23 Dominance 
Dx AA+AC CC p 
ID 16 70 1.00 
PBAD 14 57  
 
  
71 
 
4.3 Bile Acid Species Characterisation 
20 subjects had serum analysed for BA characterisation. There were 10 subjects with PBAD 
4 male, 6 female with median age 37.5 years (range 26 to 70). There were 10 subjects with 
ID 5 male, 5 female median age 59 (range 18 to 90). For PBAD the median SeHCAT was 4.9% 
(range 2 to 6.7%); ID subjects median 48% (31 to 74.5%). Clinical characteristics were similar 
between the 2 groups. 
Relative BA levels for 17 BAs are shown in Figures 28, 29 and Table 24. Values are expressed 
in arbitrary units. Median values in PBAD and ID are shown in the table with p values. 7 
unconjugated, 4 glyco-conjugated and 6 tauro-conjugated BAs have been identified. 
Table 24 BA species in PBAD and ID 
 
aMCA HCA CA UDCA HDCA CDCA DCA 
PBAD median 0.001 0.445 1.68 0.24 0.047 0.8805 4.672 
ID median 0.001 0.78 1.982 0.376 0.138 1.754 7.385 
p value 0.78 0.33 0.52 0.65 0.14 0.62 0.28 
        
 
GCDCA GDCA GCA GLCA 
   PBAD median 13.4 4.156 4.577 0.1895 
   ID median 9.86 4.577 4.156 0.1875 
   p value 0.84 0.83 0.84 0.89 
   
        
 
aTMCA TCA TUDCA TCDCA TDCA TLCA 
 PBAD median 0.01 1.298 0.01 1.414 1.34 0.01 
 ID median 0.328 1.817 0.0122 2.42 1.166 0.0385 
 p value 0.0043 0.47 0.4 0.24 1 0.44 
  
Of the 17 BAs, the highest median level across the 20 patients is GCDCA 10.4. Lowest is 
aMCA (0.001). 9 of the 17 have median values of < 1.00. 6 of the 17 BA have median levels 
of < 0.10. There is significant variation in BA levels between subjects. BA species have been 
added together for each individual. Median total BA by this technique is 30.7 and 45.5 for 
PBAD and ID (not significant p= 0.52)   
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Figure 28 BA species in PBAD and ID, medians and IQRs 
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Figure 29 BA species in PBAD and ID, medians and IQRs 
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Figure 30 Sum of BA species measured by UPLC-MS versus chemically measured total BA 
BA species levels are lower in PBAD than ID in 12 of 17. The BAs which are higher in PBAD 
are GCDCA, GCA, GLCA and TDCA. Median alpha-MCA is the same in both groups (0.001). 
The only BA in which there is a significant difference between the 2 groups is alpha-
tauromuricholic acid (ID 0.33, PBAD 0.01 p = 0.0043) This is a very minor component overall 
with uncertain relevance in humans. 
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Figure 31 alpha-tauromuricholic acid in PBAD and ID 
BA species and FGF19 
Spearman correlations have been performed between FGF19 and individual BAs. No 
correlations reaching significance were found. The BAs with the strongest correlation were 
aTMCA (r = 0.35, p = 0.13) and TCA (r = 0.39, p = 0.09). 
Correlation was also sought between FGF19 and the sum of the BAs. No significant 
correlation was found(r = 0.15, p = 0.53). 
 
  
aMCA 
 
HCA 
 
CA 
 
UDCA 
 
HDCA 
 
CDCA 
 
DCA 
 
r -0.07 0.26 0.12 0.12 0.14 0.14 0.04 
p value 0.75 0.27 0.63 0.60 0.56 0.55 0.86 
        
  
GCDCA 
 
GDCA 
 
GCA 
 
GLCA 
       
r 0.02 0.10 0.13 -0.12    
p value 0.93 0.69 0.59 0.63    
        
  
aTMCA 
 
TCA 
 
TUDCA 
 
TCDCA 
 
TLCA 
     
r 0.35 0.39 0.12 0.29 0.07   
p value 0.13 0.09 0.60 0.22 0.78   
Table 25 Correlation of BA species with FGF19 
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4.4 Meal stimulated response 
For this section of the study 10 individuals were recruited and data gathered as described in 
section 3.4. Data have been combined with that previously gathered by my predecessor 
making a total of 21. 
General Characteristics 
There were 21 subjects, 19 with PBAD and SeHCATs less than 15% and 2 subjects with ID 
with SeHCAT retention of > 15%. There were no individuals with secondary BAD, none had 
evidence of other GI disease. 6 subjects had severe PBAD with SeHCAT retention of < 5%. 
There were 10 with SeHCAT 5 – 10% and 3 with SeHCAT 10 – 15%. The 2 ID subjects had 7 
day retention of 49.2 and 53.0%. 
10 subjects were female and 11 male. Age ranged from 26 to 70 years. Over the preceding 3 
months, average bowel movements per day ranged from 3 to 20 times with average Bristol 
stool type of 6 and 7. Duration of symptoms ranged from 6 months to 27 years with a 
median of 3 years. Data for individuals is shown in table 23. 
Changes in measured FGF19 over the course of 6 hours are shown for each individual 
subject in the Figure 32. 
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Figure 32 Individual FGF19 responses over 6 hour time course. Meals at 9.00 and 12.00
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Table 26 General characteristics of subjects in meal stimulated study  
Patient Diagnosis Age Sex Ethnicity BMI Movements/24hrs av BSFS Duration years Bile Acids FGF19 SeHCAT 
6 PBAD 38 F W 32.0 7 7 3 1.5 56 5.4 
25 PBAD 38 F W 22.0 4 7 5 1.3 146 7.3 
38 PBAD 48 F W 32.0 3 7 1.5 1.7 81 8.1 
40 PBAD 70 F W 27.0 11 6 2 0.9 172 5 
81 PBAD 26 F W 33.0 12 6.5 2 2.9 125 4.8 
83 PBAD 27 M AI 27.0 10.5 7 3 1.1 145 6.68 
86 PBAD 28 M AI 24.0 10 6 6 1.2 142 11 
90 PBAD 60 F W 19.0 7 6 17 1.5 268 9.3 
93 PBAD 47 M W 26.0 7 7 2 5.9 146 2 
110 PBAD 43 M AI 27.0 10 7 7 0.9 142 6.8 
118 PBAD 38 M W 27.0 6.5 7 25 1.7 30 4 
212 PBAD 52 F W 23.0 15 6.5 35 1.2 241 8.9 
213 PBAD 49 M W 33.0 5 6.5 20 3.4 26 0.2 
214 PBAD 69 M W 26.0 4.5 6 1 2.2 199 7.3 
222 PBAD 63 F W 22.6 3 6 7 2.1 179 11.6 
224 PBAD 36 M OTHER 29.0 7.5 7 1.5 4.6 656 11 
229 PBAD 34 F W 19.0 0.5 4 0.5 3.3 286 7.5 
235 ID 32 F W 19.5 3 6 2 1.3 151 53 
244 PBAD 47 M W 28.0 5 6 20 1.9 43 4 
265 ID 50 M W 19.9 20 7 0.75 2.5 322 49.2 
281 PBAD 27 M W 21.6 13 7 27 2.5 38 0 
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Patterns of FGF19  
Data analysis refers to subjects with PBAD and not the 2 subjects with ID, unless otherwise 
stated. There was great variation in FGF19 levels between subjects. As would be expected 
the time point with lowest median FGF19 was the 9am fasting sample (143 pg/ml), very 
close to the median fasting level of 149 pg/ml in study 1. There was significant variation in 
the 9am fasting sample ranging from 16.8 to 752 pg/ml. 6 of 19 PBAD subjects had levels 
over 235 pg/ml, the median fasting level for ID subjects in study 1. There was less variation 
at the second time point (10.30am) with a range of 24.8 to 402 pg/ml, median 150 pg/ml. 
Figure 33 shows median levels of FGF19 in PBAD subjects with interquartile ranges. 
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Figure 33 Median FGF19 for PBAD subjects at each time point. IQRs shown. 
 FGF19 increases after lunch (provided at 12 midday) with median level 232 pg/ml recorded 
at time 13.30, not significantly different to 0900 or 1030 time points (p = 0.42, 0.15).  FGF19 
increases further to the 1530 time point (median 296 pg/ml) which is significantly higher 
than at 1030 (p < 0.05). 
As stated there is significant variation in the FGF19 meals response patterns seen in the 19 
individuals with PBAD. We thought it might be beneficial to sub-divide these FGF19 
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responses into different patterns in an attempt to describe FGF19 phenotypes. This has 
been done according to the following classification: 
Low – low (L-L): Serum FGF19 level < 300 pg/ml at each of the 5 time points. 
Low – high (L-H): 09:00 sample < 200 pg/ml, 13:30 or 15:00 sample > 400pg/ml. 
High – high (H – H): 09:00 and 12:00 sample> 300 pg/ml plus 13:30 or 15:00 sample > 300 
pg/ml. 
 
Low – low (L-L) phenotype 
There were 8 subjects with FGF19 less than 300 pg/ml throughout the course of the study 
day. 6 had SeHCAT retention of 5% or less, the other 2 having retention of 6.7% and 11.6%. 
L-L individuals have lower SeHCAT retention than the L-H group (4.4% vs 8.1% p < 0.05) and 
lower than the HH group (7.4% p = 0.07). 
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Figure 34 FGF19 for L-L individuals 
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Differences have been sought between L-L subjects and L-H and H-H subjects. No significant 
differences were found in age, BMI, stool form, stool frequency or duration of symptoms.
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Figure 35 SeHCAT retention in different phenotypes. Medians and 10 – 90 centile. 
There was however a difference in fasting serum Vitamin A level. Those with the L-L pattern 
have a higher Vitamin A level of 2.2 µmol/l compared with median 1.8 µmol/l (p = 0.03).  
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Figure 36 Vitamins A and D in phenotypes L-L and L-H, H-H combined 
In mice vitamin A is required for the basal production of FGF15 (41). If differences in either 
vitamin A absorption or in dietary vitamin A were causative of lower FGF19 it may be 
expected that the L-L pattern would be associated with low serum Vitamin A. The fact that 
higher levels are found in those with L-L phenotype may therefore reflect increased fat 
soluble vitamin absorption due to differences in bile acid metabolism. It must be noted 
however that no correlation was found between Vitamin A and SeHCAT or FGF19 in the 
larger main cohort of patients see section 4.1.3. A separate analysis compared vitamin A in 
those with SeHCAT < 5% with ID individuals in the larger cohort and again found no 
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difference. It may be that differences found in these L-L subjects are due to chance. Vitamin 
D has also been found to be higher in L-L than L-H H-H combined (44.0 vs 19.8 nmol/L p = 
0.25). No differences between L-L and the other phenotypes have been found in other 
biochemical parameters.  
 
Low – High phenotype (L-H) 
5 individuals have the described L-H phenotype.  SeHCAT retention ranges from 6.8 to 9.3% 
and as mentioned is higher than the L-L group. It is not significantly different to the H-H 
group. 
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Figure 37 L - H phenotype 
Significant differences in clinical and biochemical parameters have not been demonstrated 
between L – H and the other groups. 
High – High phenotype (H – H) 
4 subjects had the H – H phenotype of FGF19 with levels starting high, tending to fall until 
lunch before increasing to over 400 pg/ml in one of the final 2 readings.  
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Figure 38 H - H phenotype 
SeHCAT retention ranged from 5.4 to 11 %. Again there were no significant differences 
between these patients and those from the other groups.  
Area under the curve 
For each individual with PBAD undergoing the ‘day series’ the area under the curve (AUC) 
has been calculated expressed in pg/mlhr. 7 day SeHCAT retention correlates with the AUC 
p < 0.05, those with lower SeHCAT retention have lower AUC. Higher AUC tends to be 
associated with fewer bowel motions in 24 hours (p = 0.13) There is no correlation between 
the AUC and other symptoms. 
AUC correlates with serum vitamin A (r = -0.61, p = 0.016). Those with lower AUC FGF19 
have higher serum vitamin A.  These findings support the findings that the L-L phenotype is 
associated with higher vitamin A. As mentioned earlier, the higher levels may reflect 
increased absorption of fat soluble vitamin due to altered BA homeostasis. 
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 Figure 39 Correlation between AUC and SeHCAT (p < 0.05) 
Other correlations 
The only factor in the day series experiments found to be significantly associated with a 
clinical characteristic is the serum FGF19 taken at time point 15.00. Higher FGF19 at this 
time was found to be associated with fewer bowel movements per 24 hours ( r = 0.53 p = 
0.02). 
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Figure 40 Correlation bowel movements in 24 hours with FGF19 at 15:00 
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Bile Acids 
Total serum BAs were measured at each time point. Serum for those individuals who had 
participated in the day series prior to October 2010 were not available for further analysis 
and quantification of total bile acids. 
The lower end of the reported range by the clinical chemistry lab was 1.00mmol/L. Some 
values were reported as < 1.00 which have been analysed as 0.99 mmol/L. The highest BA 
was 10.07 mmol/L for BD25. 
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Figure 41 FGF19 and BA in L-L subjects 
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Figure 42 FGF19 and BA in L-H subjects 
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Figure 43 FGF19 and BA in H-H subjects 
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 In study 1 it was found that fasting values of FGF19 and BAs correlated. In this study a 
comparison has made of all measurements at all time-points of FGF19 with corresponding 
BA. There is a strong correlation between these values (r = 0.46, p < 0.0001). 
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Figure 44 FGF19 and BA for all samples in day series 
 
The total BA and FGF19 traces for each individual follow a similar pattern. BA traces that are 
relatively flat have accompanying relatively flat FGF19 traces. Similarly, rises in BA tend to 
have the same change in FGF19 although at the following time point. An attempt has been 
made to statistically demonstrate a correlation between changes in BAs and changes in 
FGF19 for individuals over the time period. For each time point except 09:00 the percentage 
change from the previous time point has been calculated. If there is no change then % 
change is 0%, if it doubles then then % change is 100%. This has been done for both FGF19 
and BA. These % changes have been plotted against one another and correlated. There was 
no significant correlation between % change of TBA and FGF19 at the same time points 
(Figure 45). FGF19 was then plotted against % change in TBA at the next (t + 90 mins) time 
point and with the previous time point (t – 90 min). No significant correlation found with 
FGF19 against TBA at the next time point (t + 90 min). There was however a correlation 
between FGF19 and TBA at the previous time point. Changes in TBA strongly correlate with 
changes in FGF19 90 minutes later, see figure 46 (r = 0.51, p < 0.001).  
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Figure 45 % change in FGF19 and total BA at the same time point (left) and FGF19 with TBA at next (90 min later time 
point)  
 
The finding that proportional change in FGF19 correlates strongly with proportional changes 
in serum total bile acids 90 minutes before indicates that FGF19 is synthesised and released 
in direct response to BAs. The similar patterns of FGF19 and BA are present across the range 
of SeHCAT values and phenotypes. The fact that the FGF19 profile echoes the BA profile 
applies regardless of SeHCAT retention of phenotype. When the correlation is performed on 
the L-L, L-H and H-H phenotype there is similar correlation coefficient and significance 
between the groups albeit > 0.05 due to reduced sample numbers (p = 0.13, 0.23, 0.18 r = 
0.46, 0.41, 0.42, respectively.) 
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Figure 46 Significant correlation between % change FGF19 with % change in BA 90 minutes previously. 
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 Table 27 Genotype of each individual in day series study. F = failed genotyping 
 
88 
 
Polymorphisms and day series 
As part of study 4.2 individuals in the day series study were genotyped for the 9 single 
nucleotide polymorphisms investigated earlier. The results may be seen in Table 27.  Minor 
allele frequencies are shown for the L-L phenotype and for the other PBAD phenotypes 
combined. Allele frequencies have been compared between these 2 groups using Fisher’s 
Exact Test. 
The FGFR4 SNP rs376618 shows significantly higher proportion of the C allele in L-L 
phenotype than in the other phenotypes with a MAF of 37.5 vs 9.1 %. MAF in study 4.2 for 
the whole cohort for ID and PBAD was 28.5% and 22.1% respectively. When the L-L and 
other phenotypes are compared with the entire cohort from study 4.2 there is no significant 
difference in proportions of the minor allele. 
The ASBT SNP rs188096 has a higher proportion of the A allele in the L-L phenotype 
compared with the entire cohort and compared with the other phenotypes. The difference 
does not reach significance. The FGF19 SNP rs948992 has a lower proportion of the G allele 
in the L-L group than the rest (18.8% vs 45.5%), again this does not reach significance. In 
study 4.2 the MAF for ID and PBAD was 36.6% and 33.1% respectively. 
  
89 
 
4.5 Ageing study 
27 individuals’ samples were made available for analysis. Age ranged from 23 to 92 years 
evenly spaced out across the decades (7 aged 20 – 39, 7 aged 40 – 59, 7 aged 60 – 79 and 6 
aged 80 and over). There were no gastroenterological symptoms or comorbidities. 7 
individuals took medication including anti-hypertensives, statins, warfarin and a 
bisphosphonate. Body mass index ranged from 20.4 to 26.8 kg/m2 with a median of 23.4 
kg/m2.  
Fasting serum FGF19 levels were surprisingly low in this cohort of healthy individuals, 
possibly reflecting differences in separation and storage. Levels ranged from 13.8 to 246.6 
pg/mL. Median FGF19 was 71.0 pg/mL. There was no difference in FGF19 for men and 
women (72.8 and 80.1 pg/mL, p = 0.97). There was a significant correlation with age. FGF19 
increases with age (r = 0.48 , p = 0.01), see figure 47a. 
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Figure 47(a) FGF19 against age. (b) Median ages with min and max shown 
90 
 
The 20 year age ranges were compared (Figure 47b). There was a significant difference in 
median between the 20 – 39 and the 80 + age groups. Other differences if FGF19 between 
the groups were non-significant. 
Table 28 Subject characteristics and FGF19 in ageing study 
ID Age BMI Gender FGF19 ID Age BMI Gender FGF19 
F 27 21 M 45.5 D 72 26.8 M 130.4 
N 34 22.9 F 27.7 P 79 24.1 M 40.3 
L 23 22.2 F 53.5 AA 67 25.9 M 32.1 
Y 31 20.6 F 52 AD 70 26 M 69.1 
AH 24 25.9 M 42.5 AG 75 22.5 F 102.3 
AL 29 24 F 39.1 AM 72 20.4 F 176.4 
BH 29 20.5 F 80.1 ?? 64 24.4 F 90.8 
C 54 24.2 M 52.4 M 81 26.8 F 204.5 
I 43 22.2 F 13.8 BB 80 26.3 F 72.9 
R 57 23.4 F 97.3 BJ 89 24.2 F 65.2 
V 55 22.6 F 28.5 BK 86 20.5 F 95.9 
AI 40 25 M 154.6 BM 82 21.3 F 134.3 
AT 44 24.5 M 102.6 BN 92 21.7 F 246.6 
BI 46 23.2 M 117.5      
FGF19 levels from this group of healthy individuals were much lower as a whole than in the 
larger group recruited for study 1. A comparison has been made between the FGF19 levels 
in this ageing study and subjects from study 1 within the same age and BMI ranges, with 
negative SeHCAT studies (Figure 48).  
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Figure 48 Comparison within age groups of FGF19 levels between the different study populations. Study 1 comparison 
group only includes those within same BMI range as the ageing study with negative SeHCATs (medians, min and max) 
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As can be seen at each age range median fasting FGF19 was between 2.5 and 4.7 times 
higher in the study 1 groups (p = 0.001 or less for each group).  
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4.6 OBADIAH  
4.6.1 General Characteristics 
35 subjects were recruited and entered the study. 7 withdrew prior to taking obeticholic 
acid and are therefore excluded from any analysis. There remained 28 subjects, 10 in the 
primary BAD arm, 10 in the secondary BAD arm and 8 idiopathic diarrhoea controls. Only 
PBAD and ID subjects are considered in this thesis as the SBAD patients were recruited by 
my colleague Jonathan Nolan and are included in his thesis. 
Primary BAD: There were 7 males and 3 females with median age of 47, range 24 – 74 
years. All had SeHCAT retention of under 10%, median 4.8%. 5 of the 10 used bile acid 
sequestrants prior to the study. 
 
 
Table 29 Subject demographics 
 
Idiopathic Diarrhoea: There were 8 subjects, 5 male and 3 female. The median age was 39 
years, range 25 – 61 years. SeHCAT retention ranged from 16 to 40%, median 25.7%. 
  
 PBAD  SBAD 
Number 10  8 
Sex (%) 
   Male 
   Female 
 
3 (30) 
7 (70) 
  
5 (63) 
3 (37) 
Age (y) 
  Median 
  Range 
 
47 
24 – 74 
  
39 
25 – 68  
SeHCAT (7d retention %)  
  Number 
  Median 
  Range 
 
10 
4.8 
0.8 – 9.3 
  
8 
25.7 
16.0 – 40.0  
Previous BA sequestrant use (n) 
  Yes 
  No 
 
5 
5 
  
0 
8 
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4.6.2 FGF19 
Fasting levels, pre OCA: In primary BAD the median fasting FGF19 level was 132pg/ml, with 
a range of 102 – 168. This is similar to our previously reported levels(71). Idiopathic 
diarrhoea subjects had a median fasting FGF19 on D0 of 116pg/mL; lower than in PBAD but 
the difference is not significant (p = 0.6).  
Comparison with Study 1: Median D0 fasting FGF19 for PBAD is not significantly different 
for the prospectively recruited cohort in Study 1 (medians 133 pg/mL  vs 148 pg/mL p = 
0.48). Fasting FGF19 was significantly lower in the ID group in Obadiah than in study 1 
(Medians 116.5 pg/mL vs 236 pg/mL p < 0.005). 
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Figure 49 Comparison of fasting FGF19 pre OCA Obadiah vs Study 1 fasting FGF19. Boxes show IQR, 10 – 90 centiles and 
outliers. 
Primary BAD: The fasting FGF19 level increased from 132pg/ml to 237pg/ml after 2 weeks 
treatment with OCA (p = 0.007). 9 out of 10 subject’s FGF19 increased on OCA with a 
median increase of 71%, IQR 9 – 102%.  
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 Figure 50 ??????????????????????????????????????????????????? ?????????? ?????????????????????- C. Individual values D 
- F 
Idiopathic diarrhoea: Of the 8 individuals, 6 had an increase in fasting FGF19 after 2 weeks 
treatment with OCA. (See Figure 50) Median FGF19 level increased by 130%, IQR 14 – 304%. 
This did not reach significance (p = 0.12) 
? ?
?
???
???
???
???
???
? ? ? ?
?
?
?
?
?
??
?
??
?
 
Figure 51 ID: Individual fasting FGF19 before and after 2 weeks OCA 
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Figure 52 ID group before and after 2 weeks OCA. IQR and 10 – 90 centile 
The 3 groups overall have a significant increase in FGF19 from a median of 74 pg/ml to 152 
pg/ml (p = 0.0004) 
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6 hour response to OCA:  FGF19 increased significantly in the 6 hours after OCA in all 
groups. The groups differed in D0 AUC (Kruskal-Wallis P=0.004) and peak FGF19 values 
(P=0.0003) with the responses being significantly highest in primary BAD, followed by the 
idiopathic controls.  There were no significant differences between the responses on D0 
compared to D14 in FGF19 AUC or 6h peak in any of the groups. In PBAD the median peak 
value on D0 was 1278 pg/ml, which was not significantly different from that on D14 1216 
pg/ml. Median peak FGF19 levels found in the idiopathic group were 496 pg/ml and 560 
pg/ml on D0 and D14. 
 
 
 
 
Figure 53 FGF19 and bile acid changes during serial sampling over six hours.  Individual patient results are 
shown on the day of the first dose (D0) and after 2 weeks of OCA treatment (D14).   Fasting samples were 
obtained and then OCA 25mg was taken orally
97 
 
FGF19, C4 and Bile Acids: fasting, 6h AUC and peak values on D0 and D14 
 
Values are medians and IQR.  AUC = area under the curve.  D0 and D14 values were compared by Wilcoxon paired rank tests. Significant values (P< 0.05) are in bold. 
a Data were incomplete in two patients 
 Primary BAD 
(n=10) 
Secondary BAD 
(n=10) 
Idiopathic controls 
(n=8) 
Overall 
(n=28) 
 D0 D14 P D0 D14 P D0 D14 P D0 D14 P 
FGF19 (pg/ml) 
   Fasting 
132 
102–168 
237 
116–302 0.007 
32 
24–42 
46 
24–72 0.11 
116 
57–186 
194 
126–344 0.12 
74 
31–133 
152 
49–250 0.0004 
   6h response AUC 3945 
2609–4834 
3825 
2515–6129 0.72 
401 
267–1086 
457 
316–1016 0.51 
1644 
1247–2776 
2099 
1972–2341 0.13 
1642 
484–3321 
1972 
536–3011 0.13 
   6h peak  1278 
764–1723 
1216 
687–1928 0.51 
102 
47–296 
126 
58–229 0.96 
530 
392–805 
588 
480–800 0.40 
496 
127–1011 
560 
158–902 0.90 
C4 (µg/L) 
   Fasting 
16 a 
11–37 
3 a 
1–17 0.03 
104 
48–134 
56 
14–122 0.11 
9 
3–14 
1 
1–3 0.02 
20 
9–96 
4 
1–39 0.001 
Bile Acids (µmol/L) 
   Fasting 
1.5 
1.0–4.0 
0.9 
0.9–3.0 0.13 
2.5 
2.0–6.0 
2.5 
1.0–4.0 0.12 
1.5 
1.0–2.8 
1.0 
0.9–1.8 0.12 
2.0 
1.0–3.8 
1.0 
0.9–3.0 0.04 
   6h response AUC 34.5 22.5–64.8 
20.9 
12.9–30.3 0.02 
32.0 
20.5–39.0 
22.0 
15.8–30.0 0.04 
29.0 
23.2–44.7 
17.0 
10.6–20.0 0.02 
31.5 
22.3–39.0 
20.0 
12.9–30.0 0.0001 
   6h peak 7.5 4.0–15.0 
4.0 
2.8–7.5 0.02 
6.5 
3.8–9.3 
4.5 
3.0–6.3 0.21 
8.0 
7.0–11.5 
4.0 
3.0–4.0 0.02 
7.0 
4.5–10.8 
4.0 
3.0–6.0 0.0001 
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4.6.3 ??-hydroxy-4-cholesten-3-one (C4) 
C4 decreased between D0 and D14 in response to OCA significantly in primary BAD ( 16 – 3 
μg/L, p = 0.03) and in the idiopathic diarrhoea group (9 – 1 μg/L, p = 0.02 
4.6.4 Bile acids 
There was no significant change in fasting bile acids within each group between D0 and D14. 
When the data is combined however there is a significant reduction in median fasting serum 
BA level from 2.0 μmol/L to 1.0 μmol/L ( p = 0.04). Bile acids were measured for 6 hours post 
OCA on day D0 and D14 and the AUC was calculated. There were significant falls in AUC over 
the OCA treatment period in the groups. In the primary BAD group the AUC fell in response 
to OCA from 34.5 to 20.9 μmol/LHr (p = 0.02). In the idiopathic group values fell from 29.0 
μmol/L to 20.0 μmol/L (p = 0.02).  
4.6.5 Clinical symptoms 
Primary BAD: Clinical symptoms were compared between weeks 2 and 4. There were 
significant improvements in total numbers of stool, Bristol stool form and the stool index. 
Median weekly stool fell from 23 to 14 (p = 0.03) with a change in mean BSFS from 5.2 to 4.3 
(p = 0.05). Median stool index improved from 113 to 76 a reduction of 34% (p = 0.005). 
Loperamide was used by 2 individuals however its use was reduced during the OCA 
treatment period. Symptoms of diarrhoea worsened in week 6 one full week after having 
stopped the OCA. BA sequestrants were resumed at this stage in 2 patients. Urgency was 
significantly reduced by 49% (p = 0.03). . 
 
 
 
Idiopathic diarrhoea: There was very little change in frequency, form or stool index in this 
group. There was an increase in the median number of stool and no change in stool form. 
The index decreased from 96 to 83 but this was non-significant (p= 0.61). Other symptoms 
such as urgency and pain did not change in this group.
Figure 54 PBAD: Relationships of percentage change in stool frequency, fasting FGF19 and bile AUC in PBAD patients 
after 2 weeks OCA. Symbols indicate individuals. 
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 4.6.6 Association between symptom improvement and biochemical parameters 
In the primary BAD group, the percentage change in stool number was associated with the 
percentage change in fasting FGF19 and BA AUC.  This BA response was inversely correlated 
with the change in fasting FGF19.  Additionally, the percentage change in fasting C4 was 
significantly associated with reduced urgency score (r=0.65, P=0.04) and with the change in 
FGF19 six-hour response (r=-0.62, P=0.05), indicating that increases in FGF19 resulted in 
reduction of C4 and new BA synthesis 
4.6.7 Tolerability, liver enzymes and lipid analyses 
OCA was well tolerated and only a few minor adverse effects were reported of limited 
clinical significance.  Three patients (two in the secondary BAD group and one in the 
idiopathic group) reported mild headaches during OCA treatment in week three or four. In 
the absence of a placebo-treated group, it is uncertain whether these were possibly related 
to OCA treatment.  Another patient with Crohn’s disease experienced worsening of 
abdominal pain after starting OCA and did not have a bowel movement for 24h.  Her 
symptoms settled on omitting OCA for 1d and then continuing with OCA 25mg on alternate 
days. 
Lipid measurements showed higher values for fasting total and LDL-cholesterol (median 
increases of 10.4% and 19.7% respectively, both P<0.001 overall) and a reduction in 
triglycerides (median decrease of -11.8%, P=0.06) after two weeks OCA treatment.  HDL-
cholesterol did not change significantly. Similar magnitudes of changes were found in all 
three groups and are comparable to those published previously.(109).  There were no 
significant changes in median values of liver biochemistry parameters, including alkaline 
phosphatase, alanine transaminase, bilirubin and albumin, which all remained in the normal 
range. 
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 5. Discussion 
5.1 Study 1 
This study has successfully recruited 95 subjects, mostly from the Department of Nuclear 
Medicine at the Hammersmith Hospital. Those with other GI disease were excluded and 
analysis focussed on PBAD and ID. When the data were combined with the cohort recruited 
identically by my predecessor there were 162 subjects, 93 with ID and 69 with PBAD. This 
has allowed greater statistical power and may enable more subtle interactions and weaker 
associations to be discovered. 
A cut off of 15% 7 day SeHCAT retention has been used in this study to define BAD. It has 
been found in a systematic review that using this cut off the proportion of individuals with 
chronic diarrhoea who have a positive SeHCAT scan is 26%. The prevalence rate in these 
studies ranged from 18% to 53%(60). In this study 69 of 162 subjects have positive SeHCAT 
scans: 42.6 %. 18 individuals had severe BAD with 7 day SeHCAT retention of < 5%, a 
percentage of 11.1%, similar to the proportion of 10% found in the systematic review.  
General characteristics and symptoms 
General characteristics were similar between ID and PBAD. Although this is not a case 
control study similarities in age, ethnicity and symptoms makes the prospective study more 
powerful, allowing more meaningful comparison of other factors such as biochemistry. 
Neither age, sex nor ethnic make-up were significantly different between ID and PBAD. The 
ratio of F : M was higher in ID than PBAD but not significantly so.  Those with severe PBAD 
have had the condition significantly longer than those with moderate and mild PBAD, and 
they tended to have had it longer than those with ID. It is not clear why individuals with a 
SeHCAT of < 5% have had symptoms longer. It may be that the underlying aetiology of PBAD 
worsens with time, and that those with severe PBAD have gone through a period of time 
with milder disease during which their SeHCAT retention may have been higher. In a long-
term study of PBAD (mean follow up 99.2 months) of 23 diagnosed with the condition, 3 had 
died at follow up, 3 lost to follow up and 3 diagnosed with IBD. Of the remaining 14, 7 
showed improvement and 7 were still symptomatic. With repeat SeHCAT scanning, 5 of the 
7 symptomatic had positive tests (< 5% in this study) and all of the asymptomatic subjects 
tests had become negative (110). In a similar study 20 subjects were followed up of whom 
16 had a repeat SeHCAT test. In 13 of 16 symptoms persisted and SeHCAT remained low and 
almost identical to previous values (median follow up time 88 months)(111). 3 subjects 
showed considerable increase in SeHCAT retention. There is mixed evidence regarding 
stability of SeHCAT over time, although there is no evidence of worsening SeHCAT retention 
in the literature.  
The only symptom to be significantly different in proportions between ID and PBAD was 
reported steatorrhoea (increased proportion in the severe PBAD group). This has not been 
quantified in our patients and depends on observation by the patient.  This is well described 
in PBAD and in the past has been ascribed to ‘true’ bile acid malabsorption leading to 
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 reduced BA pool and therefore reduced emulsification of fats by BA(59). In the presence of 
a normal or enlarged BA pool size, steatorrhoea may be caused by uncoordinated BA 
secretion into the small bowel as in post-cholecystectomy subjects or it may have a cause 
unrelated to BA such as bacterial overgrowth.  
Body mass index 
As has been demonstrated in our previous studies, BMI of individuals with PBAD is 
significantly higher than those with ID (86)(82). Again, BMI correlates negatively with 
SeHCAT retention, and there is a weaker association between BMI and FGF19 when taking 
all ID and PBAD subjects together. Within the PBAD diagnosis BMI has previously been 
shown to correlate with FGF19 but this significant association has not been demonstrated in 
this study (86). Further correlations have been shown between BMI and age as well as BMI 
and serum triglycerides. Higher BMI with increased age is well described in the normal 
population, and associations between BMI and triglycerides are also recognised (112)(113).  
Different mechanisms may explain the finding that PBAD subjects have higher BMIs. The 
weak association of FGF19 with BMI implicates the hormone. Previous studies have 
revealed that FGF19 plays a role in glucose disposal, lipid regulation and insulin sensitivity 
(114)(115)(116). FGF19 has also been found to be associated with the development of 
NAFLD and the metabolic syndrome in obese adolescents and lower FGF19 levels have been 
found in obese subjects compared with a healthy control group (117)(118). Despite the 
multiple metabolic effects of FGF19 its actions may not account for the difference in BMI 
found in this study. The association with SeHCAT is stronger and FGF19 independent 
mechanisms may explain BMI differences. BAs have been shown to act as metabolic 
signalling molecules through both the cell surface receptor TGR5 and the nuclear receptor 
LXR.  Changes in serum BA levels and BA pool size can affect glycaemic control, BMI and 
insulin sensitivity (119)(120)(121). No association has been found in our study between BMI 
and fasting BA however. A limitation of this part of the study is the sole measurement of 
fasting biochemical parameters. Changes or peaks values of FGF19 and/ or BAs may have 
displayed greater associations with BMI; these factors are explored in the day series study. 
Finally, factors other than the metabolic effects of FGF19 and BAs may be responsible for 
differences in BMI between ID and PBAD. Diet is a confounding variable which is impossible 
to exclude as the study was not designed to record this information. Other factors such as 
intraluminal BA concentration and differential lipid absorption may account for differences 
and are not possible to detect with the methodology used. Differences in the gut 
microbiome can lead to differences in nutrient extraction through fermentation of 
carbohydrates to absorbable short chain fatty acids (122). The BA profile and metabolism is 
highly dependent on microbial activities and therefore differences in the microbiome may 
account for differences in BA metabolism and BMI. 
FGF19 and Lipids 
This study has again confirmed the finding the finding that median fasting FGF19 is lower in 
PBAD than in diarrhoea controls, with those subjects with lowest SeHCAT retention (< 5%) 
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 having lowest, followed my moderate (5-10%) followed by mild (10 – 15%) PBAD (4)(87). 
The positive correlation with SeHCAT has also been shown again. 
It is clear that PBAD is a condition characterised by low fasting FGF19, with the most severe 
forms having the lowest values. Associations with other variables are providing insights into 
possible mechanisms. Strong associations are shown between SeHCAT retention and lipids, 
in particular triglycerides. Abnormalities in lipid composition have been demonstrated in 
subjects with aberrant bile acid metabolism previously (123), triglycerides have been shown 
to correlate with C4, a marker of bile acid synthesis(124). C4 has not been measured in this 
study but this group has previously shown a strong negative correlation between 7 day 
SeHCAT retention and fasting serum C4 (87). Therefore, findings of elevated triglycerides in 
elevated bile acid synthesis support findings from elsewhere. The higher FGF19 values found 
in the patients with fasting hypertriglyceridemia suggest these patients constitute a 
different subgroup and are in keeping with previous work.  Gälman and colleagues studied a 
large group of over 400 normal subjects without clinical diarrhoea, with measurements 
including FGF19, C4 and triglycerides(124).  Overall they found a negative correlation 
between FGF19 and corrected C4, and between C4 and triglycerides.  In their patients with 
high C4 above the 95th percentile, 35% had raised triglycerides >2.4mmol/L.  This is a similar 
proportion to that found in our PBAD patients who would also be expected to have raised 
C4.  Patients with familial hypertriglyceridemia have been shown to have an increased rate 
of bile acid synthesis and abnormal absorption has been suggested(123).  They have been 
shown to have reduced expression of ASBT mRNA and protein to about half of control 
values 21 although no increase in ASBT sequence variants has been found(125).  We have 
not shown whether these patients in our cohort with diarrhoea have reduced ASBT, and it is 
unclear why they should have essentially normal fasting FGF19 values, but they do appear 
to constitute a subgroup of about 30% with different characteristics meriting further study. 
FGF19 and BA 
Total serum BAs are influenced by factors other than new synthesis, as measured by C4, 
such as ileal BA reabsorption and hepatic uptake and may not always reflect BA pool size 
(126).  The positive correlation we have shown between FGF19 and total BA in the entire 
cohort presumably reflects varying ileal BA absorption and the stimulation of FGF19 
synthesis that occurs during this process. The relationship between total BA and FGF19 is 
maintained in the PBAD group suggesting appropriate FGF19 synthesis in response of 
enterocyte exposure to BAs.  The absence of a significantly lower BA level in PBAD does not 
support any notion of a true BA malabsorption taking place in PBAD, however nor does it 
support the theory of an enlarged BA pool size previously proposed (4). The lack of 
correlation between BA and SeHCAT likely reflects the fact that SeHCAT retention is a 
measure of BA turnover and in PBAD and ID a steady state of BA metabolism is attained 
with more than one factor influencing the measured BA level. As noted previously 
numerous factors influence fasting total serum BAs other than the BA pool size.  
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Variation of FGF19 and Reproducibility 
The results from previous work by our group has shown that FGF19 remains stable over 2 days at 
room temperature. It has also been shown that freeze – thaw cycles affect values minimally. 
Repeated measurement of fasting FGF19 within the same individual was made possible as some 
subjects from study 1 also participated in Study 4 where a 9am fasting sample was taken. Most of 
the subjects showed little variation in FGF19 however in five of the 20 the variation was much 
greater at more than 200 pg/ML. This variation may be due to different sampling times- from study 1 
the sampling time was at any time 9am – 5 pm, although subjects has always been instructed to fast. 
The study 4 samples were all taken at 9am. It is possible that in either study subjects did not in fact 
fast and that one of the samples was a post prandial sample. In future studies admitting subjects to 
the research ward the night before and ensuring compliance with fasting would exclude this 
confounding factor. 
Vitamins A and D 
In this study no significant differences has been demonstrated in serum vitamin A or vitamin 
D between diarrhoea control subjects and those with primary BAD.  This is an important 
finding as there is strong evidence that abnormalities in the FGF19 – FGFR4 signalling axis 
are the primary abnormality underlying primary bile acid diarrhoea and that vitamins A and 
D are essential to FGF15/19 synthesis.  Prospective studies by our group involving over 150 
subjects have shown reduced median levels of fasting FGF19 in PBAD versus controls (147 vs 
225pg/ml , p < 0.001) (87). Diarrhoea controls are included in this prospective study showing 
that diarrhoea per se is not the cause of reduced levels of FGF19 previously reported. 
Duration and severity of symptoms was similar between the 2 groups.  
An unexpected link was previously found between vitamins A and D and bile acid 
biosynthesis in knockout mouse models (41). Bile acid pool size was found to be bigger in 
VDR-/- mice. Quantitative PCR on liver showed that CYP7A1 was up-regulated as was ileal 
FGF15. Physiological concentrations of vitamin D were then studied in an ileal explant 
culture for 6 hours which revealed a dose-dependent relationship with FGF15 expression. 
Chromatin immunoprecipitation (CHiP) analysis was performed which demonstrated that 
VDR binds directly to the FGF15 promoter, directly regulating its expression.  
Lack of relationship between FGF19 and vitamin D in our subjects makes a causative role in 
primary BAD less likely. Further studies are required in humans to explore the role of 
vitamin D in FGF19 expression, for instance in an explant culture.  
In further work by Schmidt et al it was found that mice fed vitamin A had greatly increased 
ileal FGF15 expression and reduced CYP7A1 expression.  Through the use of selective RAR 
and RXR ligands in wild type mice it was determined that FGF15 induction occurred only 
through RXR. Analysis of liver gene expression revealed that repression of CYP7A1 also 
occurs separate to the FGF15 mechanism, through SHP induction. In another study retinoic 
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 acid was found to supress CYP7A1 and lead to increased expression of FGF19 and SHP in 
hepG2 cells and human hepatocytes (127). 
In this study serum retinol has been measured whereas in the studies mentioned retinoic 
acid or retinyl palmitate has been used. Furthermore it is acknowledged that serum retinol 
does not provide an accurate assessment of whole body vitamin A status (128). These are 
potential flaws in our study.  
It may be speculated that a deficiency in vitamins A or D may cause a deficiency of FGF19 in 
a subset of PBAD subjects. It is also possible that in another subset of subjects with low 
FGF19 but normal or high dietary vitamin A & D consumption, that excess BAs in the bowel 
lumen lead to increased emulsification and increased fat soluble vitamin absorption, 
offsetting those subjects with low serum levels. There is no evidence of a biphasic pattern to 
vitamin A and D levels to support this. 
It remains a possibility that although serum levels of the vitamins do not play a role in 
impaired FGF19 production, there may be a defect in the vitamin sensing proteins. 
Abnormalities in VDR, FXR or RXR may not lead to abnormal levels of vitamins A and D 
however they may cause aberrant signalling and impaired expression of FGF19.  
This sub-study has failed to demonstrate any association between the fat soluble vitamins A 
and D and FGF19 or SeHCAT retention in a prospectively recruited cohort of patients with 
chronic diarrhoea or bile acid malabsorption. It is unlikely dietary vitamin A or D or serum 
levels play a causative role in the pathogenesis of primary bile acid malabsorption. Given the 
central role of these vitamins to FGF15/19 expression however, further investigation into 
the roles of their receptors and downstream pathways may be warranted. 
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 Vitamin B12 
Vitamin B12 (cobalamin) is released from dietary proteins by gastric acid. It is bound initially 
by R protein in saliva. In the duodenum R protein is hydrolysed by pancreatic enzymes and 
intrinsic factor (IF) binds to the B12. IF is synthesised by gastric parietal cells.  It is resistant 
to proteolysis and passes to the terminal ileum where IF binds to specific receptors on the 
enterocyte where B12 absorption takes place. The Schilling test in which radiolabelled B12 
and IF are administered was used as a test of terminal ileal function but is no longer 
available (129). It is known that those with terminal ileal resection or disease are at risk 
vitamin B12 deficiency  however no true impairment of absorption has ever been 
demonstrated in PBAD (130). Clearly vitamin B12 levels will be affected by many factors but 
if differences in patient’s B12 levels could be demonstrated in PBAD then this may provide 
evidence of a true malabsorptive defect in the terminal ileum of those individuals.  
B12 levels will be affected by diet, particularly a vegan diet. Absorption is impaired by 
achlorhydria, protein R release is prevented by lack of proteolysis and gastric pathology can 
lead to impaired IF synthesis. B12 levels can also be affected by medication and increased by 
small intestinal bacterial overgrowth. These confounding factors may effect B12 levels in the 
study population however as most individuals have no GI disease this will remove a number 
of confounding variables. 
Although significance was not reached there is a near correlation between FGF19 and serum 
B12 levels. Furthermore, there is a nonsignificant trend to lower B12 levels in those with 
PBAD.  It is well described that small intestinal bacterial overgrowth may lead to vitamin B12 
deficiency; the finding of lower levels in PBAD may indicate that at least in some individuals 
there maybe bacterial overgrowth causing lower B12 levels and perhaps impairing BA 
absorption. BA composition can have biological effects on intraluminal bacteria and this is 
explored further in the introduction section on the microbiome. There are different possible 
explanations for the near associations seen. PBAD may be a condition in which there is a 
lower intraluminal BA concentration with reduced FXR activation and lower FGF19 levels 
and lower bactericidal properties. This may lead to SIBO and lower B12 levels. Alternatively, 
SIBO may be the primary event leading to metabolism of BA and B12 resulting in reduced 
FXR activation, lower FGF19 levels and lower B12. Finally there may be more complex 
relationships between the variables plus other factors such as the immune system. 
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 5.2 Genetic polymorphisms 
Genetic mutations in enzymes involved in BA kinetics have been linked to BA diarrhoea both 
as familial, dominant, single gene mutations and in more subtle associations discovered in 
changes in BA metabolism in large cohorts of patients (131). In study 2 we have explored 
mutations in a number of genes.  No clear single gene mutation with a large effect has been 
demonstrated.  However a number of possible smaller effect mutations have been 
uncovered.  
It has been reported that dysfunctional mutations in ASBT can lead to familial forms of PBAD 
(32). The infantile form of the disease leads to depleted BA pool size and reduced 
solubilisation of dietary lipid. The previously reported A171S mutation in ASBT has not been 
shown to significantly more prevalent in our population and no consistent abnormalities in 
the biochemistry of those individuals has been demonstrated. It is therefore highly unlikely 
that this polymorphism plays a role in the majority of subjects with PBAD. The finding that 2 
of 3 subjects with AA genotype had severe PBAD with unexpectedly normal/ high FGF19 
certainly warrants further investigation suggesting a possible role for this mutation in a very 
small subset. An insignificant increase in the proportion of the L-L individuals in the day 
series had genotype A, again suggesting a possible role for this mutation. 
Other potentially significant findings have been made in study 2. Although no strong 
relationships with any one polymorphism have been shown, a number of associations with a 
smaller effect have been uncovered by this study. 2 individuals with the FXR SNP 
rs61755050 had severe PBAD and low serum FGF19. The study is not powered adequately to 
detect associations in a polymorphism with low minor allele frequencies, however it is very 
possible that this rare polymorphism may have a very significant physiological effect and 
may be implicated in pathogenesis in a small subset of individuals. The G allele in klotho-β 
rs1761824 has been shown by others to be associated with faster gut transit in response to 
chenodeoxycholic acid and proportionally is higher in our PBAD group (70). With 6 out of 7 
AA subjects having ID there is a possibility that homozygosity is protective. A 
pharmacogenetic study has shown that both the KLB SNP above and the FGFR4 SNP 
rs376618 influenced the degree of acceleration in constipation predominant IBS in response 
to chenodeoxycholate (69). The FGFR4 SNP in study 2 revealed significant findings in a 
significantly increased proportion of ID subjects being heterozygous. The significance of this 
finding is currently unclear; however further enquiry may be worthwhile.  
What has become clear through the genotyping of SNPs in our cohort of subjects divided 
into PBAD or ID according to 7 day SeHCAT retention is that no clear relationship exists for 
any single polymorphism. Instead a number of potential future lines of enquiry have been 
uncovered. A number of SNPs have been shown to possibly confer a minor degree of 
disease susceptibility and an additive effect may exist with increasing risk burden according 
to number of SNPs as has been shown in other diseases. This risk may involve interaction 
with an environmental agent to trigger the condition; for example an infective precipitant as 
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 in post infectious IBS. Others have performed complete exome sequencing in those with 
IBS-D and controls but without the benefit of further subdividing according to SeHCAT 
retention (105). Further studies are warranted including exome sequencing on this existing 
cohort of patients. 
It is important to emphasise the hypothesis generating nature of these genetic studies. The 
sample size is only able to pick up strong genetic associations such as in a single gene 
disorders. Most diseases are not single gene disorders and this is likely to be the case in 
PBAD. If there is a genetic contribution it is likely to be a much more subtle contribution 
from multiple genes as is the case in other diseases such as coeliac and Crohn’s. There are 
multiple levels at which genetic variation may play a role in the disorder from BA absorption 
at the enterocyte, to FGF19 sensing at FXR, to FGF19 production and so on through the 
hormonal axis. The individual’s response to excess BAs in the colon may also have a genetic 
basis. Minor contributions may be made by polymorphisms at multiple levels. This study has 
highlighted possible weaker associations discussed above that may be further explored in 
future studies.  
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 5.3 Bile Acid Species Characterisation 
In study 1 significant associations were discovered with regard to chemically measured total 
fasting bile acids in the prospectively recruited cohort. Total BA correlated strongly with 
fasting FGF19; however BA did not correlate with 7 day SeHCAT retention. Comparison of 
median BA between PBAD and ID also did not reveal significant differences. 
In study 3 10 subjects each from the ID and PBAD groups were selected. They were 
intentionally selected to have either strongly positive or negative SeHCAT scans; otherwise 
the 2 groups were similar in terms of age, sex and clinical characteristics. The BA species 
have their results expressed in arbitrary units which allows comparison between the 2 
groups and allows for potential correlation with other factors. The sum of BA species in each 
individual correlates very strongly with the previously chemically measured total BA. This is 
an expected but important finding as it validates the results. The total bile acids were not 
significantly different between PBAD and ID. This mirrors the findings in the larger cohort 
with chemically measured BA. 
The 17 BA were compared between PBAD and ID and only one species was found to be 
significantly different. αTauro-muricholic acid was significantly lower in PBAD. With a p 
value of 0.0043 this is highly significant, uncorrected. Using a Bonferroni correction, a value 
of 0.003 would have to be attained.  
Bile acid characterisation using UPLC-MS has been performed by others in conventionally 
raised and in germ free mice (132). It is well known that the gut microbiota affects bile acid 
composition through deconjugation, dehydroxylation and dehydrogenation of primary BAs 
in the colon. The gut microbiota have been shown to reduce the BA pool size in rats 
compared with germ free animals(133). Sayin et al have shown significantly reduced levels 
of muricholic acid but not cholic acid in conventionally raised compared with germ free 
mice. They also found that tauro conjugated alpha and beta muricholic acids functioned as 
FXR antagonists, resulting in reduced expression of FXR dependent genes including FGF15. 
In mice therefore it has been shown that the gut microbiota regulated BA metabolism 
through increased levels of the FXR antagonistic BAs alpha and beta tauromuricholic acids. 
We have found lower levels of alpha-muricholic acid in PBAD. If this BA functions as a 
human FXR antagonist one would expect to see higher levels of serum FGF19 in PBAD, 
however as has been shown, lower levels exist. It must therefore be assumed that either 
alpha-tauromuricholic acid levels are not involved in the aetiology of PBAD, or potentially 
that this BA is profoundly agonistic. The latter is unlikely as the amino acids in the ligand 
binding domain are greatly conserved between species(134). 
The BA pool size consists of those BA in the systemic circulation, those in the portal 
circulation, BA in the biliary system including the gall bladder and those BA in the small 
bowel. Therefore this study does not measure the BA pool size directly and will be affected 
by a number of factors including BA absorption from the small bowel. It has been shown 
that systemic BA levels correlate strongly with total BA pool size and although accurate 
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 estimation of BA pool size is not possible the systemic  BA levels does allow comparison of 
pool size levels between patients (135). It has been shown that the BA pool size may be 
elevated in PBAD (84) but this has not been found to be the case in this study. No significant 
difference in total BA was found, nor were there any significant differences in the individual 
major BAs. Different BAs have differing affinity for FXR and it is possible that FGF19 
differences are accounted for through more subtle interactions between different BAs and 
FXR(35).  
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 5.4 Meal stimulated response 
Elsewhere in this study and published previously is clear evidence of abnormalities in fasting 
FGF19 in PBAD (4)(87). Post prandial FGF19 has also been explored briefly (4). This study has 
aimed to further describe abnormalities in FGF19 over a period of time including the post-
prandial period. This aimed to allow descriptions of different patterns of FGF19 levels and 
allow analysis of FGF19 at different time points, exploring associations with other 
parameters. 
The main finding has been the description of the different phenotypes of FGF19 response. 
Almost half the PBAD patients had the L – L pattern, where no sample was above 300pg/mL, 
which differs from the typical meal-stimulated normal response shown previously(40). The 
lack of significant FGF19 response resembles a fasting pattern but is also similar to that 
which has recently been shown in ileal Crohn’s disease (136). Those subjects with the L - L 
response have higher BA turnover as measured by 7 day SeHCAT retention than those with 
the other described phenotypes. The L – H phenotype is characterised by low ( < 200pg/mL) 
fasting FGF19 followed by levels that rise to over 400pg/mL, which is similar in post prandial 
response to the pattern in healthy volunteers(40). It is not clear what would cause low 
fasting but normal post prandial FGF19 response. It may be presumed that low fasting levels 
do not reflect any defect in synthesis but may be low in response to reduced FXR activation 
by luminal BAs.  
The H – H pattern of persistently elevated FGF19 has also been described. This could be due 
to prolonged stimulation overnight, lack of fasting or perhaps a stress response. An impaired 
hepatic response to FGF19 due to receptor differences in FGFR4 or KLB-β (or further 
downstream) could result in excessive bile acid synthesis and high FGF19 levels.  Variants in 
the FGFR4 and KLB genes described by Camilleri and colleagues are particularly interesting 
in this regard(69)(105). They have been shown to be associated with colonic transit and to 
interact with each other.  Although we found no overall significant differences in any allele 
frequency between the PBAD and ID groups, there were borderline differences in genotype 
frequencies for the FGFR4 and KLB variants in the small subgroups, and higher FGF19 levels, 
suggesting these genes should undergo appropriately powered further studies in patients 
with well-defined PBAD. 
This study only examined responses for a 6 hour time period and it would be useful to 
measure FGF19 over a 24 hour time period. This would be most helpful to further examine 
the H - H pattern to investigate FGF19 levels in the hours preceding breakfast. The 
description of FGF19 patterns has helped define subtypes of PBAD and has been shown to 
reflect different severity of SeHCAT retention. What it has not done, however, is 
demonstrate any differences in clinical parameters such as symptoms, duration of the 
condition or co-morbidity. The finding of a significant association between the 3pm FGF19 
and bowel movements per 24 hours may give insight into what time point is the most 
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 clinically significant for measurement of FGF19. This could be further investigated as in the 
Obadiah trial with formal diary carding on larger numbers(137). 
An important finding from the study 5 is the discovery that FGF19 correlates with serum BA 
levels at the previous time point (90 minutes earlier). It is clear from examining the 
individual FGF19 and BA traces that they exhibit a similar topography, albeit with FGF19 
changes following the changes in BA. Following the description of different FGF19 patterns 
this finding goes someway to potentially explain abnormalities in FGF19. The fact that BA 
changes are followed by FGF19 clearly suggests that abnormalities in BA may be an 
underlying abnormality. 
This study has allowed clearer definition of the abnormalities in FGF19 in PBAD and has 
uncovered possible underlying causes. Limitations are that there were too few diarrhoea 
controls or healthy controls to allow meaningful comparison. A lack of formal diary carding 
meant that patient memories were relied upon for symptom data which may have 
introduced bias. Finally, the time was limited to 6 hours which although providing much 
greater information than the fasting only sample ‘snap shot’, still does not allow a 
description of nocturnal BA metabolism that a 24 hour study would.  
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 5.5 Ageing Study 
Reviewing the literature there is no clear relationship between age and fasting serum 
FGF19. Our group has previously demonstrated a significant positive association of FGF19 
with age (87). A study of BA and lipid metabolism in 435 healthy and 23 cholecystectomised 
individuals showed no relationship between age and FGF19(124). In a further study of 81 
healthy subjects with normal glucose tolerance and 91 with impaired fasting glucose 
tolerance a significant negative association was found between fasting serum FGF19 and 
age(138). 
There are 2 highly significant findings from study 5, the ageing study. Firstly it has been 
found that fasting levels of FGF19 are between 2 and 4.7 times lower than median levels in 
the prospectively recruited cohort in study 1. Secondly, a statistically highly significant 
positive association between age and FGF19 has been found.  
The median fasting FGF19 levels are unexpectedly low in this ageing study. The serum 
values are much lower than both the diarrhoea control subjects from study 1 and lower 
than published values in healthy individuals in the literature. Median fasting FGF19 levels 
from study 1 in diarrhoea controls is 235 pg/mL, similar to values found in healthy 
individuals by other groups(139)(118). The cause of this discrepancy is not obvious. 
Confounding in recruitment is unlikely as the ageing cohort was carefully recruited to have 
no significant co-morbidities and was carefully sex and BMI matched. Behaviour of subjects 
with regard to fasting may confound the results, however both study groups were both 
asked to fast before the sample was taken. Other possibilities relate to sample preparation, 
storage and processing. Venesection and centrifuge protocols were the same between the 2 
studies. In the ageing study samples were kept for over 6 months at –20oc, considerably 
longer than the samples from study 1 which were kept for 3 months at most at -80oc. 
Thawing and ELISA was performed by the same individual by the same protocol. 
Furthermore, a standard mid-pool sample was use as a comparator in different ELISA 
batches and this was not found to be significantly different between the relevant batches. 
Sample storage therefore is the likeliest cause for the discrepancy in FGF19 values. 
Despite the possibility of degradation of FGF19 during storage the association with age is 
nevertheless strong and it might be assumed that it remains valid as storage related 
degradation would affect all samples equally. That the subjects were BMI matched is 
important as BMI increases with age and this would have been a strong confounding 
variable. Unfortunately other serum parameters were not available for the study group 
including lipids and serum BAs. In future studies on the effect of age it will be important to 
analyse other variables to determine if the age association of FGF19 is independent of these 
factors. 
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 5.6 OBADIAH Study 
In this study it has been demonstrated that Bile Acid Diarrhoea may be treated with a 
potent FXR agonist which in certain subgroups leads to significant clinical improvement and 
significant alterations in bile acid homeostasis. A significant increase in the primary end 
point, fasting FGF19 was shown in PBAD. No significant change in fasting FGF19 in ID was 
seen. 
It has been shown in previous work that subjects with primary and secondary BAD have 
lower fasting FGF19 compared with diarrhoea controls. Furthermore it has been shown in 
serial measurements of FGF19 over the course of 6 hours different patterns of FGF19 
secretion between different individuals with BAD and compared with healthy individuals. It 
has been shown in Study 4 that some individuals have lower fasting levels of FGF19 while 
others have levels which are higher pre-prandially and stay high post prandially, suggestive 
of a possible ‘upstream’ defect in the FXR – CYP7A1 axis (40)(140). Others have 
demonstrated differences in klotho β genotype in some subjects with IBS-D (69). With 
OBADIAH it was hypothesised that OCA would lead to changes in fasting FGF19 and would 
also lead to higher post prandial FGF19 levels, through activation of FXR.  
Evidence of FXR activation 
Changes in BA homeostasis have been demonstrated in this study through the activation of 
FXR. Activation of FXR was shown through significant increases in fasting FGF19 in PBAD. It 
was also demonstrated through high levels of circulating FGF19 after OCA administration, 
up to 1723pg/mL with a median peak level of 1278pg/mL in PBAD. These levels are 
consistent with work that has been done in other studies and significantly higher than in 
previously done 6 hour post prandial studies (without OCA) on those with PBAD where the 
peak FGF19 level was 866pg/mL (91). Changes in bile acid metabolism were reflected in 
significantly reduced total BAs in the entire cohort as well as reductions in C4 level in the 
groups. These changes indicate that in PBAD OCA was able to enter the ileal enterocyte and 
activate the nuclear BA receptor. Within the idiopathic diarrhoea cohort there was an 
increase in fasting FGF19 which did not reach significance. This may in part be due to 
smaller cohort size. Previously published work using an in vitro ileal explant system has 
shown that incubation with OCA leads to increased FGF19 transcript expression. FGF19 
protein secretion was also seen to be potently induced through incubation with OCA (141). 
PBAD 
Significant clinical improvement was seen in this group. All 10 subjects had an improvement 
in the composite score, the Diarrhoea Index. A limitation of this study is the lack of placebo 
control groups so clinical improvement may be due to the ‘placebo effect’. Of note, 
however, is the correlation between % change in fasting FGF19 and % change in stool 
frequency and the correlation between % change in BA AUC also with % change in stool 
frequency. Therefore, those with greater increase in FGF19 had the greatest improvement 
in stool frequency suggesting that clinical improvement is related to altered BA physiology 
and its effects on GI function, rather than placebo or psychological causes. Elevation by OCA 
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 of FGF19 to levels found in normal individuals leads to reduction in BA synthesis as shown 
by the significant reduction in C4.  This reduction in biosynthesis leads a reduction in BA 
secretion into the small bowel which is then reflected in a significant reduction in peak BA 
and BA AUC. This reduction in BA in the TI may lead to reduced concentrations in the colon 
where their effects on water and electrolyte secretion plus motility effects is not realised. 
Other potential mechanisms for action of OCA may be a direct effect on colonic mucosa, it 
has been shown to attenuate colonic secretory function and prevent diarrhoea in an 
experimental model by others (142).  
Idiopathic diarrhoea 
Changes in serum FGF19 were less marked in the ID group. Fasting FGF19 significantly lower 
in OBADIAH than in Study 1, the prospective cohort study (116 vs 236 p=0.06). Indeed, 
fasting FGF19 was lower in the ID group than in PBAD in this study although not significantly 
so. The median FGF19 was also lower in the ID group in OBADIAH compared with the PBAD 
group in Study 1, but again not significantly so (116 vs 148 p = 0.192. The increase in fasting 
FGF19 after 2 weeks of OCA was also non-significant although there were significant 
changes in C4 and peak BA and BA AUC. Although overall symptoms did not improve in the 
ID group overall, symptoms change did correlate with % change in BA AUC (R=-0.83 p = 
0.021). The ID group with their normal SeHCAT retention would not have been expected to 
respond clinically to OCA as they have no defect in BA metabolism. The fact that they have 
significantly different fasting FGF19 to Study 1 ID subjects does suggest that either the 8 
subjects recruited to OBADIAH are in some way atypical or different to those recruited to 
previous studies, or that there may have been problem with sample storage or the FGF19 
assay.  
Tolerance and safety 
 In this study OCA was well tolerated with minimal potential side effects and has been noted 
without a placebo arm it is not possible to say whether side effects such as headache are 
due to OCA. The most significant finding was a significant increase in LDL and HDL 
cholesterol, due to significantly decreased bile acid synthesis as reflected by an 80% 
decrease in C4 overall. BA synthesis is the primary route for cholesterol excretion and 
therefore this increase in cholesterol is unsurprising. The findings in OBADIAH with regard 
cholesterol levels mirror those found in previous study in subjects with non-alcoholic fatty 
liver disease. It is not known what effect these changes in serum cholesterol would have in 
the long-term but clearly this would need to be explored further before using OCA for 
longer periods in bile acid diarrhoea.  
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 6. Summary 
This research has, through the recruitment of a large number of individuals allowed the 
exploration of a number of different lines of enquiry into the pathogenesis and diagnosis of 
primary bile acid diarrhoea. It has attempted to further describe the condition and factors 
that differentiate it from diarrhoea predominant IBS. Significant clinical characteristics 
include longevity of symptoms, presence of steatorrhoea and elevated body mass index.  
Importantly, it has again been shown the central role FGF19 plays in the aetiology of this 
condition with low fasting median levels found in PBAD. Different patterns of FGF19 
secretion have been described in individuals with PBAD, potentially allowing further 
investigation into different underlying aetiologies relating to the different FGF19 patterns or 
phenotypes. Associations between FGF19 and other factors have been investigated 
including bile acids, lipids, B12 and the fat soluble vitamins A and D.  
For the first time a possible group of individuals with severe PBAD, high triglycerides and 
high/ normal FGF19 has been identified likely to represent a subset with a different 
aetiology to their disease, potentially an ileal transporter defect. 
Among the strongest correlations demonstrated in this research has been that between 
FGF19 and total bile acids. This applies both to the fasting levels shown in study 1 as well as 
postprandial levels explored in the day series in study 4. There is evidence from study 4 that 
changes in BA level may precede changes in FGF19 and may therefore be the factor 
determining abnormalities in serum FGF19. There are many factors determining systemic 
serum BA level including TI and hepatic BA transport, spill-over rate between portal and 
systemic circulations as well as other factors including the role of the microbiome in 
degradation and conversion of BAs.  There is evidence from work on ileal tissue that FGF19 
expression is lower in those with lower SeHCAT retention (143). This may suggest a role of 
reduced BA transport in enterocytes however it has also been shown that FGF19 response 
to incubated chenodeoxycholate acid (unconjugated and therefore transmembrane 
transport is not transporter dependent) is also proportional to SeHCAT retention suggesting 
that reduced ileal transporter expression or activity is not the primary underlying 
abnormality. Other possibilities include abnormalities in transcellular transport but 
differences in these transporters has not been demonstrated(80). Inflammation has been 
shown to reduce FGF19 in Crohn’s disease(143) and inflammatory cytokines can inhibit 
FXR(144), however there is no histological evidence of inflammation in PBAD. Bile acids have 
been further explored in this research through the characterisation of BA sub species 
through UPLC-MS. This revealed a significant reduction of the FXR antagonistic BA α tauro-
muricholic acid in PBAD subjects, the significance of which remains unclear.  
In study 6 the OBADIAH study this research has shown that PBAD may be treated with the 
FXR agonist obeticholic acid leading to significant clinical improvement which correlate with 
significant alteration in BA homeostasis. This study showed that a significant increase in 
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 fasting FGF19 subjects is possible through the use of OCA to levels comparable with healthy 
volunteers. The significance of this finding is firstly that it suggests that lower FGF19 in PBAD 
is not due to a defect in production but possibly an abnormality in the pathway that leads to 
FXR exposure to BA. Secondly OBADIAH has shown clear potential therapeutic benefit which 
should be explored further. 
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 7. Weaknesses 
Study 1.  This part of the study relies on self-reported symptoms to define diarrhoea. It is 
defined as 3 or more Bristol Stool Form stools of type 6 or 7 for more than 3 months. This 
inherent subjectivity makes analysis and comparison of symptom severity challenging to 
interpret. The nature of this investigation is to explore underlying physiological mechanisms 
and reliance on self-reported symptoms introduces undesirable bias. Although much more 
time consuming a study which examines stool weight and form objectively would allow 
more meaningful analysis.  
FGF19 increases very significantly post-prandially and therefore it is of great importance 
that the samples taken were genuine fasting samples. All patients were asked to fast before 
the sampling period but it was not possible to check that this was actually done. The 
sampling period was early afternoon for most patients so it is quite likely that some will 
have eaten in the preceding few hours. This could only be negated by admitting patients to 
a research ward in the hours before or by using a reliable serum marker of the post prandial 
phase. 
Study 2. This part of the project investigated polymorphisms in candidate genes involved in 
BA homeostasis. It explored specific polymorphisms that have been linked to other diseases 
involved with BA metabolism or diarrhoeal conditions. By only exploring 9 SNPs it was a very 
narrow search and has not investigated other polymorphism or genetic factors. Due to the 
sample size it was only powered to pick up very strong genetic effects. It is possible that 
PBAD has a partly genetic basis due to weaker contribution from a large number of 
polymorphisms which this study is not powered to detect. Exome sequencing would provide 
a much greater yield of information. Genome Wide Association Study (GWAS) would involve 
much greater subject numbers and expense but would explore weaker associations. 
Study 3. This study aimed to measure BA species in 10 individuals with PBAD and 10 with ID. 
For a study with this sample size measuring biochemical factors with extreme accuracy it 
would have been beneficial to ensure subjects had exactly the same diet for the preceding 
few days and to measure other factors such as stool form and weight. Measurement of BA 
species in stool the same time would have provided further information for analysis and 
allowed comparison with systemic circulation BA species. 
Study 4. This meal stimulated study corrected a number of factors that were missing in the 
above studies by examining subjects under the same conditions. The main weakness was 
not being 100% certain that the 9am FGF19 sample was a true fasting sample. Another 
weakness is that the study was limited to 6 hours. Both of these issues could be solved by 
admitting patients to research ward at 6pm staying NBM until 9am with sampling starting at 
midnight and continuing for 24 hours. Stool form and weight could also be measured.  
19 of the 21 subjects had PBAD. There is effectively no diarrhoea or healthy control group. 
These are important to have to define normal FGF19 patterns post-prandially. 
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 Study 5. This study examined fasting FGF19 levels in a healthy group of volunteers of normal 
BMI. This study has shown fasting FGF19 significantly lower than in other studies in this 
project or by others. The results are consistently lower throughout different ages and 
individuals. Compared with the other studies the difference is that these samples were not 
taken or immediately processed or stored by our immediate research group. The 
measurement of FGF19 was done in exactly the same way by our group. Possibilities for 
lower FGF19 include: 
• Different storage temperature. These were stored at -20oc instead of -80oc. It is not 
known if this would lead to significantly greater degradation of FGF19 protein. 
• Extra freeze – thaw cycles. As not stored by our group may have undergone thawing 
by others. 
• Other factors – eg unrecorded dilution at some point by original research group 
• Genuine lower FGF19 levels for physiological reasons. 
A weakness of this study is that the samples were taken and stored by another group and it 
is not possible to completely certain of these conditions. 
Study 6. The main limitation of this study is the lack of blinding or placebo control. 
Recording of symptoms in a diary is subjective and could be influenced by the placebo 
effect. There were however objective components to this study including the primary 
outcome measure serum FGF19 as well as secondary outcomes including C4 and BAs. Future 
studies must be double blinded placebo controlled to avoid potential biases. They may also 
include comparison with current standard therapies including cholestyramine and 
loperamide. 
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 8. Future Work 
The identification in study 4 of 3 distinct variants of dynamic FGF19 levels would benefit 
from being explored further both to validate the findings and to investigate these 
phenotypic differences over a longer time period of 24 hours. This study should include a 
determination of normal FGF19 pattern through the recruitment of normal healthy 
individuals and diarrhoea controls. Changes in BA should be explored further and 
determination of total BA pool size through different methodology will help determine 
abnormalities in overall BA homeostasis. The increased steatorrhoea found in subjects with 
severe PBAD raises the possibility of genuine BA malabsorption and reduction in BA pool 
size. Terminal ileal biopsy and explant culture from the different phenotypes, including 
individuals with high triglycerides will allow further investigation of a possible transporter 
defect in this subset. 
Extracted DNA from our large cohort of PBAD subjects and controls can now undergo whole 
exome sequencing in an attempt to seek underlying genetic differences that confer 
susceptibility to the condition. Identification of candidate genes could be explored further 
for abnormalities in expression and function through an explant system and quantitative 
real-time RT-PCR. 
The role of the microbiome in the pathogenesis should be explored further in light of 
findings of possible reduced B12 in PBAD.  
Finally, obeticholic acid has shown clear potential benefit in the treatment of PBAD in the 
proof of concept study OBADIAH. This should be explored further to determine clinical 
efficacy in a larger double-blind, placebo-controlled trial. This should include an existing 
treatment arm. For blinding purposes the use of colesevelam would be preferable to 
cholestyramine.  
 
Summary of future work 
Meal stimulated study 
• Recruitment of 10 – 20 subjects in each of following groups: 1. Healthy controls 2. 
Diarrhoea controls 3. PBAD subjects with normal triglycerides. 4 PBAD with high 
triglycerides. 
• Study period 24 hours and to include stool form and weight. 
• Determination of BA pool size through use of isotope dilution studies. 
• Collection of stool for measurement of BAs 
Genetics study 
• Exome sequencing of DNA of existing cohort of subjects – PBAD and ID controls. 
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 Obeticholic Acid 
• Multi-centre double blind randomised control trial Obeticholic Acid in treatment of 
PBAD 
• 3 arms: 1. Placebo 2. OCA 3. Colesevelam 
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 8. Appendices 
Appendix 1 Study 1 proforma 
 
Participant Number:       Date: 
 
Site                HH                 CXH                   SMH Consultant 
Name 
 
Hospital No. 
 
DOB 
 
Post Code 
Age                       Sex                                M/F 
 
Ethnicity     White          Asian-Indian       Mixed 
                           
                    Afro-carib  SE Asian             Other 
 
Phone 
Height                                                         Weight                                                         BMI 
Diarrhoea Characteristics 
No. bowel movements                        /day                                 /night                    >25% of time       Y/N 
 
Duration: 
 
Stool type (Bristol Stool Chart):                        Abdo pain:                                        Urgency: 
 
Blood in stool:                                                    Bloating:                                           Incontinence: 
 
Steatorrhoea:                                                       Dietary factors: 
Past Medical History 
IBD                     Cancer                   DM                    Pancreatic                      Thyroid                 Coeliac 
 
Other 
 
 
 
Surgical History 
Ileal Resection                          Cholecystectomy                        Gastric surgery                           Other GI 
Family History 
Colorectal neoplasia                                               IBD                                                          Coeliac 
Medications and Social History 
Drugs 
 
 
Alcohol                           units/week                                  Cigarettes                             /day and years 
Foreign Travel                        Y/N                                     Coffee                                  /day 
Examination 
+ve findings 
Investigations 
Bloods 
Clinical 
FBC Iron studies U&E Bili 
CRP B12 Ca ALP 
ESR RCF Alb ALT 
Gluc TTG/EMA Trig&Chol GGT 
Research Serum EDTA(DNA) Vit A Vit D 
Stool              MC&S                  OCP                      Elastase 
 
Colonoscopy                               TI Bx                     Colonic Bx                     Research Bx 
 
Lactose H2 Breath Test                Glucose H2 Breath Test                              Other 
 
Imageing 
 
 
SEHCAT RESULT 
 
 
 
 
Group          1. Primary Bile Acid Diarrhoea                  3. Idiopathic Diarrhoea                  5. Other 
                     2. Secondary Bile Acid Diarrhoea               4. Control 
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 Appendix 2: Study 2 SNP Primers 
SNP ID rs1789170 Gene FGF19 
Location Chr.11:69509343  
GTGCCGTGGGTTTTCCTCTGGGGAA[A/G]TGTCTCTCCCCTTCTTAGTCCTAGC 
 Polymorphism A/G, Transition Substitution 
 
SNP IDrs948992 Gene FGF19 
Location Chr.11:69513338  
GTGGGCAGAGGGCTGGTGGGCTGGG[A/G]GATGGAAGCAGGTGACACCGGGACA 
Polymorphism A/G, Transition Substitution 
 
SNP IDrs61755050 Gene NR1H4 FXR 
Location Chr.12:100926308 
AACGGGGGCAACTGTGTGATGGATA[C/T]GTACATGCGAAGAAAGTGTCAAGAG 
Polymorphism C/T, Transition Substitution 
 
SNP IDrs56163822 Gene NR1H4 FXR 
Location Chr.12:100887101 
AAGTGCATTTCAATTGAAAAATTTG[G/T]ATGGGATCAAAAATGAATCTCATTGPhenotypeMIM: 603826 
Polymorphism G/T, Transversion Substitution 
 
SNP ID rs376618 Gene FGFR4 
Location Chr.5:176517797 
GAGGACCCCAAGTCCCATAGGGACC[C/T]CTCGAATAGGCACAGTTACCCCCAG 
Polymorphism C/T, Transition Substitution 
 
SNP ID rs17618244 klotho β 
Location Chr.4:39448529 
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 GCCCTGGCCTGGCGCCTCTACGACC[A/G]GCAGTTCAGGCCCTCACAGCGCGGG 
PolymorphismA/G, Transition Substitution 
 
SNP ID rs188096 ASBT 
Location Chr.13:103705044 
CCAATGGAAACAGGAACAACGAGAG[A/C]AACCAGAGATGTACCTAAAGATGA 
Polymorphism A/C, Transversion Substitution 
 
SNP ID rs939885 OSTα 
Location Chr.3:195955762 
GCTGACCCTGGTGGGCCTGTTTCTC[A/G]TCCCCGACGGCATCTATGACCCAGC 
Polymorphism A/G, Transition Substitution 
 
SNP ID rs7848647 TNFS15 
Location Chr.9:117569046 
CATTGACCATTGTTTAATCAGAGTA[C/T]GAGGCCACAGATCGAGGTGACTGTC 
Polymorphism C/T, Transition Substitution 
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 Appendix 3: Schedule of events Study 4. Meal stimulated study 
Day before sampling day 
Nil by mouth from 9pm, except usual medications and small sips of water 
Sampling day 
08.30 Attend Sir John McMichael Centre 
08.45 Interview and assessment 
09.00 Peripheral venous cannula inserted. 5ml Blood drawn and processed (described 
 elsewhere) 
09.10 Standard breakfast consisting of cornflakes, 2 slices of toast with butter and jam, a 
banana and tea/coffee provided 
10.30 5ml Blood drawn and processed 
12.00 5ml Blood drawn and processed 
12.10 Standard lunch provided: cheese and lettuce sandwich, crisps, yoghurt and drink. 
13.30 5ml Blood drawn and processed 
15.00 5ml Blood drawn and processed, cannula removed and participant discharged home. 
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 Appendix 4 OBADIAH symptom diary 
 
126 
 
  
127 
 
 9. References 
1.  Hofmann AF. The syndrome of ileal disease and the broken enterohepatic circulation: 
cholerheic enteropathy. Gastroenterology. 1967 Apr;52(0016-5085 (Print)):752–7.  
2.  Hofmann AF. Bile acids: trying to understand their chemistry and biology with the 
hope of helping patients. Hepatology. Division of Gastroenterology, Department of 
Medicine, University of California, San Diego, San Diego, CA 92093-0063, USA. 
ahofmann@ucsd.edu; 2009 May;49(1527-3350 (Electronic)):1403–18.  
3.  Appleby RN, Walters JRF. The role of bile acids in functional GI disorders. 
Neurogastroenterol Motil. 2014;26(8):1057–69.  
4.  Walters JRF, Tasleem AM, Omer OS, Brydon WG, Dew T, Le Roux CW. A new 
mechanism for bile acid diarrhea: defective feedback inhibition of bile acid 
biosynthesis. Clin Gastroenterol Hepatol. 2009;7:1189–94.  
5.  Hofmann AF, Mangelsdorf DJ, Kliewer SA. Chronic diarrhea due to excessive bile acid 
synthesis and not defective ileal transport: a new syndrome of defective fibroblast 
growth factor 19 release. Clin Gastroenterol Hepatol. 2009 Nov;7(1542-7714 
(Electronic)):1151–4.  
6.  Khalid U, Lalji A, Stafferton R, Andreyev J. Bile acid malabsorption: a forgotten 
diagnosis? Clin Med. 2010;10(2):124–6.  
7.  Walters JR. Defining primary bile acid diarrhea: making the diagnosis and recognizing 
the disorder. Expert RevGastroenterol Hepatol. Section of Hepatology & 
Gastroenterology, Department of Medicine, Imperial College London and, Imperial 
College Healthcare, London, UK. julian.walters@imperial.ac.uk; 2010 Oct;4(1747-
4132 (Electronic)):561–7.  
8.  Fromm H, Malavolti M. Bile acid-induced diarrhoea. Clin Gastroenterol. 1986 
Jul;15(0300-5089 (Print)):567–82.  
9.  Thaysen EH, Pedersen L. Idiopathic bile acid catharsis. Gut. 1976 Dec;17(0017-5749 
(Print)):965–70.  
10.  Williams AJK, Merrick M V, Eastwood MA. Idiopathic bile acid malabsorption -- a 
review of clinical presentation, diagnosis, and response to treatment. Gut. 
1991;32:1004–6.  
11.  Baldi D. Arch ital biol. Arch ital biol. 1883;(iii):389.  
12.  Broun BYGO, Mcmaster PD, Rous P. STUDIES ON THE TOTAL BILE . According to 
accepted opinion the pigment of the bile represents waste from the hemoglobin 
128 
 
 molecule , and as such is eliminated from the organism . Yet the belief is well-nigh 
general that this waste , after undergoing a change. 1922;699–710.  
13.  Hofmann AF, Hagey LR. Bile Acid Chemistry, Biology, and Therapeutics During the Last 
80 Years: Historical Aspects. J Lipid Res [Internet]. 2014;55:1553–95. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24838141 
14.  Rosenheim O, King H. The Chemistry of the Sterols, Bile Acids, and other Cyclic 
Constituents of Natural Fats and Oils. Ann Rev Biochem. 1934;3:87–110.  
15.  Griffiths WJ, Sjövall J. Bile acids: analysis in biological fluids and tissues. J Lipid Res. 
2010;51(1):23–41.  
16.  Borgstrom B. Studies of intestinal digestion and absorption in the human. J Clin Inv. 
1957;36:1521–36.  
17.  WEINER IM, LACK L. Absorption of bile salts from the small intestine in vivo. Am J 
Physiol. Not Available; 1962 Jan;202:155–7.  
18.  BORGSTROEM B, LUNDH G, HOFMANN A. THE SITE OF ABSORPTION OF CONJUGATED 
BILE SALTS IN MAN. Gastroenterology. UNITED STATES; 1963 Aug;45:229–38.  
19.  Krag E, Phillips SF. Active and passive bile acid absorption in man. Perfusion studies of 
the ileum and jejunum. J Clin Invest. UNITED STATES; 1974 Jun;53(6):1686–94.  
20.  HOLT PR. INTESTINAL ABSORPTION OF BILE SALTS IN THE RAT. Am J Physiol. UNITED 
STATES; 1964 Jul;207:1–7.  
21.  Wilson FA, Dietschy JM. Characterization of bile acid absorption across the unstirred 
water layer and brush border of the rat jejunum. J Clin Invest. UNITED STATES; 1972 
Dec;51(12):3015–25.  
22.  Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res. 
Department of Molecular Genetics, University of Texas Southwestern Medical Center, 
5323 Harry Hines Boulevard, Dallas, TX 75390-9046, USA. 
david.russel@utsouthwestern.edu; 2009 Apr;50 Suppl(0022-2275 (Print)):S120–5.  
23.  Low-Beer TS, Pomare EW. Regulation of bile salt pool size in man. BrMed J. 1973 May 
12;2(0007-1447 (Print)):338–40.  
24.  Brunner H, Northfield TC, Hofmann AF, Go VL, Summerskill WH. Gastric emptying and 
secretion of bile acids, cholesterol, and pancreatic enzymes during digestion. 
Duodenal perfusion studies in healthy subjects. Mayo Clin Proc. 1974 Nov;49(0025-
6196 (Print)):851–60.  
25.  Susan Standring, PhD Ds. Gray’s Anatomy 40th edition [Internet]. Churchill 
Livingstone. 2009. Available from: http://www.us.elsevierhealth.com/anatomy/gray-
anatomy-expert-consult/9780443066849/ 
129 
 
 26.  Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea associated with ileal 
resection. N Engl J Med. 1969 Aug 21;281(0028-4793 (Print)):397–402.  
27.  Wong MH, Oelkers P, Craddock AL, Dawson PA. Expression cloning and 
characterization of the hamster ileal sodium-dependent bile acid transporter. J Biol 
Chem. 1994;269:1340–7.  
28.  Bjerknes M, Cheng H. Gastrointestinal stem cells. II. Intestinal stem cells. Am J Physiol 
Gastrointest Liver Physiol. United States; 2005 Sep;289(3):G381–7.  
29.  Bosse T, Piaseckyj CM, Burghard E, Fialkovich JJ, Rajagopal S, Pu WT, et al. Gata4 is 
essential for the maintenance of jejunal-ileal identities in the adult mouse small 
intestine. MolCell Biol. GI/Cell Biology, EN 720, Children’s Hospital Boston, 300 
Longwood Avenue, Boston, MA 02115, USA; 2006 Dec;26(0270-7306 (Print)):9060–
70.  
30.  Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. Department of Internal 
Medicine and Department of Pathology, Wake Forest University School of Medicine, 
Winston-Salem, NC 27157, USA. pdawson@wfubmc.edu; 2009 Dec;50(0022-2275 
(Print)):2340–57.  
31.  Amelsberg A, Schteingart CD, Ton-Nu HT, Hofmann AF. Carrier-mediated jejunal 
absorption of conjugated bile acids in the guinea pig. Gastroenterology. Division of 
Gastroenterology, Department of Medicine, University of California San Diago, La 
Jolla, California, USA; 1996 Apr;110(0016-5085 (Print)):1098–106.  
32.  Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by 
mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin 
Invest. 1997;99:1880–7.  
33.  Montagnani M, Love MW, R�ssel P, Dawson PA, Qvist P. Absence of dysfunctional 
ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset 
idiopathic bile acid malabsorption. Scand J Gastroenterol. 2001;36:1077–80.  
34.  Ballatori N, Christian W V, Lee JY, Dawson PA, Soroka CJ, Boyer JL, et al. OSTalpha-
OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, 
renal, and biliary epithelia. Hepatology. Department of Environmental Medicine, 
University of Rochester School of Medicine, NY 14642, USA. 
ned_ballatori@urmc.rochester.edu; 2005 Dec;42(0270-9139 (Print)):1270–9.  
35.  Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a 
nuclear receptor for bile acids. Science (80- ). 1999;284:1362–5.  
36.  Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. 
AnnuRevBiochem. Department of Molecular Genetics, University of Texas 
Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390-9046, 
USA. david.russell@utsouthwestern.edu; 2003;72(0066-4154 (Print)):137–74.  
130 
 
 37.  Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast 
growth factor 15 functions as an enterohepatic signal to regulate bile acid 
homeostasis. Cell Metab. Department of Molecular Biology, University of Texas 
Southwestern Medical Center, Dallas, Texas 75390, USA; 2005 Oct;2(1550-4131 
(Print)):217–25.  
38.  Triantis V, Saeland E, Bijl N, Oude-Elferink RP, Jansen PL. Glycosylation of fibroblast 
growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated 
down-regulation of cytochrome P450 7A1. Hepatology. Tytgat Institute for Liver and 
Intestinal Research, Amsterdam, the Netherlands. v.triantis@amc.uva.nl; 2010 
Aug;52(1527-3350 (Electronic)):656–66.  
39.  Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, et al. Differential regulation of bile 
acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, 
Bethesda, MD 20892, USA; 2007 Dec;48(0022-2275 (Print)):2664–72.  
40.  Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth 
factor 19 has a pronounced diurnal variation and modulates hepatic bile acid 
synthesis in man. J InternMed. Metabolism Unit, Department of Endocrinology, 
Metabolism and Diabetes, Center for Nutrition and Toxicology, Karolinska Institute, 
Karolinska University Hospital Huddinge, Stockholm, Sweden; 2006 Dec;260(0954-
6820 (Print)):530–6.  
41.  Schmidt DR, Holmstrom SR, Fon TK, Bookout AL, Kliewer SA, Mangelsdorf DJ. 
Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem. UT 
Southwestern Medical Center, United States; 2010 Mar 16;(1083-351X (Electronic)).  
42.  Sagar NM, Cree IA, Covington JA, Arasaradnam RP. The interplay of the gut 
microbiome, bile acids, and volatile organic compounds. Gastroenterol Res Pract. 
Egypt; 2015;2015:398585.  
43.  Gerard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathog 
(Basel, Switzerland). Switzerland; 2013;3(1):14–24.  
44.  Jones B V, Begley M, Hill C, Gahan CGM, Marchesi JR. Functional and comparative 
metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. 
Proc Natl Acad Sci U S A. United States; 2008 Sep;105(36):13580–5.  
45.  Duboc H, Taché Y, Hofmann AF. The bile acid TGR5 membrane receptor: From basic 
research to clinical application. Dig Liver Dis [Internet]. Editrice Gastroenterologica 
Italiana; 2014;46(4):302–12. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24411485 
46.  Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, et al. Regulation of 
antibacterial defense in the small intestine by the nuclear bile acid receptor. 
ProcNatlAcadSciUSA. Department of Molecular Biology, University of Texas 
131 
 
 Southwestern Medical Center, Dallas, TX 75390, USA; 2006 Mar 7;103(0027-8424 
(Print)):3920–5.  
47.  Stenman LK, Holma R, Eggert A, Korpela R. A novel mechanism for gut barrier 
dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J 
Physiol Gastrointest Liver Physiol. United States; 2013 Feb;304(3):G227–34.  
48.  Begley M, Gahan CGM, Hill C. The interaction between bacteria and bile. FEMS 
Microbiol Rev. Netherlands; 2005 Sep;29(4):625–51.  
49.  Codling C, O’Mahony L, Shanahan F, Quigley EMM, Marchesi JR. A molecular analysis 
of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci. 
United States; 2010 Feb;55(2):392–7.  
50.  Carroll IM, Chang Y-H, Park J, Sartor RB, Ringel Y. Luminal and mucosal-associated 
intestinal microbiota in patients with diarrhea-predominant irritable bowel 
syndrome. Gut Pathog. England; 2010;2(1):19.  
51.  Le Gall G, Noor SO, Ridgway K, Scovell L, Jamieson C, Johnson IT, et al. Metabolomics 
of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative 
colitis and irritable bowel syndrome. J Proteome Res. United States; 2011 
Sep;10(9):4208–18.  
52.  Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, et al. 
Distinct microbial populations exist in the mucosa-associated microbiota of sub-
groups of irritable bowel syndrome. Neurogastroenterol Motil. England; 2012 
Jan;24(1):31–9.  
53.  Mekhjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes 
induced by bile acids: perfusion studies in man. J Clin Invest. 1971;50:1569–77.  
54.  Sun Y, Fihn BM, Sjovall H, Jodal M. Enteric neurones modulate the colonic 
permeability response to luminal bile acids in rat colon in vivo. Gut. Department of 
Physiology, University of Goteborg, Goteborg, Sweden; 2004 Mar;53(0017-5749 
(Print)):362–7.  
55.  Pedersen L, Arnfred T, Thaysen EH. Rapid screening of increased bile acid 
deconjugation and bile acid malabsorption by means of the glycine-l-(14C) 
cholylglycine assay. Scand J Gastroenterol. 1973;8(0036-5521 (Print)):665–72.  
56.  Schiller LR, Hogan RB, Morawski SG, Santa Ana CA, Bern MJ, Norgaard RP, et al. 
Studies of the prevalence and significance of radiolabeled bile acid malabsorption in a 
group of patients with idiopathic chronic diarrhea. Gastroenterology. 1987 
Jan;92(0016-5085 (Print)):151–60.  
57.  Boyd GS, Merrick M V, Monks R, Thomas IL. Se-75-labeled bile acid analogs, new 
radiopharmaceuticals for investigating the enterohepatic circulation. J Nucl Med. 
1981 Aug;22(0161-5505 (Print)):720–5.  
132 
 
 58.  Van Tilburg AJ, de Rooij FW, van den Berg JW, van Blankenstein M. Primary bile acid 
diarrhoea without an ileal carrier defect: quantification of active bile acid transport 
across the ileal brush border membrane. Gut. Department of Internal Medicine II, 
University Hospital Dijkzigt, Rotterdam, The Netherlands; 1991 May;32(0017-
5749):500–3.  
59.  Sinha L, Liston R, Testa HJ, Moriarty KJ. Idiopathic bile acid malabsorption: qualitative 
and quantitative clinical features and response to cholestyramine. Aliment Pharmacol 
Ther. 1998;12:839–44.  
60.  Wedlake L, A’Hern R, Thomas K, Walters JRF, Andreyev HJN. Systematic review: the 
prevalence of idiopathic bile acid malabsorption (I-BAM) as diagnosed by SeHCAT 
scanning in patients with diarrhoea-predominant irritable bowel syndrome (IBS). 
Aliment Pharmacol Ther. 2009;30:707–17.  
61.  Sciarretta G, Vicini G, Fagioli G, Verri A, Ginevra A, Malaguti P. Use of 23-selena-25-
homocholyltaurine to detect bile acid malabsorption in patients with ileal dysfunction 
or diarrhea. Gastroenterology. 1986 Jul;91(0016-5085 (Print)):1–9.  
62.  Bajor A, Kilander A, Sjovall H, Rudling M, Ung KA. The bile acid turnover rate assessed 
with the (75)SeHCAT test is stable in chronic diarrhoea but slightly decreased in 
healthy subjects after a long period of time. DigDisSci. Institute of Medicine at 
Sahlgrenska Academy, University of Gothenburg, 41345, Gothenburg, Sweden. 
antal.bajor@telia.com; 2008 Nov;53(0163-2116 (Print)):2935–40.  
63.  Sciarretta G, Fagioli G, Furno A, Vicini G, Cecchetti L, Grigolo B, et al. 75SeHCAT test in 
the detection of bile acid malabsorption in functional diarrhoea and its correlation 
with small bowel transit. Gut. Department of Nuclear Medicine, Ospedale Maggiore 
USL, 27, Bologna, Italy; 1987 Aug;28(0017-5749 (Print)):970–5.  
64.  Smith MJ, Cherian P, Raju GS, Dawson BF, Mahon S, Bardhan KD. Bile acid 
malabsorption in persistent diarrhoea. J R Coll Physicians L. 2000;34:448–51.  
65.  Brydon WG, Nyhlin H, Eastwood MA, Merrick M V. Serum 7 alpha-hydroxy-4-
cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the 
assessment of bile acid induced diarrhoea. EurJ GastroenterolHepatol. 
Gastrointestinal Laboratory, Western General Hospital, Edinburgh, UK; 1996 
Feb;8(0954-691X (Print)):117–23.  
66.  Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha-
hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-
cholesten-3-one in peripheral blood. J Lipid Res. Metabolism Unit, Center for 
Metabolism and Endocrinology, S-141 86 Stockholm, Sweden; 2003 Apr;44(0022-
2275 (Print)):859–66.  
67.  Camilleri M, Nadeau A, Tremaine WJ, Lamsam J, Burton D, Odunsi S, et al. 
Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate 
test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome 
133 
 
 using liquid chromatography-tandem mass spectrometry. NeurogastroenterolMotil. 
Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), 
College of Medicine, Mayo Clinic, Rochester, MN 55905, USA. 
camilleri.michael@mayo.edu; 2009 Jul;21(1365-2982 (Electronic)):734–e43.  
68.  Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, et 
al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on 
intestinal transit and bowel function. Clin Gastroenterol Hepatol. Clinical Enteric 
Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, 
Minnesota 55905, USA; 2010 Feb;8(1542-7714 (Electronic)):159–65.  
69.  Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, et al. 
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a 
pharmacodynamic and pharmacogenetic analysis. Gastroenterology. Clinical Enteric 
Neuroscience Translational and Epidemiological Research, Division of Biomedical 
Statistics and Informatics, College of Medicine, Mayo Clinic, Rochester, Minnesota, 
USA; 2010 Nov;139(1528-0012 (Electronic)):1549–58,1558.  
70.  Wong BS, Camilleri M, Carlson PJ, Guicciardi ME, Burton D, McKinzie S, et al. A Klotho-
beta Variant Mediates Protein Stability and Associates with Colon Transit in Irritable 
Bowel Syndrome with Diarrhea. Gastroenterology. Division of Gastroenterology and 
Hepatology, Department of Health Sciences Research, Mayo Clinic College of 
Medicine, Rochester, Minnesota; 2011 Mar 8;140(1528-0012 (Electronic)):1934–42.  
71.  Pattni SS, Brydon WG, Dew T, Walters JRF. Fibroblast Growth Factor 19 and 7�-
hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid 
diarrhea. Clin Trans Gastroenterol. 2012 Jul 26;3:e18.  
72.  Lenicek M, Duricova D, Komarek V, Gabrysova B, Lukas M, Smerhovsky Z, et al. Bile 
acid malabsorption in inflammatory bowel disease: Assessment by serum markers. 
InflammBowelDis. Department of Clinical Biochemistry and Laboratory Diagnostics, 
1st Faculty of Medicine, Charles University in Prague, Czech Republic; 2010 Nov 
5;(1536-4844 (Electronic)).  
73.  Wedlake L, Thomas K, Lalji A, Anagnostopoulos C, Andreyev HJN. Effectiveness and 
tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with 
cancer: a retrospective chart review and patient questionnaire. Clin Ther. 
2009;31(11):2549–58.  
74.  Bajor A, Tornblom H, Rudling M, Ung KA, Simren M. Increased colonic bile acid 
exposure: a relevant factor for symptoms and treatment in IBS. Gut. Department of 
Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, 
University of Gothenburg, , Gothenburg, Sweden; 2014 Apr 12;(1468-3288 
(Electronic)).  
134 
 
 75.  Jung D, Fantin AC, Scheurer U, Fried M, Kullak-Ublick GA. Human ileal bile acid 
transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. 
Gut. 2004;53:78–84.  
76.  Ung KA, Gillberg R, Kilander A, Abrahamsson H. Role of bile acids and bile acid binding 
agents in patients with collagenous colitis. Gut. Division of Gastroenterology, 
Department of Internal Medicine, Sahlgrenska University Hospital, S-413 45 
Goteborg, Sweden; 2000 Feb;46(0017-5749 (Print)):170–5.  
77.  Fernandez-Banares F, Esteve M, Salas A, Forne TM, Espinos JC, Martin-Comin J, et al. 
Bile acid malabsorption in microscopic colitis and in previously unexplained functional 
chronic diarrhea. DigDisSci. Department of Gastroenterology, Hospital Universitari 
Mutua de Terrassa, Spain; 2001 Oct;46(0163-2116 (Print)):2231–8.  
78.  Miehlke S, Madisch A, Bethke B, Morgner A, Kuhlisch E, Henker C, et al. Oral 
budesonide for maintenance treatment of collagenous colitis: a randomized, double-
blind, placebo-controlled trial. Gastroenterology. Medical Department I, Technical 
University Hospital, Dresden, Germany. Stephan.Miehlke@uniklinikum-dresden.de; 
2008 Nov;135(1528-0012 (Electronic)):1510–6.  
79.  Bajor A, Kilander A, Galman C, Rudling M, Ung KA. Budesonide treatment is 
associated with increased bile acid absorption in collagenous colitis. Aliment 
Pharmacol Ther. Department of Internal Medicine, Sahlgrenska University Hospital, 
Goteborg, Sweden. antal.bajor@telia.com; 2006 Dec;24(0269-2813 (Print)):1643–9.  
80.  Balesaria S, Pell RJ, Abbott LJ, Tasleem A, Chavele KM, Barley NF, et al. Exploring 
possible mechanisms for primary bile acid malabsorption: evidence for different 
regulation of ileal bile acid transporter transcripts in chronic diarrhoea. EurJ 
GastroenterolHepatol. Gastroenterology Section, Faculty of Medicine, Imperial 
College London, Hammersmith Hospital, Du Cane Road, London, UK; 2008 
May;20(0954-691X (Print)):413–22.  
81.  Bajor A, Kilander A, Fae A, Galman C, Jonsson O, Ohman L, et al. Normal or increased 
bile acid uptake in isolated mucosa from patients with bile acid malabsorption. EurJ 
GastroenterolHepatol. Division of Gastroenterology, Department of Internal 
Medicine, Sahlgrenska University Hospital, Goteborg, Sweden; 2006 Apr;18(0954-
691X (Print)):397–403.  
82.  Sadik R, Abrahamsson H, Ung K-A, Stotzer P-O. Accelerated regional bowel transit and 
overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol. 
2004;99:711–8.  
83.  Bajor A, Ung KA, Ohman L, Simren M, Thomas EA, Bornstein JC, et al. Indirect 
evidence for increased mechanosensitivity of jejunal secretomotor neurones in 
patients with idiopathic bile acid malabsorption. Acta Physiol. Institute of Medicine, 
The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 2009 Apr 
27;197(1748-1716 (Electronic)):129–37.  
135 
 
 84.  Van Tilburg AJ, de Rooij FW, van den Berg JW, van Blankenstein M. Primary bile acid 
malabsorption: a pathophysiologic and clinical entity? ScandJ GastroenterolSuppl. 
Dept. of Internal Medicine II, University Hospital Dijkzigt, Rotterdam, The 
Netherlands; 1992;194(0085-5928 (Print)):66–70.  
85.  Pai R, French D, Ma N, Hotzel K, Plise E, Salphati L, et al. Antibody-mediated Inhibition 
of Fibroblast Growth Factor-19 Results in Increased Bile Acids Synthesis and Ileal 
Malabsorption of Bile Acids in Cynomolgus Monkeys. ToxicolSci. Department of 
Safety Assessment, Genentech Incorporated, South San Francisco, CA 94080; 2012 
Jan 19;126(1096-0929 (Electronic)):446–56.  
86.  Pattni SS, Dew T, Walters JRF. A prospective study of Fibroblast Growth Factor 19 in 
patients with chronic diarrhoea and possible bile acid malabsorption. Gut. 2010;59 
(Suppl :A48.  
87.  Pattni SS, Brydon WG, Dew T, Johnston IM, Nolan JD, Srinivas M, et al. Fibroblast 
growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of 
FGF19 serum assay and SeHCAT retention. AlimentPharmacolTher. Department of 
Medicine, Section of Hepatology & Gastroenterology, Imperial College London & 
Imperial College Healthcare, London, UK; 2013 Oct;38(1365-2036 (Electronic)):967–
76.  
88.  Miyata M, Takamatsu Y, Kuribayashi H, Yamazoe Y. Administration of ampicillin 
elevates hepatic primary bile acid synthesis through suppression of ileal fibroblast 
growth factor 15 expression. J Pharmacol ExpTher. Division of Drug Metabolism and 
Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku 
University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai, 980-8578, Japan. 
miyata@mail.pharm.tohoku.ac.jp; 2009 Dec;331(1521-0103 (Electronic)):1079–85.  
89.  Lindor KD. New treatment strategies for primary sclerosing cholangitis. DigDis. Mayo 
Clinic, Rochester, MN 55905, USA. lindor.keith@mayo.edu; 2011;29(1421-9875 
(Electronic)):113–6.  
90.  Kowdley K V, Jones D, Luketic V, Chapman R, Burroughs A, Hirschfield G, et al. An 
international study evaluating the farnesoid x receptor agonist obeticholic acid as 
monotherapy in PBC. J Hepatol. Elsevier; 2011;54:S13.  
91.  Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy 
and safety of the Farnesoid X Receptor agonist obeticholic acid in patients with type 2 
diabetes and nonalcoholic fatty liver disease. Gastroenterology. Center for Metabolic 
Research, VA San Diego Healthcare System and University of California, San Diego, 
San Diego, California. Electronic address: smudaliar@vapop.ucsd.edu; 2013 
Sep;145(1528-0012 (Electronic)):574–82.  
92.  Fgf- H. Human FGF-19 Immunoassay. 19.  
93.  Chen H, McCoy LF, Schleicher RL, Pfeiffer CM. Measurement of 25-hydroxyvitamin D3 
(25OHD3) and 25-hydroxyvitamin D2 (25OHD2) in human serum using liquid 
136 
 
 chromatography-tandem mass spectrometry and its comparison to a 
radioimmunoassay method. Clin Chim Acta [Internet]. 2008;391(1-2):6–12. Available 
from: http://www.scopus.com/inward/record.url?eid=2-s2.0-
41849136467&partnerID=40&md5=51a3d2a6a6739c152cbf07193fdeb1fd 
94.  Miller KW, Lorr NA, Yang CS. Simultaneous determination of plasma retinol, alpha-
tocopherol, lycopene, alpha-carotene, and beta-carotene by high-performance liquid 
chromatography. Anal Biochem. 1984;138(2):340–5.  
95.  Technologies A. November 2007 QIAamp ® DNA Mini and Blood Mini Handbook For 
DNA purification from whole blood. Blood [Internet]. 2007;104(April):101–8. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/16509153 
96.  Biosystems A. Assays Protocol.  
97.  Want EJ, Coen M, Masson P, Keun HC, Pearce JTM, Reily MD, et al. Ultra performance 
liquid chromatography-mass spectrometry profiling of bile acid metabolites in 
Biofluids: Application to experimental toxicology studies. Anal Chem. 
2010;82(12):5282–9.  
98.  Moss C. An investigation into age-associated under nutrition. Imperial College 
London. 2012. p. https://spiral.imperial.ac.uk:8443/bitstream/10044.  
99.  Duane WC, Hartich LA, Bartman AE, Ho SB. Diminished gene expression of ileal apical 
bile acid transporter explains impaired absorption of bile acid in patients with 
hypertriglyceridemia. J Lipid Res. 2000;41:1384–9.  
100.  S GR. No Title. Principles of Nutritional Assessment. 2nd ed. New York: Oxford 
University Press; 2005. p. 908.  
101.  Holick MF. Vitamin D deficiency. N Engl J Med [Internet]. 2007; Available from: 
http://www.nejm.org/doi/full/10.1056/NEJMra070553\npapers://a66046c0-dbb4-
40a6-bbd3-742e9e241be6/Paper/p10307 
102.  No Title [Internet]. Imperial College London NHS Trust. [cited 2015 May 20]. Available 
from: 
http://pathology.imperial.nhs.uk/index.php?mact=Products,cntnt01,default,0&cntnt
01showall=1&cntnt01categorylisttemplate=az_footer_block&cntnt01summarytempla
te=test_directory&cntnt01detailpage=test-
directory&cntnt01fieldid=2&cntnt01fieldval=b&cntnt01return 
103.  Pattni SS. Mechanisms of Idiopathic Bile Acid Malabsorption and Diarrhoea. Imperial 
College London; 2012.  
104.  Van Mil SW, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, et al. 
Functional variants of the central bile acid sensor FXR identified in intrahepatic 
cholestasis of pregnancy. Gastroenterology. Maternal and Fetal Disease Group, 
137 
 
 Institute of Reproductive and Developmental Biology, Imperial College London, 
London, England; 2007 Aug;133(0016-5085 (Print)):507–16.  
105.  Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I, Bondar O, et al. Increased 
Bile Acid Biosynthesis Is Associated with Irritable Bowel Syndrome with Diarrhea. 
ClinGastroenterolHepatol. Clinical Enteric Neuroscience Translational and 
Epidemiological Research (C.E.N.T.E.R.), College of Medicine, Mayo Clinic, Rochester, 
Minnesota; 2012 May 17;10(1542-7714 (Electronic)):1009–15.  
106.  Connelly TM, Berg AS, Hegarty JP, Deiling S, Brinton D, Poritz LS, et al. The TNFSF15 
gene single nucleotide polymorphism rs7848647 is associated with surgical 
diverticulitis. Ann Surg [Internet]. 2014 Jun [cited 2015 Apr 27];259(6):1132–7. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24814505 
107.  Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, et al. Identifying 
and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): 
association with TNFSF15 and TNFα. Gut [Internet]. 2013 Jul [cited 2015 Apr 
27];62(7):985–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22684480 
108.  NCBI. No Title [Internet]. The Single Nucleotide Polymorphism Database (dbSNP) of 
Nucleotide Sequence Variation. 2011 [cited 2015 May 20]. Available from: 
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=188096 
109.  NIDDK. The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment 
Trial (FLINT). ClinicalTrials.gov. 2014.  
110.  Luman W, Williams AJ, Merrick M V, Eastwood MA. Idiopathic bile acid 
malabsorption: long-term outcome. Eur J Gastroenterol Hepatol. 1995;7:641–5.  
111.  Rossel P, Sortsoe JH, Qvist P, Arveschoug A. Prognosis of adult-onset idiopathic bile 
acid malabsorption. ScandJ Gastroenterol. Dept. of Medical Gastroenterology, 
Aalborg Hospital, Denmark; 1999 Jun;34(0036-5521 (Print)):587–90.  
112.  Kok FJ, Matroos AW, van den Ban AW, Hautvast JG. Characteristics of individuals with 
multiple behavioral risk factors for coronary heart disease: the Netherlands. Am J 
Public Health. 1982;72(9):986–91.  
113.  Greenfield MS, Kraemer F, Tobey T, Reaven G. Effect of age on plasma triglyceride 
concentrations in man. Metabolism. 1980;29(11):1095–9.  
114.  Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine 
regulation of the fasting response by PPARalpha-mediated induction of fibroblast 
growth factor 21. Cell Metab. 2007;5(6):415–25.  
115.  Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, et al. Transgenic mice 
expressing human fibroblast growth factor-19 display increased metabolic rate and 
decreased adiposity. Endocrinology. 2002;143(5):1741–7.  
138 
 
 116.  Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation 
and reversal of malignant changes in colon cancer through PPARg. Nat Med. 
1998;4:1046–52.  
117.  Mráz M, Lacinová Z, Kaválková P, Haluzíková D, Trachta P, Drápalová J, et al. Serum 
concentrations of fibroblast growth factor 19 in patients with obesity and type 2 
diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and 
PPAR-alpha agonist treatment. Physiol Res. 2011;60(4):627–36.  
118.  Wojcik M, Janus D, Dolezal-Oltarzewska K, Kalicka-Kasperczyk A, Poplawska K, Drozdz 
D, et al. A decrease in fasting FGF19 levels is associated with the development of non-
alcoholic fatty liver disease in obese adolescents. J Pediatr Endocrinol Metab 
[Internet]. 2012 Jan [cited 2015 Apr 27];25(11-12):1089–93. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23329754 
119.  Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J. 
2006;25(7):1419–25.  
120.  Chiang JYL. Bile acid metabolism and signaling. Compr Physiol. 2013;3(3):1191–212.  
121.  Patti M-E, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, et al. Serum bile acids 
are higher in humans with prior gastric bypass: potential contribution to improved 
glucose and lipid metabolism. Obesity (Silver Spring). 2009;17(9):1671–7.  
122.  Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T, Konigsrainer A, 
et al. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota 
composition and nutrient absorption. Biomed Res Int. United States; 
2015;2015:806248.  
123.  Angelin B, Hershon KS, Brunzell JD. Bile acid metabolism in hereditary forms of 
hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial 
hypertriglyceridemia. Proc Natl Acad Sci U S A. 1987;84(15):5434–8.  
124.  Galman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in 
humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast 
growth factor 19. JInternMed. Department of Endocrinology, Metabolism & Diabetes, 
Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, Sweden; 
2011 Dec;270(1365-2796 (Electronic)):580–8.  
125.  Love MW, Craddock AL, Angelin B, Brunzell JD, Duane WC, Dawson PA. Analysis of the 
ileal bile acid transporter gene, SLC10A2, in subjects with familial 
hypertriglyceridemia. Arter Thromb Vasc Biol. 2001;21:2039–45.  
126.  Angelin B, Bjorkhem I, Einarsson K, Ewerth S. Hepatic uptake of bile acids in man. 
Fasting and postprandial concentrations of individual bile acids in portal venous and 
systemic blood serum. JClinInvest. 1982 Oct;70(0021-9738 (Print)):724–31.  
139 
 
 127.  Cai S-Y, He H, Nguyen T, Mennone A, Boyer JL. Retinoic acid represses CYP7A1 
expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and 
independent mechanisms. J Lipid Res. 2010;51(8):2265–74.  
128.  Tanumihardjo SA. Assessing vitamin A status: past, present and future. J Nutr. 
2004;134(1):290S – 293S.  
129.  Feldman M, Friedman L, Brandt L. Sleisenger and Fordtran’s Gastrointestinal and Liver 
disease. Saunders; 2007.  
130.  Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and 
therapy. NatRevGastroenterolHepatol. Imperial College London, Hammersmith 
Campus, Du Cane Road, London W12 0HS, UK; 2014 Mar 25;(1759-5053 (Electronic)).  
131.  Camilleri M. Advances in understanding of bile acid diarrhea. Expert Rev 
Gastroenterol Hepatol [Internet]. 2014;8(1):49–61. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24410472 
132.  Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, et al. Gut microbiota 
regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a 
naturally occurring FXR antagonist. Cell Metab. Wallenberg Laboratory, Department 
of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and 
Metabolic Research, University of Gothenburg, 413 45 Gothenburg, Sweden; 2013 
Feb 5;17(1932-7420 (Electronic)):225–35.  
133.  Madsen D, Beaver M, Chang L, Bruckner-Kardoss E, Wostmann B. Analysis of bile 
acids in conventional and germfree rats. J Lipid Res. 1976;17(2):107–11.  
134.  Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR 
paradigm. Nucl Recept Signal. 2010;8:e005.  
135.  Van der Werf SD, van Berge Henegouwen GP, van den Broek W. Estimation of bile 
acid pool sizes from their spillover into systemic blood. J Lipid Res. 1985;26(2):168–
74.  
136.  Johnston IM, Nolan JD, Dew T, Shapiro D, Walters JRF. A New Therapy for Chronic 
Diarrhea? A Proof of Concept Study of the FXR Agonist Obeticholic Acid in Patients 
With Primary Bile Acid Diarrhea. Gastroenterology. 2013;144(5):S60.  
137.  Walters JRF, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro D a. The 
response of patients with bile acid diarrhoea to the farnesoid X receptor agonist 
obeticholic acid. Aliment Pharmacol Ther [Internet]. 2015;41(1):54–64. Available 
from: http://doi.wiley.com/10.1111/apt.12999 
138.  Fang Q, Li H, Song Q, Yang W, Hou X, Ma X, et al. Serum fibroblast growth factor 19 
levels are decreased in chinese subjects with impaired fasting glucose and inversely 
associated with fasting plasma glucose levels. Diabetes Care. 2013;36(9):2810–4.  
140 
 
 139.  Reiche M, Bachmann A, Lössner U, Blüher M, Stumvoll M, Fasshauer M. Fibroblast 
growth factor 19 serum levels: relation to renal function and metabolic parameters. 
Horm Metab Res [Internet]. 2010 Mar [cited 2015 Apr 27];42(3):178–81. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/20013647 
140.  Johnston IM, Pattni SS, Lin J., Nolan JD, Dew T, Dixon PH, et al. Meal stimulated FGF19 
response and genetic polymorphisms in Primary Bile Acid Diarrhea. Gastroenterology. 
2012;142:(Suppl 1) S – 268.  
141.  Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, et al. Potent 
stimulation of fibroblast growth factor 19 expression in the human ileum by bile 
acids. AmJPhysiol GastrointestLiver Physiol. Gastroenterology Dept., Imperial College 
Healthcare, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. 
julian.walters@imperial.ac.uk; 2013 May;304(1522-1547 (Electronic)):G940–8.  
142.  Mroz MS, Keating N, Ward JB, Sarker R, Amu S, Aviello G, et al. Farnesoid X receptor 
agonists attenuate colonic epithelial secretory function and prevent experimental 
diarrhoea in vivo. Gut. Department of Molecular Medicine, RCSI Education and 
Research Centre, Beaumont Hospital, , Dublin, Ireland; 2013 Oct 8;(1468-3288 
(Electronic)):Oct 8. doi: 10.1136/gutjnl – 2013–305088.  
143.  Nolan JD, Johnston IM, Pattni SS, Dew T, Orchard T, Walters JR. Diarrhea in Crohn’s 
Disease: investigating the role of the ileal hormone Fibroblast Growth Factor 19. J 
Crohns Colitis. 2014 Dec;  
144.  Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, et 
al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal 
barrier in inflammatory bowel disease. Gut. Department of Gastroenterology and 
Hepatology, UMC Utrecht, The Netherlands; 2011 Apr;60(1468-3288 
(Electronic)):463–72.  
 
141 
 
